Title of Invention	"BENZOXAZINONE-DERIVED SULFONAMIDE COMPOUNDS AND PROCESS FOR PREPARATION THEREOF"
Abstract	wherein R1 to R9, and W are as described in the specification. The present invention also relates to a process for the preparation thereof.

Full Text

The present invention relates to benzoxazinone-derived sulfonamide compounds and process for preparation thereof. The present invention relates to benzoxazinone-derived sulphonamide compounds of general formula (1), (Formula Removed) a process for their preparation, a medicament comprising these compounds and the use of benzoxazlnone-darived sulphonamide compounds for the preparation of medicaments for 5-HT6 receptor regulation as well as for the treatment of disorders related thereto. The superfamlly of serotonin receptors (5-HT) indudes 7 dasses (5-HTi-S-HT7) encompassing 14 human subclasses [D. Hoyer, et al., Neuropharrnaeotogy, 1997, 38.4191. The 5-HTe receptor Is the latest serotonin receptor identified by molecular efoning both in rats [FJ. Monsma, et al., Mol. Pharmacol., 1993, 43,320; M. Ruat, et al., Brochem, Btophys. Res. Commun., 1993,193,288] and in humans [R. Kohen, et al, J. Neunochem., 1996,66, 47]. Compounds with 5-HT6 receptor affinity are useful for the treatment of various disorders of the Central Nervous System and of the gastrointestinal tract, such as Irritable Intestine syndrome. Compounds with 5-HTg receptor affinity are also useful in the treatment of anxiety, depression and cognitive memory disorders [M. Yoshioka, et a!., Ann. NY Acad. Sci., 1998, 861, 244; A. Bourson, et al., Br. J. Pharmacol., 1998,125,1562; D.C. Rogers, et al., Br. J. PharmacoL Suppl., 1999,127, 22P; A. Bourson, et al., J. Pharmacol. Exp. Ther., 1995, 274,173; A.J. Sleight, et al,, Behav. Brain Res., 1996, 73, 245; T.A. Brancliek, et al., Annu. Rev. Pharmacol. Toxicol., 2000, 40, 319; C. Routledge, et al., Br. J. Pharmacol., 2000,130,1606]. It has been shown that typical and atypical antipsychotic drugs for treating schizophrenia have a high affinity for 5-HTe receptors [B.L Roth, et al., J. Pharmacol. Exp. Ther., 1994,268,1403; C.E. Glatt, et al., Mol. Med., 1995,1, 398; F.J. Mosma, et al., Mol. Pharmacol., 1993,43, 320; T. Shinkai, et al., Am. J. Med. Genet., 1999,88,120]. Compounds with 5-HTe receptor affinity are useful for treating infant hyperklnesla (ADHD, attention deficit / hyperactivity disorder) [W.D. Hirst, et al., Br. J. Pharmacol., 2000,130,1597; C. Gerard, et al., Brain Research , 1997, 746, 207; M.R. Pranzatelli, Drugs of Today, 1997, 33, 379J. Moreover, it has been shown that the 5-HT6 receptor also plays a role in food ingestion [Neuropharmacology, 41, 2001,210-219]. Food ingestion disorders, particularly obesity, are a serious, fast growing threat to the health of humans of all age groups, since they increase the risk of developing other serious, even life-threatening diseases such as diabetes or coronary diseases. Thus, it was an object of the present invention to provide novel compounds that are suitable in particular as active substances in medicaments, preferably in medicaments for the regulation of 5-HTe receptors, for cognitive enhancement, for the prophylaxis and/or treatment of food-intake related disorders, disorders of the central nervous system, disorders of the gastrointestinal tract, such as irritable intestine syndrom, anxiety, panic, depression, cognitive memory disorders, senile dementia disorders, such as Morbus Alzheimer, Morbus Parkinson and Morfous Huntington, schizophrenia, psychosis, infantile hyperkinesia, ADHC (attention deficit, hyperactivity disorders) and other 5-HT6 mediated disorders particularly in mammals, including humans. It has been found that the benzoxazinone-derived sulphonamide compounds of general formulas (I), (la) and (Ib) given below show affinity for the 5-HTe-receptor. These compounds are therefore also suitable for the manufacture of a medicament for cognitive enhancement, for the prophylaxis and/or treatment of food ingestion (food intake) disorders, particularly for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, bulimia, anorexia, cachexia or type II diabetes (Non-Insulin Dependent Diabetes Mellitus), preferably type II diabetes, which is caused by obesity, disorders of the central nervous system, disorders of the gastrointestinal tract, such as irritable intestine syndrom, anxiety, panic, depression, cognitive memory disorders, senile dementia disorders, such as Morbus Alzheimer, Morbus Parkinson and Morbus Huntington, schizophrenia, psychosis, infantile hyperkinesia, ADHC (attention deficit, hyperactivity disorders) and other 5-HT6 mediated disorders particularly in mammals, including man. Thus, one aspect of the present invention are benzoxazinone-derived sulfonamide compounds of general formula (I), (Figure Removed) wherein R1, R2, R3, R4 are each Independently selected from the group consisting of hydrogen, halogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least monosubstituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least monosubstituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem, a nitro group, a cyano group, - OR10, xOC(=0)R11, -(00)-0-R11, -SR12, -SOR12, -S02R12, -NH-SO2R12, -S02NH2 and a -NR13R14 moiety, R5 represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical or a saturated or unsaturated, optionally at [east mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, R6, R7, R8, R9 are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, a cyano group and a -COOR15 moiety, W represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least mono-substituted heteroaryl radical, which may be bonded via an optionally mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or poJycycllc ring-system, an optionally at least mono-substituted, monocycllc aryl1 radical, which is condensed with an optionally at least mono-substituted mono- or polycyclic ring-system and which may be bonded via an optionally at least mono-substituted alkylene group, a NR16R17-molety, a COR18-moiety, or a phenyl radical, which is at least mono-substituted with one of the substituents selected from the group consisting of: 2,2,2,-Trifluoroethoxy-, C2-6-Alkenyl-, 1,3-Dihydro-1-oxo-2H-isoindol-2-yJ-, NPhthalimidinyK [(2-chlon1,3-thlazolyl-5-yl)-methoxyr Ethyl-5-yl2-methyl-3- furoate, C11-20-alkyl-, 1,3-Dioxo-2-azasplro[4,4]non-2~yl-, pyrazolyl-, (1,3-oxazol- 5-yl)-, (5-Methy!-1,3l4-oxadiazol-2-yl)-, difluoromethoxy, dichloromethoxy, 1- pyrrolidinylsulfonyl, morpholinosulfonyl, 2-methyl-4-pyrimidinyl-, a phenoxy group, which is at least mono-substituted with C1-5-alkoxy, a phenyl group, which is at least mono-substituted with one of the substituents selected from the group consisting of nftro, C1-5alkoxy, F, Cl, Br, at least partially fluorlnatedC1-5- alkyl, at least partially chlorinated C1-5-alkyl, [(2-Cfiloro-1,3-thlazol-5-yl)- methoxy]-, -(C=O)-H and -(C=0)-Ci-alkyl, a pyridlnyl group, which Is at least mono-substituted with C1-5-alkoxy, a pyrldinyloxy group, which is at least monosubstituted with C1-5-alkoxy, a phenoxy group, which is at least di-substituted and a pyrldinyloxy group, which is at least di-subsituied, with the proviso that W does not represent unsubstituted furyl-, unsubstituted thienylor thienyl substituted with a substituent selected from the group consisting of C1-5- alkoxycarbonyl, C1-5-alkylcarbonyl, carboxyl and pyridyl, unsubstituted pyrrolyl-, unsubstituted naphthyl, unsubstituted indolyl, unsubstituted tetrahydronaphthyl, substituted or unsubstituted pyridyl, unsubstituted pyrazinyl, unsubstituted quinolinyi-, C1-5-alkyJsubstituted pyrrolyl- and unsubstituted cyclohexyl or cyclohexyl substituted with one or two members selected from the group consisting of oxo, hydroxyl, C1- alkoxyl, C1-5-alkoxy-carbonylamino-C1-5 alkyl and amino-C1-5 alkyl, R10 represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, R11 represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, R12 represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least monosubstituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least monosubstituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, R13 and R14 each are independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least monosubstituted aliphatic radical, a saturated or unsaturated, optionally at'least monosubstituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least monosubstituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least monosubstituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or poiycyclic ring-system, or R13 and R14 together with the bridging nitrogen atom form a saturated, unsaturated or aromatic heterocyclic ring, which may be at least mono-substituted and/or contain at least one further heteroatom as a ring member, R15 represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least monosubstituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, R16 represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, R17 represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, and R18 represents an optionally at least mono-substituted aryl radical, optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate. A mono- or polycyclic ring-system according to the present invention means a monoor polycyclic hydrocarbon ring-system that may be saturated, unsaturated or aromatic. If the ring system is polycyclic, each of its different rings may show a different degree of saturation, i.e. it may be saturated, unsaturated or aromatic. Optionally each of the rings of the mono- or polycyclic ring system may contain one or more heteroatoms as ring members, which may be Identical or different and which can preferably be selected from the group consisting of N, O, S and P, more preferably be selected from the group consisting of N, O and S. Preferably the polycyclic ring-system may comprise two rings that are condensed. The rings of the mono- or polycyclic ring-system are preferably 5- or 6-membered. If one or more of the residues R1-R17 and W represents an aliphatic radical, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, halogen, branched or unbranched d-4-alkoxy, branched or unbranched C1-4-perfluoroalkoxy, branched or unbranched C1-4-perfluoroalkyl, amino, carboxy, amido, cyano, nitro, -SO2NH2l -CO-C1-4-alkyl, -SO-C1-4-alkyl, -SO2-C1-4-alkyl, -NH-S02-C1-4-alkyl, wherein the CC1-4-alkyl may in each case be branched or unbranched, an unsubstituted or at least mono-substituted phenyl or naphthyl radical and an unsubstituted or at least mono-substituted furanyl-, thienyl-, pyrrolyl-, imldazolyl-, pyrazolyl-, pyridinyl-, pyrimidinyl-, quinolinyl- and isoqulnollnyl radical, more preferably be selected from the group consisting of hydroxy, F, Cl, Br, methoxy, ethoxy, CFa and an unsubstituted phenyl radical. If any one of the above mentioned substitutents itself is at least mono-substituted, said substituents may preferably be selected from the group consisting of F, Cl, methyl and methoxy. If one or more of the residues R1-R15 represents or comprises a cycloaliphatic radical, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, halogen, branched or unbranched C1-4-alkyl, branched or unbranched C1-4-alkoxy, branched or unbranched C1-4-perfluoroalkoxy, phenoxy, benzoyl, cyclohexyi, branched or unbranched C1-4-perfluoroalkyl, -NRARB wherein RA, RB are each independently selected from the group consisting of H, a branched or unbranched C-i- 4-alkyl-radical, -CH2-CH2-OH and phenyi, carboxy, amido, cyano, nitro, -SOsNHjj, - CO-C1-4-alkyl, -CO-OC1-4-aikyl, -SO-C1-4-alkyl( -SO2-C1-4-alkyl, -NH-SO2-C1-4-alkyl, wherein C^-alkyl may in each case be branched or unbranched, unsubstituted or at least mono-substituted phenyi or naphthyl and unsubstituted or at least monosubstituted furanyl-, thienyl-, pyrrolyl-, imidazolyl-, pyrazolyl-, pyridinyl-, pyrimidlnyl-, quinolinyl- and isoquinolinyl radical, more preferably be selected from the group consisting of hydroxy, F, Cl, Br, methyl, ethyl, methoxy, ethoxy, benzoyl, phenoxy, cyclohexyi, -CF3, -CO-CH3 -CO-OCH3, -NRARB wherein RA, RB are each independently selected from the group consisting of H, a branched or unbranched C1-4-alkyl-radical, -CH2-CH2-OH and phenyi, and an unsubstituted phenyi radical. If any one of the above mentioned substitutents itself is at least mono-substituted, said substituents may preferably be selected from the group consisting of F, Cl, methyl and methoxy. If one or more of the residues R1-R4, R10-R15 and W comprises an alkylene group, which Is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, halogen, branched or unbranched d-4-alkoxy, branched or unbranched d-4-perfluoroalkoxy, branched or unbranched d-4-perfluoroalkyl, amlno, carboxy, amldo, cyano, nitro, -SO2NH2r -CCKWalkyl, -SO-d-4-alkyl, -SO2-d-4-alkyl, -NH-SO2-d-4-alkyl, wherein d-4-alkyl may be branched or unbranched, an unsubstituted or at least mono-substituted phenyi or naphthyl radical and an unsubstituted or at least mono-substituted furanyl-, thienyl-, pymolyh imidazolyl-, pyrazolyl-, pyridinyl-, pyrimidlnyl-, quinolinyl- and Isoquinolinyl radical, more preferably be selected from the group consisting of hydroxy, F, Cl, Br, methoxy, ethoxy, CF3 and unsubstituted phenyi. If any one of the above mentioned substitutents itself is at (east mono-substituted, said substituents may preferably be selected from the group consisting of F, CI, methyl and methoxy. If one or more of the residues R1-R4 and R10-R15 comprises a mono- or polycyclic ringsystem, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, halogen, branched or unbranched C-alky!, branched or unbranched CM-alkoxy, branched or unbranched Ci-4-perfluoroalkoxy, branched or unbranched C-perfluoroalkyl, amlno, carboxy, amldo, cyano, keto, nitro, -SO2NH2, -CO-d-4-alkyl, -SO-CM-alkyl, -SOz-Ci^-alkyl, -NH-SOz-Ci-4-alkyl, wherein Ci^-alkyl may be branched or unbranched, an unsubstituted or at least mono-substituted phenyl or naphthyl radical and unsubstituted or at least mono-substituted furanyK thienyl-, pyrrolyl-, imidazolyl-, pyrazolyl-, pyridinyl-, pyrimidinyl-, quinolinyl- and isoquinolinyl, more preferably from the group consisting of hydroxy, F, CI, Br, methyl, ethyl, methoxy, ethoxy, CF3l keto, cyano and an unsubstituted phenyl radical. If any one of the above mentioned substitutents itself is at least mono-substituted, said substituents may preferably be selected from the group consisting of F, CI, methyl and methoxy. If one or more of the residues R1-R4, R10-R15 and R18 represents or comprises an aryl radical, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, halogen, branched or unbranched C1-4-alkoxy, branched or unbranched C1-4-alkyl, branched or unbranched C1-4-perfluoroalkoxy, unsubstituted or at least mono-substituted phenoxy, unsubstituted or at least mono-substituted benzoyl, cyclohexyl, branched or unbranched C1-4-perfluoroalkyl, NRARB wherein R*. RB are each independently selected from the group consisting of H, a branched or unbranched C1-4-alkyl-radlcal, -CHrChk-OH and phenyl, carboxy, amldo, cyano, -CH(OH)(phenyl), nitro, -SOzNHa, -COCn-alkyl, -CO-OC14-alkyl, -SO-C1-4-alkyl, - SCk-C1-4-alkyl, -NH-S02-C1-4-alkyl, whereinC1-4-alkyl may be branched or unbranched, an unsubstituted or at least mono-substituted phenyl or naphthyl radical and unsubstituted or at least mono-substituted furanyl-, thienyl-, pyrrolyl-, imidazolyl-, pyrazolyl-, pyridinyl-, pyrimidinyl-, quinolinyl- and isoquinolinyl radical, more preferably be selected from the group consisting of hydroxy, F, CI, Br, methyl, ethyl, cyano, -CH(OH)(phenyl), methoxy, ethoxy, unsubstituted or at least mono-substituted benzoyl, unsubstituted or at least mono-substituted phenoxy, cyclohexyl, CF3 -COCH3, -CO-OCH3, -NF^R0 wherein RA, RB are each independently selected from the group consisting of H, a branched or unbranched C1-4-alkyl-radical, -CH2-CH2-OH and phenyl, and an unsubstituted phenyl radical. If any of the above mentioned substitutents itself is at least mono-substituted, said substituents may preferably be selected from the group consisting of F, Cl, methyl and methoxy. If one or more of the residues R1-R4 and R1D-R15 represents or comprises a heteroaryl radical, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, halogen, branched or unbranched C1-4-alkoxy, branched or unbranched C1-4-alkyl, branched or unbranched C1-4-perfluoroalkoxy, unsubstituted or at least mono-substituted phenoxy, unsubstituted or at least mono-substituted benzoyl, cyclohexyl, branched or unbranched C1-4-perfluoroalkyl, NRARB wherein RA, RB are each independently selected from the group consisting of H, a branched or unbranched C1-4-alkykadical, -CH2-CHrOH and phenyl, carboxy, amido, cyano, nitro, -CH(OHXphenyl), SO2NH2, -CO-C1-4-alkyl, -CO-OC1-4alkyl, SO-C1-4alkyl, SOrd-4-alkyl, -NH-SCVC1-4-alkyl, wherein C1-4-alkyl may be branched or unbranched, an unsubstituted or at least mono-substituted phenyl or naphthyl radical and an unsubstituted or at least mono-substituted furanyl-, thienyl-, pyrrolyl-, imidazolyl-, pyrazolyl-, pyridinyl-, pyrimidinyl-, quinolinyl- and isoquinolinyl radical, more preferably be selected from the group consisting of hydroxy, F, Cl, Br, methyl, ethyl, cyano, methoxy, ethoxy, unsubstituted or at least mono-substituted benzoyl, unsubstituted or at least mono-substituted phenoxy, cyclohexyl, CF3| - CH(OH)(phenyl), -CO-CH3, -CO-OCH3l -NRARB wherein RA, RB are each independently selected from the group consisting of H, a branched or unbranched C1-4-alkyl-radicaI, -CH2-CH2-OH and phenyl, and an unsubstituted phenyl radical. If any one of the above mentioned substitutents itself is at least mono-substituted, said substituents may preferably be selected from the group consisting of F, Cl, methyl and methoxy. If R13 and R14 form a heterocyclic ring, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, halogen, branched or unbranched C1-4-alkoxy, branched or unbranched C1-4-alkyl, branched or unbranched C1-4-- perfluoroalkoxy, branched or unbranched C1-4-perfluoroalkyl, amino, carboxy, amido, cyano, nitro, -SO2NH2, -CO-C1-4alkyl, -SO-C1-4-alkyl, -SO2-C1-4-alkyl, -NH-SO2-C1-4-aIkyl, wherein Ci.4-alkyl may be branched or unbranched, an unsubstituted or at least mono-substituted phenyl or naphthyl radical and an unsubstituted or at least mono-substituted furanyi-, thienyl-, pyrrolyl-, imidazolyl-, pyrazolyl-, pyridinyl-, pyrimidinyl-, quinolinyl- and Isoquinolinyl radical, more preferably be selected from the group consisting of hydroxy, F, Cl, Br, methoxy, ethoxy, methyl, CF3 and an unsubstituted phenyl radical. If any of the above mentioned substttutents itself is at least mono-substituted, said substituents may preferably be selected from the group consisting of F, Cl, methyl and methoxy. If R13 and R14 form a heterocyclic ring, which contains one or more further heteroatoms as ring members, unless defined otherwise, each of these heteroatoms may preferably be selected from the group consisting of N, O and S, more preferably from the group consisting of N and O. If one or more of the residues R1-R15 and W represents or comprises a cycloaliphatic radical, which contains one or more heteroatoms as ring members, unless defined otherwise, each of these heteroatoms may preferably be selected from the group consisting of N, 0, S and P, more preferably from the group consisting of N, O and S. If one or more of the residues R1-R4, R10-R15 and W represents or comprises an heteroaryl radical, which contains one or more heteroatoms as ring members, unless defined otherwise, each of these heteroatoms may preferably be selected from the group consisting of N, 0, S and P, more preferably from the group consisting of N, 0 and S. If W represents or comprises a cycloaliphatic radical, a heteroaryl radical, an aryl "radical and/or a mono- or polycycllc ring system, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, nitro, carboxy, cyano, keto, halogen, C1-20-aikyl, partially fluorinated C1-4 alkyl, partially chlorinated CM alkyl, partially brominatedC1-4alkyl, C1-4-alkoxy, partially fluorinated CM alkoxy, partially chlorinated CM alkoxy, partially brominated CM alkoxy, C1-4-alkenyl, SO2-C1-4-alkyl, - (C=0)-d^alkyl, -(C=O)-O-C1-4-alkyl, -(C=O)-Clr -S-CM-alkyl-, -(C=O)-H, -NH- (C=O>NH-Ci-5-alkyl, -(C=0)-C1-4-perfluoroalkyl. -NRARB, wherein RA and RB are independently selected from the group consisting of H, C1-4-alky! and phenyl, NH- (C=O)-C1-4-alkyl, -C1-4-alkylen-tCOJ-C1-4-alkyl, (1,3-Dihydro-1 -oxo-2H-isoindol-2-yl), N-Phthalimidinyl-, (1,3-Dioxo-2-azaspiro[4,4]-non-2-yl, substituted or unsubstituted phenyl, -SO2-phenyi, phenoxy, pyridinyl, pyridinyloxy, pyrazolyl, pyrimidinyl, pyrrolidinyl-, -SOz-pyrrolidinyl, morphollnyl, SO2-morpholinyl-, thiadiazolyl, oxadiazolyl, oxazolyl, thiazolyl, isoxazolyl, O-CHa-thfazolyl,-, NH-phenyl, and -CMAlkylen- NH-(C=O)-phenyl, more preferably from the group consisting of hydroxy, nitro, carboxy, cyano, keto, F, Cl, Br, I, Ci-i2-alkyl, CH2F, CHF2, CF3, CH2CI, CH2CI2, CCI3, CH2Br, CHBr2, CBr3, OCF3, OCHF2l OCH2F, O-CH2-CF3, vinyl, SOrCHs, - (CO)-CH3, -(C=Q)-C2H5l -(C=0)-0-CH3, -(C=O)-O-C2CH5, -(C=O)-CI, -S-CH3-( - (C=O)-H, -NH-(C=0)-NH-CH3 -(Cy-CFdlmethylamlno, dlethylamlno, di-npropylamino, di-lso-propylamino, di-n-butylamino, di-tert-butyamino, NH-(C=O)-CH3, - CHHC=O)-CH3, -CHHC^J-CjiHs, (1,3-Dihydro-1-oxo-2H-isoindol-2-yl), NPhthalimidinyl-, (I.S-Dioxo-Z-azaspiro-non-yl, substituted or unsubstituted phenyl, -S02-phenyl, phenoxy, pyridinyl, pyridinyloxy, pyrazolyl, pyrimidinyl, pyrrolidinyl-, -SO2-pyrrolidinyl, morpholinyl, SOa-morpholinyl-, thiadiazolyl, oxadiazolyl, oxazolyl, thiazolyl, isoxazolyl, O-CHz-thiazoly!,-, NH-phenyl, and CH2- NH-(C=O)-phenyl. If any of the afore mentioned substituents itself is substituted by one or more substituents, said substituents may preferably be selected from the group consisting of halogen, nitro, cyano, hydroxy, -(P=O)-CM-alkyl, C1-4-alkyi. at least partially fluorinated C1-4-aikyl, at least partially chlorinated C1-4-alkyd at least partially brominated C1-4-alkyi, -S-C1-4-alkyl, -C(=O)~0-Ci-6-alkyi, -(C=O)-CH2-F, -(C=O)-CH2- Cl, -(C=O)-CH2-Br, preferably from the group consisting of F, Cl, Br, CH2F, CHF2| CF3, CH2CI, CHCI2, CCI3, CH2Br, CHBr2, CBr3, nitro, cyano, hydroxy, -(C=O)-CH3, CH3| CaHs, -S-CH3, -C^OJ-O-CHa, -C(=O)-O-C2H5, -(C=0)-CH2-F, -(C=O)-CH2-Cl and -(C=O)-CH2-Br. Preferred compounds of general formula (I) are those, wherein R1, R2, R3, R4 are each independently selected from the group consisting of H, F, CI, Br, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C1-6- aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C1-4-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C1-6- alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least mono-substituted, 5- or 6- membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C1-6-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem, a nitro group, a cyano group, -OR10, -OC(=O)R11, -SR12, -SOR12, -S02R12, -NH-SO2R12, -SO2NH2 and a -NR13R14 moiety, preferably selected from the group consisting of H, F, Ci, Br, a saturated, branched or unbranched, optionally at least mono-substituted C1-3-aliphatic radical, a saturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing Cg- or C6- cycloaliphatlc radical, which may be bonded via an optionally at least mono-substituted Cr or C2-alkylene group, a nitro group, a cyano group, -OR10, -OC(=O)R11, -SR12 and -NR13R14 moiety, more preferably selected from the group consisting of H, F, CI, -CHs, -CH2CH3> -CF2CF3, cyclopentyl, cyclohexyl, a nitro group, a cyano group and -OR10, and R5-R18 and W have the meaning as defined above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates. Also preferred are compounds of generals formula (I), wherein R5 represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted d-e-aliphatic radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C1-4-cycloaliphatic radical, preferably represents H or a branched or unbranched Ci-3-alkyl radical, more preferably H, CHa or and R1-R4, R6-R1fl and W have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates. Preferred compounds of general formula (I) are also those, wherein R6, R7, R8, R9 are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least monosubstituted C1-6-aliphatic radical, a saturated or unsaturated, optionally at least monosubstituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, a cyano group and a -COOR16 moiety, preferably selected from the group consisting of H, a branched or unbranched alkyl radical, a cyano group and a -COOR16 group, more preferably from the group consisting of H, -CHa, -ChfeCHa and a cyano moiety, and R1-R5, R10-R1B and W have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates. Also preferred are compounds of general formula (I), wherein W represents an unbranched or branched, optionally at least mono-substituted C11-20-alkyl radical, a napthyf group, which is at least mono substituted, a quinolinyl group, which is at least mono-substituted, a pyrrolyl group, which is at least mono-substituted by a substituent other than C1-5--alkyl, an optionally at least mono-substituted thiazolylbenzo[ b]-thiophenyK benzo{b]-furanyK isoquinolinyJ-, tetrahydrolsoquinolinyl-, pyrazolyK isoazolyl-, chromanyK benzothiadiazolyl-, imidazolyl-, benzofurazany)- dibenzojb.dj-furanyl-, benzoxadiazolyl-, lmidazo[2,1-b]-thiazolyK anthracenyK coumarinyK 2,3-Dlhydro-1,4-benzodioxlnyl-, 2,3-Dihydrobenzo[bJfuranyl-, 3,4- Dihydro-2H-1,4-Benzoxazinyl-, 3,4-Dihydro-2H-1,5-Benzodioxepinyl-, Benzothlazolyl- lmidazo[1,2-aI-pyridinyl-, a chromonyl- group, an isatinyl group, a pentamethyldihydrobenzofuranyl group, an optionally at least mono-substituted cyclopropyl- or cyclopentyl-group, a 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl-)-ethyI, a thienyl group, which Is at least mono-substituted by one or more substituents independently selected from the group consisting of F, Cl, Br, C1-5-alkoxy-, CFs, -SOa-C1-5-alkyl and optionally at least mono substituted benzoylaminomethy!-, phenylsulfonyl-, isoxazolyl-, benzamldomethyl-, pyrimldyl-, thlazolyf-, pyrazolyl-, phenyl-, 1,2,4-thiadiazolyl-, 1,3-oxazolyl- or 1,2,4-oxddlazoJyl-, afuryl group, which is at least mono-substituted by one or more subsltutents independently selected from the group consisting of a C-i-s-alkyl radical, which may be at least partially fluorinated or chlorinated, an optionally at least mono-substituted phenyl and a -(C=O)-O-C1.5- alkyl group, a NR16R17-moieiy, a COR18-moiety, or a phenyl radical, which is at least mono-substituted with one of the substituents selected from the group consisting of: 2,2,2,-Trifluoroethoxy-, C2-6-Alkenyl-, 1,3-Dihydro-1-oxo-2H-lsoindol-2-yh NPhthalimidinyl-, [(2-chIoro-1,3-thiazolyl-5-yl)-methoxy, Ethyl-5-yl-2-methyl-3-furoate, C11-20-alkyl-, 1,3-Dioxo-2-azaspiro[4,43non-2-yl-, pyrazolyl-, (I.S-oxazol-S-yl)-, (5- Methyl-1,3,4-oxadiazol-2-yl)-, difluoromethoxy, dichloramethoxy, 1- pyrrolidinylsulfonyl, morpholinosulfonyl, 2-methyI~4-pyrimidinyl-, a phenoxy group, which is at least mono-substituted with d-s-alkoxy, a phenyl group, which is at least mono-substituted with one of the substrtuents selected from the group consisting of nitro, Ci-5-akoxy, F, Cl, Br, at least partially fluorinated C^-alky!, at least partially chlorinated Ci-s-alkyI, [(2-Chloro-1,3-thiazol-5-yl)-methoxy]-, -{C=O)-H and -{C=O)-Ci, s-alkyi, a pyridinyl group, which is at least mono-substituted with C-alkoxy, a pyridinyloxy group, which is at least mono-substituted with Ci.5-alkoxy, a phenoxy group, which is at least di-substituted and a pyridinyloxy group, which is at least disubsituted, more preferably W represents a moiety selected from the group consisting of 5- Dimethylamino-napth-1 -yl, 2-Acetamido-4-methyl-5-thlazolyl-, Trifluoromethyl-, Trichloromethyl-, Isopropyi-, Methyl-, 2,2,2-Trrfluoroethyh Ethyl-, Hexadecyl-, 2- Chloroethyl-, n-Propyi-, 3-Chloro-propyl-, n-Butyl-, Dichloromethyl-, Chloromethyl-, Dodecyl-, 1-Octyl-, 6-(phtoluidino)-naphth-2-yl-, 4,5-Dibromo-thiophene-2-yl-1 Benzoylchloride-2-yl-, 1-Octadecyl-, 4-Bromo-2,5-dichloro-thiophene-3-yl-, 2,5- Dichloro-thiophene-3-yl-, 5-Chioro-thiophene-2-yl-, 1-Decyl-, 3,5-Dichloro-4-(2-chloro- 4-nitrophenoxy)-phenyl-1 2,3-Dichlorothiophene-5-yl->3-Bromo-2-chloro-thiophene-5- yl, 3-Bromo-5-chloro-thiophene-2-yl-, 2-(BenzoyIamlnomethyl)-thlophene-5-yl-> 4- (Phenyl-sulphonyl)-thlophene-2-yl-, 2-Phenyl-sulphonyl-thlophene-5-yi-, 2-[1 -Methyl- S^trifluoromethyOpyrazol-S-yQ-thiophene-S-yl-, 5-Chloro-1,3-dimethyJpyrazole-4-yl-, 3,5-Dlmethylisoxazole-4-yl-, 2-(2,4-Dichlorophenoxy)-phenyl, 4-(2-ChlorO"6-nltrophenoxy)- phenyl-t 4-(3-chloro-2-cyanophenoxy)-phenyl, 2,4-Dimethyl-1,3-th!azole-5- yl-, Methyl-methane-sulfonyl-, 215-Bis-(2,2,2-Trifluoroethoxy)-phenyl-, 5-(Di-npropylamino)- naphth-1 -yl-, 2t2,5,7,8-Pentamethyl-chrornan-8-yl-, 5-Chloro-4-nitrothiophene- 2-yl-, 2,1,3-Benzothiadiazole-4-yl-, 1 -Methyl-imidazole-4-yl-, Benzofurazan-4-yl-, 5-(lsoxazol-3-yl)-thiophene-2-yl-, Vinyl-phenyi-4-yl-, 5-Dichloromethyl- furan-2-yl-, 5-Bromo-thiophene-2-yl-, 5-(4-Chlo robenzamidomethyl)- thiophene-2-yl-, Dibenzo[b ,d]-furan-2-yi-, 5-Chloro-3-methylbenzo[b]-thiophene-2-yl-, 3-Methoxy-4-(methoxycarbonyl)-thiophene-2-yl-, 5-[2-(Methylthio)-pyrimidin-4-yl- thiophene-2-yl-, 4-Chloro-2,1,3-Benzoxadiazole-7-yl-, 5-Chloro-2,1,3- Benzoxadiazole-4-yl-, 6-Chloro-!mldazo(2,1 -B)-thiazo!e-5-yl-, 3-Methyl-benzo[b]- thiophene-Z-yl-^-p-Chioro-S-fTriffuoromethylJ^-pyridyfJoxy-phenyl-, 5-Chloronaphth- 1-yl-, 5-Chloro-naphth-2-yl-, 9,10-Dibromoanthracene-2-yl-, lsoquinoline-5-yi-, 17 4-Methoxy-2,3,6-trimethylbenzoyl-, 4'-Nitro-biphenyl-4-yl-. (1,3-Dihydro-1-oxo-2Hisoindo[- 2-yl-H-pheny[-, 5-(2-Methyl-1,3-thia2ole-4-yl)-thiophene-2-yl-l 5-(1-Methyl-3- (trtfluoromethy()pyra2ol-5-yl-]-thiophene-2-yl-,5-[5-TrifluoromethyI)-isoxazo[-3-yrithiophene- 2-yl-, p-Dodgcyl-phenyl-^-KS-Cyano-^methoxy^-pyridinylJoxyJ-phenyl-, 4-(N-phtha]imidinyl)-phenyl-, 1,2,3,4-Tetrahydro-2-(trifIuoroacety])-isoquJnollne-7-yl-, 1 -Dimethylimidazole-^yK 2l2f4r6l7-Pentamethyldihydnobenzofuran-5-y]-14-Chloronaphth- 1-y!-, 2,5-Dichloro-4-nitro-thiophene-3-yl-, 4-(4-Methoxy-phenoxy)-phenyl-, [4- {3,5-Dichlorophenoxy)phenylK [4-{3,4-DichIorophenoxy)phenyl]-, [4-(3,5)- Bis(trifluoromethylphenoxy)phenyl]-, 3-(2-Methoxy-phenoxy)-phenyi, 3-(4-Methoxyphenylj- phenyl-, 3-(4-Chloro-phenyl)-phenyl-l S^S.S-Dlchloro-phenylJ-phenyl-, 3-{3,4- Dichloro-phenylJ-phenyl-, 3-(4-Fluorophenyl)-phenyl-, 3-[4-(Trifluoromethyl)-phenyl]- phenyl-, 3-[3,5-Bis-(Trifluoramethyl)-phenyl]-phenyl-, 4-{2-Methoxy-phenoxy)-phenyl-, 4-(2-Methyl-phenoxy)-phenyl-,4-(4-Methoxy-phenoxy-phenyl-14-(4-Chlorophenyl)- phenyl-, 4-(3,5-Dichlorophenyl)-phenyl-, 4-(3,4-Dichlorophenyl)-phenyf-, 4-(4- Fluorophenyl)-phenyl-, 4-[4-(Trifluormethy!)-phenyl]-phenyl-, 4-[3,5-B is- (Trlfluoromethyl)-phenyl]-phenyl-, Cyclopropyl-, 2-(2-Chlorophenyl)-2-Phenylethyl-, 2- (2-Trifluoromethylphenyl)-2-phenylethyK 5-[4-Cyano-1 -methyl-5-(methylthio)-1 Hpyrazol- 3-yl-thiophene-2-yl-, 3-Cyano-2,4-bls-(2,2,2-Trlfluonothoxy)-phenyl-l4-[(2- Chloro-1,-Thlazol-5-yl)-methoxy]-pheny]-, 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)- ethyl-, 5-lodo-naphth-1 -yl-, Ethyl-2,5-dimethyH-phenylpyiTOle-4-carboxylate-3-yl-, Ethyl-2-methyl-1,5-dlphenyl-1 H-pyrrole-3-carboxylate-4-yl-, Ethyl-5-(4-chlorophenyJ- 2"methyl-3-furoate-4-yl, Ethyl-5-(4-chlorophenyl)-2-methyH-phenyl-3-carboxylate-4- yl-, Ethyl.S-dimetiiyl-S-furoate-yl-, 3-Chloro-4-(1 .S-dloxo-AzaspiroJnon-yl)- phenyl-, Coumarin-6-yl, 3-(4-Methoxy-phenoxy)-phenyl-, [3-(3,5-Dichlorophenoxy)]- phenyl-, [3-(3,4 Dichlorophenoxy)]-phenyl-, 3,5-Bls(Trifluoromethyl)phenoxyphenyl-, 2,2-Diphenylethyl-, 4-Phenyl-5-{trifluoromethyl)-thlophene-3-yl-, Methyl-4-Phenyl-5- (Trifluoromethyl)-thiophene-2-carboxylate-3-yl-, Methyl-1,2,5-trimethylpyrrole-3- Carboxylate-4-yl-, 4~Fluoro-naphth-1 -yl-, 5-Fluoro-3-methylbenzo[b]-thiophene-2-yl-, Methyl-2,5-dlmethyl-3-furoate-4-yl-, Methyl-2-furoate-5-yl-, Methyl-2-methyl-3-furoate- 5-yl-, Methyl-1-methyl-1H-pyrrole-2-Carboxylate-5-yl-, 2-(5-Chloro-1 AThiadiazol-Syl)- thlophene-5-y]-t 1 .S.S-Trimethyl-IH-pyrazole-yl-, Pentafluoroethoxytetrafluoroethyl-, 5-(5-Isoxazyl)-thiophene-2-yI-, 5-(5-lsoxazol-yl)-2- furyl-, 5-Methyl-2,1,3-benzothiadiazole-4-yl-, 2>3-Dihydro-1,4-benzodioxine-6-yl-f 4- Methyl-Naphth-1 -yl-, 5-Methyl-2-(Trffluormethyl)-3-Furyl-r 2,3-Dlhydrabenzo[b]furan- 5-yh 1-Benzothiophene-3-yl-, 4-Methyl-3,4-dihydro-2H-1,4-Benzoxazine-7-yl-, 5- MethyM-phenyI-1 H-pyrazoIe-4-yl-, 6-Morpholino-3-Pyridinyl-, 4-(1 H-Pyrazol-1-yl)- phenyl-, 6-Phenoxy-3-PyridyJ-, 3,4-Dihydro-2H-1,5-benzodioxepine-7-yK 5-(1,3- Oxazof-5-yl)-2-thienyl-, 4-(1,3-Oxazol-5-yl)-phenyl-, 5-Methyl-4-isoxazolyl, 2,1,3- Benzothiadiazole-5-yl-, 5-Acetamido-naphth-1-yl-, 3-Methyl-8-Quinollnyl-, 1,3- Benzothiazole-6-yl-, 2-Morphollno-3-Pyridyl-, 2,5-Dimethyl-3-thienyl-, 5-[5- (ChloromethylH ,2,4-oxadiazol-3-y|]-2-thienyK Ethyl-3-[5-yl-2-thienyl-]1,2,4- oxadiazole-5-carboxylate-, 3-(5-Methyl-1I3,4-oxadlazol-2-yi)-phenyI-l 4- (Difluoromethoxy)-phenyf-, 3-(Difluonomethoxy)-phenyl-, 2,2-Dimethyl-6-Chromany- Ethyl-3,5-dimethyl-1 H-pyrrole-2-carboxylate-4-yl-, lmidazo[1,2-A]pyridine-3-yK 3- (1,3-Oxazol-5-yl)-phenyl-, Ethyl-5-[4-yl)-phenyl]-2-methyl-3-furoate> 1- Pyrrolidlnylphenylsulfonyl-, Methyl-5-yl-4-methyl-2-thiophene-carboxylate, Methyl-3- yl-isopropylsulfonyO^-thiophene, 7-Chlorochromone-3-yl-, 4'-Bromoblphenyl-4-yl- 4'-Acetyl-b(phenyJ-4-yl-f 4'-Bromo-2'-fluoro-biphenyl-4-yl-, 1-Methyl-5-isatinyl-, 2- ChIoro-3-thiophenecarboxyllc-acld-5-yl-, 2-Methoxy-5-(N-phthalimldlnyf)-phenyl-, 1- Benzothiophene-2-yh Morphollnophenylsulfonyl- and 3-(2-Methyf-4-pyrimidinyl)- phenyl- and R1-R18 have the meaning given above, optionally in form of one of their stereoisomers, preferably enantlomers or dfastereomers, their racemates or in form of a mixture of at least two of Its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates. Furthermore, compounds of general formula (I) are preferred, wherein R10 represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C1-6-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C1-6- cycloallphatic radical, which may be bonded via an optionally at least monosubstituted C1-6-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least monosubstituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C1-6-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably H, a linear or branched C1-4-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably H, -CH3l -CzHg or phenyl, and R1-R9, R12-R18 and W have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or In form of a mixture of at least two of Its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates. Moreover, compounds of general formula (I) are preferred, wherein R11 represents hydrogen, an unbranched or branched, saturated or unsaturated, optionaliy at least mono-substituted C1-6-aliphatic radical, a saturated or unsaturated, optionaliy at least mono-substftuted, optionally at least one heteroatom as ring member containing C1-6- cycloaliphatic radical, which may be bonded via an optionally at least monosubstituted C1-6-alkyiene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least monosubstituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C1-6-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably H, a linear or branched C1-4-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably H, -CHa, -CaHs or phenyl, and R1-R10, R12-R18 and W have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of Its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates. Preference is also given to compounds of general formula (I), wherein R1Z represents an unbranched or branched, saturated or unsaturated, optionally at least monosubstituted C1-6-aliphatic radical, a saturated or unsaturated, optionally at least monosubstituted, optionally at least one heteroatom as ring member containing C1-6 cycloaliphatic radical, which may be bonded via an optionally at least monosubstituted Ci-e-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least monosubstituted, 5- or 6- membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C1-6--alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably represents H, a linear or branched C1-4-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably H, -Chfe, -CaHg or phenyl, and R1-R11, R13-R18 and W have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates. Also preferred are compounds of general formula (I), wherein R13 and R14 are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C1-6-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6- membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C1-6-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably are each independently selected from the group consisting of H, a linear or branched C1-4-alkyl radical, a cyclonexyl radical and a phenyl radical, more preferably are each independently selected from the group consisting of H, CH3f C2H5 and phenyl, and R1-R12, R1S-R18 and W have the meaning given above, optionally In form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates. Furthermore, compounds of general formula I are preferred, wherein R13 and R14 together with the bridging nitrogen atom form a saturated, unsaturated or aromatic, 5- or 6-membered heterocyclic ring, which may be at least mono-substituted and/or contain at least one further heteroatom as a ring member, preferably form an unsubstituted piperidin or morpholine group, and R1-R12, R15-R18 and W have the meaning given above, optionally In form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or In form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates. Also preferred are compounds of general formula (I), wherein R15 represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C1-6-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C1-6- cycioaliphatic radical or an optionally at least mono-substituted, 5- or 6- membered aryl- or heteroaryl radical, which may be bonded via an optionally at least monosubstituted C1-6-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably represents H, a linear or branched C1-4-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably represents H, -CH3, -C2Hs or phenyl, and R1-R14, R16, R17, R18 and W have the meaning given above, optionally in form of one of their stereoisomers, preferably enantlomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates. Also preferred are compounds of general formula (I), wherein R16 represents an unbranched or branched, saturated or unsaturated, optionally at least monosubstituted C-ue aliphatic radical, preferably an unbranched or branched, saturated, unsubstituted Ci-3 alkyl radical, more preferably a methyl radical, and R1-R16, R17, R18 and W have the meaning given above, optionally In form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of Its stereoisomers, preferably enantiomers or diastereomers, In any mixing ratio, or corresponding salts thereof, or corresponding solvates. Also preferred are compounds of general formula (I), wherein R17 represents an unbranched or branched, saturated or unsaturated, Optionally at least monosubstituted C1-6 aliphatic radical, preferably an unbranched or branched, saturated, unsubstituted C1-3 alkyl radical, more preferably a methyl radical, and R1-R1e, R18 and W have the meaning given above, optionally in form of one of Iheir stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates. Also preferred are compounds of general formula (I), wherein R18 represents a phenyl radical, which is optionally at least mono-substituted by a C1-6 aliphatic radical, more preferably a phenyl radical, which Is optionally at least monosubstituted by a methyl group, and R1-R17 and W have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or In form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates. Particularly preferred are compounds of general formula (I) selected from the following list A: List A: (Table Removed) More particularly preferred are compounds of general formula (1) selected from the consisting of 1 -[1 -(5-Chloro-3-methyl-benzo[b]thiophenyl-2-sulfonyl)-piperidine-4-yQ-1 ,4-dihydrobenzo[ d][1 ,3]oxazin-2-one, 1 -{1 -(5-Dimethylami no-naphthyl-1 -sulfonyl)-piperidine-4-yl]-8-methyl-1 ,4-dihydrobenzo[ d][1 ,3]oxazin-2-one, 1 -[1 -(5-Dimethylamino-naphttiyl-1-sulfonyl)-piperldine-4-yI)-1 ,4-dihydrobenzo[ d][1 ,3]oxazin-2-one, and corresponding salts thereof, and corresponding solvates. In a further aspect the present invention also provides a process for the preparation of benzoxazinone-derived sulphonamide compounds of general formula (I), wherein R1-R9 and W have the meaning given above, comprising reacting at least one piperidine compound of general formula (II) and/or a corresponding salt thereof, preferably a hydrochloride salt, (Figure Removed) wherein R1 to R9 have the meaning given above, with at least one compound of general formula (III), (Figure Removed) wherein W has the meaning given above, In a suitable reaction medium, optionally in the presence of at least one base and/or at least one auxiliary agent, to yield a compound of general formula (I). Suitable reaction media include e.g. organic solvents, such as ethers, preferably diethyl ether, dioxane, tetrahydrofurane, dimethyl glycol ether, or alcohols, e.g. methanol, ethanol, propanol, isopropanol, butanol, isobutanol, tert-butanol, or hydrocarbons, preferably benzene, toluene, xylene, hexane, cyclohexane, petroleum ether, or halogenated hydrocarbons, e.g. dichloromethane, trichioromethane, tetrachloromethane, dichloroethylene, trichloroethylene, chlorobenzene or/and other solvents, preferably ethyl acetate, triethylamine, pyridine, dimethylsulfoxide, diemthylformamlde, hexamethylphosphoramide, acetonitril, acetone or nftromethane, are included. Mixtures based one or more of the afore mentioned solvents may also be used. Bases that may be used in the processes according to the present invention are generally organic or inorganic basesxpreferably alkali metal hydroxides, e.g. sodium hydroxyde or potassium hydroxyde, or obtained from other metals such as barium hydroxyde or different carbonates, preferably potassium carbonate, sodium carbonate, calcium carbonate, or alkoxides, e.g. sodium methoxlde, potassium methoxide, sodium ethoxide, potassium methoxide, potassium ethoxlde or potassium tert-butoxide, or organic amines, preferably triethylamine, djisopropyethylamine or heterocycles, e.g. 1,4-diazabicyclo[2.2.2] octane, 1,8-diazabicyclo[5AO]urKlec-7-ene pyridine, diamino pyridine, dimethylarninopyridine, methylpiperidine or morpholine. Alkali metals such as sodium or ist hydrides, e.g. sodium hydride, may also be used, fixtures based one or more of the afore mentioned bases may also be used. During the synthetic reactions described above or while preparing the compounds of general formulas (II) or (III) the protection of sensitive groups or of reagents may be necessary and/or desirable. This can be performed by using conventional protective groups like those described in the literature [Protective groups in Organic Chemistry, ed. J. F.W. McOmie, Plenum Press, 1973; T.W. Greene & P.G.M.Wuts, Protective Groups in Organic Chemistry, John Wiley & sons, 1991. Said literature description is hereby Incorporated by reference as part of the disclosure. The protective groups may also be eliminated as convenient by means well-known to those skilled in the art. The compounds of genera! formulas (II) and (HI) are either commercially available or can be produced according to methods known to those skilled in the art. The reaction of compounds of general formulas (II) and (III) to yield benzoxazinone-derived sulphonamide compounds of general formula (I) may also be facilitated by conventional methods known to those skilled in the art. The substituted benzoxazinone compounds of general formula (II), wherein R5 represents H, are preferably synthesized from substituted anthranlllc acid or a corresponding ester via the corresponding substituted benzylalcohol (see scheme 1, method A). By reductive arnination with 1-Boc-(tert.-Butylcarbonylo)cy)-4-plperidone the Boc-piperidin-moiety is introduced into the substituted benzylalcohol. The benzoxazinone-ring is formed by cyclisatlon with triphosgene. The elimination of the Boc-protecting group is carried out by treatment in acidic media according to the method described in Williams et al., J. Med. Chem. 1995 38,4634 and later by Bell et al., J. Med. Chem., 1998, 41,2148 which are hereby Incorporated by reference and form part of the disclosure. By reacting such a substituted benzoxazinone compound of general formula (II) with a substituted sulfuryl chloride of general formula (III) (Figure Removed) compounds of general formula (I) are obtained. By reduction of the corresponding ketones via conventional methods known to those skilled in the art, e.g. by reduction with sodium borohydrtde (see scheme 1, method B, R5=Z) benzoxazinone derived sulphonamide compounds of general formula (Figure Removed) wherein R5 represents an unbranched or branched, saturated or unsaturated, nationally at least mono-substituted aliphatic radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical (denoted by Z in method B) can be obtained. The respective reagents used in said process for the preparation of benzoxazinone derived sulphonamide compounds of general formula (I) are either commercially available or can be obtained by methods well known to those skilled in the art. Scheme 1: (Figure Removed) In a further aspect the present invention also provides a process for the preparation of salts of benzoxazinone-derived sulphonamide compounds of general formula (Figure Removed) wherein at least one compound of general formula (I) having at least one basic group is reacted with at least one inorganic and/or organic acid, preferably in the presence of a suitable reaction medium. Suitable reaction media are, for example, the ones given above. Suitable inorganic acids include hydrochloric acid, hydrobromic acid, fljosphoric acid, sulfuric acid, nitric acid, suitable organic acids are e.g. citric acid, maleic acid, fumaric acid, tartaric acid, or derivatives thereof, p-toluenesulfonic acid, methanesulfonic acid or camphersulfonic acid. in yet a further aspect the present invention also provides a process for the preparation of salts of benzoxazinone-derived sulphonamide compounds of general formula (I), wherein at least one compound of general formula (I) having at least one acidic group is reacted with one or more suitable bases, preferably in the-presence of a suitable reaction medium. Suitable bases are e.g. hydroxides, carbonates or alkoxides, which include suitable cations, derived e.g. from alkaline metals, alkaline earth metals or organic cations, e.g. [NHnFLnvT, wherein n is 0,1,2,3 or 4 and R represents a branched or unbranched Ci.4-aikyl-radical. Suitable reaction media are, for example, the ones given above. Solvates, preferably hydrates, of the Benzoxazinone-derived sulphonamide compounds of general formula (I) or of the salts thereof may also be obtained by standard procedures known to those skilled in the art. If the Benzoxazinone-derSved compounds of general formula (I) are obtained In form of a mixture of stereoisomers, particularly enantiomers or diastereomers, said mixtures may be separated by standard procedures known to those skilled In the art, e.g. chromatographic methods or crystallization with chiral reagents. The purification and isolation of the Benzoxazinone-derived sulphonamide compounds of general formula (I) or a corresponding stereoisomer, or salt, or solvate respectively, if required, may be carried out by conventional methods known to those skilled in the art, e.g. chromatographic methods or recrystallization. The Benzoxazinone-derived sulphonamide compounds of general formula (1), their stereoisomers, the corresponding salts and the corresponding solvates are toxicologically acceptable and are therefore suitable as pharmaceutical active substances for the preparation of medicaments. The present invention therefore also provides for a medicament comprising at least The benzoxazinone-derived sulphonamide compound of general formula (1), optionally in form of one of Its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate, and optionally one or more pharmaceutically acceptable adjuvants. Furthermore, the present invention also provides for a pharmaceutical composition comprising at least one benzoxazinone-derived sulphonamide compound of general formula (I), optionally in form of one of Its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate and optionally one or more pharmaceutically acceptable adjuvants, which is not yet formulated into a medicament. Preferably the medicament Is suitable for 5-HTrreceptor regulation, for cognitive enhancement, for the prophylaxis and/or treatment of food Ingestion (food Intake) disorders, particularly for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, bulimia, anorexia, cachexla or type II diabetes (Non-Insulin Dependent Diabetes Mellitus), preferably type II diabetes, which Is caused by obesity, disorders of the central nervous system, disorders of the gastrointestinal tract, such as irritable intestine syndrom, anxiety, panic, depression, cognitive memory disorders, senile dementia disorders, such as Morbus Alzheimer, Morbus Parkinson and Morbus Huntington, schizophrenia, psychosis, infantile hyperkinesia, ADHC (attention deficit, hyperactivity disorders) and other 5-HT6 mediated disorders particularly in mammals, including humans. A further aspect of the present invention is the use of at least one benzoxazinonederived compound of general formula (I) for the manufacture of a medicament for 5- HTe-receptor regulation, for cognitive enhancement, for the prophylaxis and/or treatment of food ingestion (food intake) disorders, particularly for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, bulimia, anorexia, cachexia or type II Tabetes (Non-Insulin Dependent Diabetes Mellitus), preferably type II diabetes, which is caused by obesity, disorders of the central nervous system, disorders of the gastrointestinal tract, such as irritable intestine syndram, anxiety, panic, depression, cognitive memory disorders, senile dementia disorders, such as Morbus Alzheimer, Morbus Parkinson and Morbus Huntington, schizophrenia, psychosis, infantile hyperkinesia, ADHC (attention deficit, hyperactivity disorders) and other 5-HT6 mediated disorders particularly in mammals, including humans. in yet a further aspect, the present invention also provides for the use of at least one benzoxazinone-derived sulphonamide compound of general formula (la) (Figure Removed) wherein R1a, R28, R3a, R48 are each independently selected from the group consisting of hydrogen, halogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least monosubstituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least mono- ibstituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem, a nitno group, a cyano group, - OR10a, -OC(=0)R11a, -C(=0)-OR11a, -SR12a, -SOR12a, -SO2R12a, -NH-SO2R12a, - S02NH2 and a -NR13aR14a moiety, R53 represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, R6", R7a, R83, R93 are each Independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, a cyano group and a -COOR15a moiety, Wa represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least monosubstituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least monosubstituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, a NR16aR17a-moiety or a -COR18amoiety, R10a represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, R11a represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteraatom as ring member containing cycloaliphatlc radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, R12a represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least monosubstituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least monosubstituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, R13a and R14a each are independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least monosubstituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least monosubstituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or R13a and R14a together with the bridging nitrogen atom form a saturated, unsaturated or aromatic heterocycfic ring, which may be at least mono-substituted and/or contain at least one further heteroatom as a ring member, R16a represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least monosubstituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, R16a represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, R17a represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, R18a represents an optionally at least mono-substituted aryl radical, optionally in form of one of its stereoisomers, preferably enantlomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a solvate, respectively, for the manufacture of a medicament for 5-HT6-recepior regulation, for cognitive enhancement, for the prophylaxis and/or treatment of food ingestion (food intake) disorders, particularly for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, bulimia, anorexia, cachexia or type II diabetes (Non-Insulin Dependent Diabetes Meliitus), preferably type II diabetes, which Is caused by obesity, disorders of the gastrointestinal tract, such as irritable intestine syndrom, anxiety, panic, depression, lgnitive memory disorders, senile dementia disorders, such as Morbus Alzheimer, Morbus Parkinson and Morbus Huntington, schizophrenia, psychosis, infantile hyperkinesia, ADHC (attention deficit, hyperactivity disorders) and other 5-HT6 mediated disorders particularly in mammals, preferably humans. If one or more of the residues R1a-R17a and W* represents an aliphatic radical, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, halogen, branched or unbranched C-alkoxy, branched or unbranched Ci.4-perfluoroalkoxy, branched or unbranched Ci-4-perfluoroalkyl, amlno, carboxy, amido, cyano, nitro, -SO2NH2) »CO-Ci^-alkyI, -SO-C^-alkyl, -SC>2-Ci-4-alkyl, -NH-SO2-Ci-4-alkyl, wherein the C-M-alkyl may In each case be branched or unbranched, an unsubstituted or at least mono-substituted phenyl or naphthyl radical and an unsubstituted or at least mono-substituted furanyl-, thienyf-, pyrrolyl-, imidazoly!-, pyrazolyl-, pyridinyl-, pyrimldlnyl-, qulnolinyl- and Isoquinolinyl radical, more preferably be selected from the group consisting of hydroxy, F, Cl, Br, methoxy, ethoxy, CF3 and an unsubstituted phenyl radical. If any one of the above mentioned substftutents itself is at least mono-substituted, said substituents may preferably be selected from the group consisting of F, Cl, methyl and methoxy. If one or more of the residues R1a-R16a represents or comprises a cycloaliphatic radical, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, halogen, branched or unbranched C1-4-alkyl, branched or unbranched C1-4- alkoxy, branched or unbranched C1-4-perfluoroalkoxy, phenoxy, benzoyl, cyclohexyl, branched or unbranched C1-4-perfluoroalkyl, -NRARB wherein RA, RB are each Independently selected from the group consisting of H, a branched or unbranched C1- 4-alkyl-radical, -CHrCHa-OH and phenyl, carboxy, keto, amido, cyano, nitro, - SO2NH2, -CO-C1-4-alkyl, -CO-OC1-4-alkyl, -SO-C1-4alkyl, -SO2-Ci.4-alkyl, -NH-SOrCi. 4-alkyl, whereinC1-4-alkyl may in each case be branched or unbranched, unsubstituted or at least mono-substituted phenyl or naphthyl and unsubstituted or at least mono-substituted furanyl-, thlenyl-, pyrrolyl-, Imldazolyl-, pyrazolyl-, pyridinyl-, pyrimidinyl-, quinolinyl- and isoquinolinyl radical, more preferably be selected from the group consisting of hydroxy, F, Cl, Br, methyl, ethyl, methoxy, ethoxy, keto. benzoyl, phenoxy, cydohexyl, -CF3, -CO-CH3, -CO-OCH3, -NRARB wherein RA, RB are each independently selected from the group consisting of H, a branched or unbranched C1-4-alkyl-radical, -CHrCHrOH and pheny!, and an unsubstituted phenyl radical. If any one of the above mentioned substitutents itself is at least monosubstituted, said substituents may preferably be selected from the group consisting of F, Cl, methyl and methoxy. If one or more of the residues R^-R48 and R1Da-R15a and Wa comprises an alkylene group, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, halogen, branched or unbranched C1-4-alkoxy, branched or unbranched C1- 4-alkyl, branched or unbranched C1-4-perfluoroalkoxy, branched or unbranched C1-4- perfluoroalkyl, amino, carboxy, amido, cyano, nitro, -SCNHz, -CO-C1-4alkyi, -SO-Ci-4-alkyl, -SO2-C1-4-alkyl, -NH-SO2-C1-4-alkyl, wherein C1-4-alkyl may be branched or unbranched, an unsubstituted or at least mono-substituted pheny] or naphthyl radical and an unsubstituted or at least mono-substituted furanyl-, thlenyl-, pyrroly!-, imidazolyl-, pyrazolyl-, pyridinyl-, pyrlmldinyl-, quinolinyl- and Isoqulnollnyl radical, more preferably be selected from the group consisting of hydroxy, F, Cl, Br, methyl, methoxy, ethoxy, CF3 and unsubstituted phenyl. If any one of the above mentioned substitutents Itself Is at least mono-substituted, said substituents may preferably be selected from the group consisting of F, Cl, methyl and methoxy. If one or more of the residues R^-R43 and R10a-R15a comprises a mono- or polycyclic ringsystem, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy/halogen, branched or unbranched C1-4-alkyl, branched or unbranched C1-4-alkoxy, branched or unbranched C1-4-perfluoroalkoxy, branched or unbranched C1-4-perfluorocarbonyl, branched or unbranched C1-4-perfluoroalkyl, amino, carboxy, amido, cyano, keto, nitro, -SO2NH2l -CO-C1-4-alkyl, -SO-C1-4-alkyl, - SO2-C1-4-alkyl, -NH-SO2-C1-4ralkyl, wherein C1-4-alkyl may be branched or unbranched, an unsubstituted or at least mono-substituted phenyl or naphthyl radical and unsubstituted or at least mono-substituted furanyl-, thienyl-, pyrrolyl-, imidazolyl-, pyrazolyh pyridinyl-, pyrimidinyl-, quinolinyl- and Isoquinolinyl, more preferably from the group consisting of hydroxy, F, Cl, Br, methyl, ethyl, methoxy, ethoxy, CF3, -(C=O)-CF3, keto, cyano and an unsubstituted phenyl radical. If any one of the above mentioned substitutents itself is at least mono-substituted, said substituents may preferably be selected from the group consisting of F, Ci, methyl and methoxy. If one or more of the residues R^-R48, R10a-R15a and R18a represents or comprises an aryl radical, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, halogen, branched or unbranched C1-4-alkoxy, branched or unbranched C1-4-alkyl, branched or unbranched C1-4-perfluoroalkoxy, unsubstituted or at least mono-substituted phenoxy, unsubstituted or at least mono-substituted benzoyl, cyclohexyl, branched or unbranched C1-4-perfluoroalkyl, NR^8 wherein R RB are each Independently selected from the group consisting of H, a branched or unbranched C1-4-alkyl-radical, -CH2-CH2-OH and phenyl, carboxy, amldo, cyano, -CH(OH)(phenyl), nitro, -SO2NH2, -CO-C1-4-alkyl, -CO-OC1-4-alkyl. -SO-C1-4-alkyl, SO2-C1-4-alkyl, -NH-SO2-C1-4-alkyl, wherein C1-4-alkyl may be branched or unbranched, an unsubstituted or at least mono-substituted phenyl or naphthyi radical and unsubstituted or at least mono-substituted furanyl-, thienyl-, pyrrolyK imidazolyi-, pyrazolyl-, pyridinyl-, pyrimidinyl-, quinolinyl- and isoquinolinyl radical, more preferably be selected from the group consisting of hydroxy, F, Cl, Br, methyl, ethyl, cyano, nitro, -CH(OH)(phenyl), methoxy, ethoxy, unsubstituted or at least monosubstituted benzoyl, unsubstituted or at least mono-substituted phenoxy, cyclohexyl, CF3, OCF3l-CO-CH3, -CO-OCH3, SO2-CH3, -NR^8 wherein RA, RB are each independently selected from the group consisting of H, a branched or unbranched C1- 4-alkyl-radical, -CH2-CH2-OH and phenyl, and an unsubstituted phenyl radical, if any of the above mentioned substitutents itself Is at least mono-substituted, said substituents may preferably be selected from the group consisting of F, Cl, Br, CF3, OCF3, methyl and methoxy. If one or more of the residues R^-R48 and R10a-R15a represents or comprises a heteroaryl radical, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, halogen, branched or unbranched C1-4-alkoxy, branched or unbranched C1-4-alkyl, branched or unbranched C1-4-perfluoroalkoxy, unsubstltuted or fat least mono-substituted phenoxy, unsubstituted or at least mono-substituted benzoyl, cyclohexyl, branched or unbranched C1-4-perfluoroalkyl, NRARB wherein RA, RB are each independently selected from the group consisting of H, a branched or unbranched C1-4-alkyl-radical, -CH2-CH2-OH and phenyl, carboxy, amido, cyano, -CH(OH)(phenyl), nitro, -SO2NH2, -CO-C1-4-alky!, -CO-OC1-4-alkyl, -SO-C1-4-alkyl, SOrC1-4alkyl, -NH-SOrC1-4-alkyi, wherein C1-4-alkyl may be branched or unbranched, an unsubstituted or at least mono-substituted phenyl or naphthyl radical and unsubstituted or at least mono-substituted furanyl-, thienyl-, pyrrolyl-, imidazolyh pyrazolyl-, pyridinyl-, pyrimidinyi-, quinolinyl- and isoquinolinyl radical, more preferably be selected from the group consisting of hydroxy, F, Cl, Br, methyl, ethyl, cyano, nitro, -CH(OH)(phenyl), methoxy, ethoxy, unsubstituted or at least monosubstituted benzoyl, unsubstituted or at least mono-substituted phenoxy, cyclohexyl, CF3, OCF3l-CO-CH3, -CO-OCHg, SO2-CH3, -NRARB wherein R*, RB are each independently selected from the group consisting of H, a branched or unbranched Cj. 4-alkyl-radical, -CH2-CH2-OH and phenyl, and an unsubstituted phenyl radical. If any of the above mentioned substitutents itself is at least mono-substituted, said substituents may preferably be selected from the group consisting of F, Cl, Br, CF3, OCFa, methyl and methoxy. If R13a and R14a form a heterbcyclic ring, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, halogen, branched or unbranched C1-4-aikoxy, branched or unbranched C1-4-alky!, branched or unbranched C1-4- perfluoroalkoxy, branched or unbranched C1-4-perfluoroalkyl, amino, carboxy, amido, cyano, nitro, -SO2NH2, -CO-C1-4-alkyl, -SO-C1-4-alkyl, -SO2-C1-4-aikyl, -NH-SO2-C1-4-alkyl, wherein C1-4-alkyl may be branched or unbranched, an unsubstituted or at least mono-substituted phenyl or naphthyl radical and an unsubstituted or at least mono-substituted furanyl-, thienyl-, pyrrolyi-, imidazoryf-, pyrazolyl-, pyridinyl-, pyrimidinyi-, quinolinyl- and Isoquinolinyl radical, more preferably be selected from the group consisting of hydroxy, F, Cl, Br, methoxy, ethoxy, methyl, CF3 and an unsubstltuted phenyl radical. If any of the above mentioned substitutents Itself is at least mono-substituted, said substituents may preferably be selected from the group consisting of F, Cl, methyl and methoxy. and R14a form a heterocyclic ring, which contains one or more further heteroatoms as ring members, unless defined otherwise, each of these heteroatoms may preferably be selected from the group consisting of N, O and S, more preferably from the group consisting of N and O. If one or more of the residues R1a-R18a and Wa represents or comprises a cycloaliphatic radical, which contains one or more heteroatoms as ring members, unless defined otherwise, each of these heteroatoms may preferably be selected from the group consisting of N, O, S and P, more preferably from the group consisting of N, O and S. If one or more of the residues R1a-R4a, R10a-R15a and Wa represents or comprises an heteroaryi radical, which contains one or more heteroatoms as ring members, unless defined otherwise, each of these heteroatoms may preferably be selected from the group consisting of N, O, S and P, more preferably from the group consisting of N, O andS. If Wa represents or comprises a cycloaliphatic radical, a heteroaryi radical, an aryl radical and/or a mono- or polycyclic ring system, which is substituted by one or more substituents, unless defined otherwise, each of these substrtuents may preferably be selected from the group consisting of hydroxy, nitro, carboxy, cyano, keto, halogen, C1-20-alkyl, partially fluorinated C1-4 alkyl, partially chlorinated CM alky], partially brominated CM alkyl, C1-5alkoxy, partially fluorinated C1-4 alkoxy, partially chlorinated C1-4alkoxy, partially brominated C1-4alkoxy, C1-4alkenyl, SO2-C1-4-alkyl, - (C=0)-C1-5-alkyl, -(C=O)-O-C1-5alkyl( -(C=O)CI, -S-C1-4-alkyl-, -(C=O)-H, -NH- (C=0)-NH-C1-5-alkyl, -(C=O)-C1-4-perfluoroalkyl, -NRARB, wherein RA and RB are Independently selected from the group consisting of H, C1-4-alkyl and phenyl, NH- (COJ-C1-5-alkyl, -Ci.5-alkylen-(C=0)-C1-5-alkyl, (1,3-Dihydro-1 -oxo-2H-lsoindol-2-yl), N-Phthalimidinyl-, (1,3-Dioxo-2-azaspiro[4,4]-non-2-yl, substituted or unsubstituted phenyl, -SCVphenyl, phenoxy, pyridinyl, pyridlnyloxy, pyrazolyl, pyrimidlnyl, pyrrolidinyl-, -SO2-pyrrolidinyl, morpholinyl, SO2-morpholinyl-, thiadiazolyl, oxadlazolyl, oxazolyl, thiazolyl, isoxapolyl, O-Chfe-thlazolyl,-, NH-phenyl, and -C1-4-Alkylen-NH-(C=O)-phenyl, more preferably from the group consisting of hydroxy, nitro, carboxy, cyano, ketd, F, Cl, Br, I, d-tralkyl, ChfcF, CHF2, CF3, CH2CI, CH2CI2l CI3, CH2Br, CHBr2, CBr3l OCF3 OCHF2l OCH2F, O-CHrCFg, vinyl, SO2-CH3, - TC=0)-CH3, -(C=0)-C2HS, -(C=OK)-CH3, -(C=O)-O-C2CH5, -(C=O)-C1, -S-CH3-, - (OOJ-H, -NH-(C=O)-NH-CH3, -(CsCO-CFs, dimethylamino, dlethylamino, di-npropylamlno, di-iso-propylamlno, di-n-butylamino, di-tert-butyamlno, NH-(C=O)-CH3, - CH2-(C=O)-CH3, -CH2-(C=O)-C2H5, (1,3-Dihydro-1-oxo-2H-lsoindol-2-yl), NPhthalimidinyl-, (1,3-Dioxo-2-azasplro[4,4]-non-2-yl, substituted or unsubstituted phenyl, -SO2-phenyl, phenoxy, pyrldinyl, pyridinyloxy, pyrazolyl, pyrimidinyl, pyrrolidinyl-, -SO2-pynrolidinyl, morpholinyl, SO2-morpholinyl-, thiadiazolyl, oxadiazolyl, oxazolyl, thiazolyl, isoxazolyl, O-CH2-thlazolyl,-, NH-phenyl, and -CH2- NH-(C=O)-phenyl. If any of the afore mentioned substituents itself is substituted by one or more substituents, said substituents may preferably be selected from the group consisting of halogen, nitro, cyano, hydroxy, -(CsOJ-C1-4alkyl, C1-4-alkyl, at least partially fluorinated C1-4alkyl, at least partially chlorinatedC1-4-alkyl, at least partially brominated C1-4-alkyl, -S-C1-4-alkyl, -C(=O)-O-d.5-alkyl, -(C=O)-CH2-F, -(C=0)-CH2- Cl, -{C=O)-CH2-Br, preferably from the group consisting of F, Cl, Br, CH2F, CHF2> CF3, CH2CI, CHCI2, CCI3, CH2Br, CHBr2, CBr3l nitro, cyano, hydroxy, -(C=O)-CH3I CH3) C2H5, -S-CH3, -C(=O)-O-CH3, -C(=0)-O-C2HSl -(C«O)-CH2-F, -(C=O)-CH2-CI and -(C=0)-CH2-Br. Preferred is the use of compounds of general formula (la), wherein R1a, R28, R38, R4 are each independently selected from the group consisting of H, F, Cl, Br, an unbranched or branched, saturated or unsaturated, optionally at least monosubstituted C1-6-aliphatlc radical, a saturated or unsaturated, optionally at least monosubstituted, optionally at least one heteroatom as ring member containing C1-4- . cycloaliphatic radical, which may be bonded via an optionally at least monosubstituted C1-6-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least monosubstituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C1-6-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem, a nitro group, a cyano group, -OR10a, -OC(=O)R11a, -SR12a, -SOR12a, -SO2R12a, -NHS02R12a, -S02NH2 and a -NR13aR14a moiety, preferably selected from the group consisting of H, F, Cl, Br, a saturated, branched or unbranched, optionally at least mono-substituted C1-3-aliphatic radical, a saturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing Cs- or C6- cycloaliphatlc radical, which may be bonded via an optionally at least mono-substituted Cr or C2-alkylene group, a nitro, cyano, -OR10a, - OC(=O)R11a, -SR12a and -NR13aR14a moiety, more preferably selected from the group consisting of H, F, Cl, CHa, CHaCHs, CF2CF3, cyclopentyl, cyclohexyl, a nitro group, a cyano group and -OR10a, and R5a-R18a and Wa have the meaning as defined above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or In form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates. Also preferred is the use of compounds of general formula (la), wherein R5a represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted (^aliphatic radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing CM-cycloaliphatic radical, preferably represents H or a branched or unbranched C1-3-alkyl radical, more preferably H, -CH3 or -CH2CH3, and R-R43, R6a-R18a and Wa have the meaning given above, optionally In form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates. Preference Is also given to the use of compounds of general formula (la), (Figure Removed) wherein fi88, R7a, R8a, R are each independently selected from the group consisting of Hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C1-6-aiiphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, a cyano group and a -COOR16a moiety, preferably selected from the group consisting of H, a branched or unbranched alkyl radical, a cyano group and a -COOR15" group, more preferably from the group consisting of H, -CH3, -CHaCHa and a cyano moiety, and R-R58, R-R188 and Wa have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or dlastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates. Also preferred Is the use of compounds of general formula (la), wherein Wa represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C10-20 aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C1-4 cycloaliphatic radical, which may be bonded via an optionally at least monosubstituted C1-6-alkyiene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least monosubstituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C1-6- alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem, a NR16aRl7a-moiety or a COR18a-moiety, preferably is selected from the group consisting of 1-NaphthyI-, 5-Dimethyfaminonapth- 1-yl, 2-NaphthyK 2-Acetamido-4-methy1-5-thiazolyl-, 2-Thieny!-, 8-Quinolinyl-t Phenyl-, PentafluorophenyK 2,4,5-Trichloro-phenyl-, 2,5-Dichloro-phenyl-, 2- NrtrophenyK 2,4-Dinitro-phenyK 3,5-Dichloro-2~hydroxy-phenyK 2,4,6-Trisisopropylpheny!-, 2-Mesityl-, 3-Nitro-phenyl-, 4-Bromo-phenyK 4-Fluoro-phenyl-, 4- Chlorophenyl-, 4-Chloro-3-nitro-pheny!-, 4-Iodo-phenyl-, N-Acetyl-suIfanilyt-, 4-Nitrophenyl-, 4-Methoxy-phenyI-, Benzoic-acid-4-y!-, 4-tert-Butyl-phenyl-, p-Tolyi-, TrifluoromethyK Trichloromethyl-, Isoprapyl-, Methyl-, Benzyl-, trans-styryl-, 2,2,2-TrtfluoroethyI-, Ethyl-, Hexadecyl-, 2-Chloroethyl-, n- Propyl-, 3-Chloro-propyl-, n-Buty!-, Methyl-benzoate-2-yl-, 2-Nitro-4-(trifluoromethyl)- phenyk, Pentamethyl-pheny!-, 2,3,5,6-TetramethyI-phenyl-, 3-(Trlfluoromethyl)- phenyl-, S.S-Bis-CTrifluoromethyl^phenyl-, Dichloromethyl-, Chloramethyl-, Dodecyl-, 1-OctyK 2,3,4-TricHloro-ph6nyl-1 2,5-Dimethoxy-phenyl-, o-Tolyl-, p-xyIyl-2-yl-, Benzoic-acid-3-yl-14-Chloro-3-(trifluoromathyl)-ph0nyl-, 4-Chloro-5-nitro-benzoic acld-3-yl-, 6-(p-toluidino)-naphth-2-yI-, 4-Methoxy-2,3,6-trimethylphenyI-, 3,4- Dlchlorophenyl-, 4,5-Dibromo-ttiloph6ne-2-yl-1 3-Chloro-4-fluoro-phenyl-, 4-Ethylphenyl-, 4-n-Propyi-phenyl-, 4-(1,1-Dimethylpropyl)-phenyl-, 4-lsopropyl-phenyl-, 4- Bromo-2,5-difluora-phenyl-, 2-Fluoro-phenyl-, 3-Fluoro-phenyl-, 4-(Triiluoromethoxy)- phenyl-, 4-{Trifluoromethyl)-phenyl-, 2,4-Difluoro-phenyl-, 2,4-Dlchloro-5-mettiylphenyl-, 4-Chloro-2,5-dimethyl-phenyl-, 5-Dlethylamlno-napth-2-yK BenzoyI chloride- 3-yl-, 2-Chloro-phenyl-, 1-Octadecyl-, 4-Bromo-2,5-dlchlortHhlophene-3-yl-, 2,5- Dichloro-thiophene-3-yl-, 5-Chloro-thtophene-2-yl-, 2-Methyl-5-nitro-phenyl-, 2- (Trifluoromethyl)-phenyl-, 3-Chloro-phenyl-, 3,5-Dichloro-phenyl-, 1-Decyl-, 3-Methylphenyl-, 2-Chloro-6-methyl-, 5-Bromo-2-methoxy-phenyl-, 3,4-Dimethoxy-phenyl-, 2- 3-Dichtoro-phenyl-, 2-Bromo-phenyl-, 3,5-Dichloro-4-(2-chloro-4-nltrophenoxy)- phenyl-, 2,3-Dichloro-thiophene-5-yl-, 3-Bromo-2-chloro-thiophene-5-yl-, 3-Bromo-5- chloro-thiophene-2-yl-, 2-(Benzoylaminomethyl>thlophene-5-yI-, 4-(PhenyJsulphonyl)- thiophene-2-yl-,2-Phenyl-sulphonyl-thlophene-5-yl-l3-Chtoro-2-methylphenyl-, 2-[1 -Methy1-5-(trifluoromethyl)pyrazol-3-ylHhIophene-5-yl-, 5-Pyrid-2-ylthiophene- 2-yl-, 2-Chlono-5-(trifluoromethyl)-phenyl-, 2,6-Dichtoro-phenyl-, 3-Bramophenyl-, 2-{TrifIuoromethoxy)-phenyl-, 4-Cyano-phenyl-, 2-Cyano-phenyl-, 4-n- Butoxy-phenyl-, 4-Acetamido-3-chloro-phenyl, 2,5-Dibromo-3,6-dlfIuoro-phenyl-, 5- Chtoro-1,3-dimethylpyrazole-4-yl-, 3,5-Dimethyl[soxazoIe-4-yl-, 2-(2,4- Dichlorophenoxy)-phenyl-, 4-(2-Chloro-6-nltro-phenoxy)-phenyl-, 4-(3-Chloro-2- cyano-phenoxy)-phenyl-, 2,4-Dlchtoro-phenyl-, 2,4-Dimethyl-1,3-thiazole-5-yl-, Methyl-methane-sulfonyl-, 2,5-Bis-(2,2,2-Trifliioroethoxy)-phenyl-, 2-Chloro-4- (trifluoromethyl)-phenyK 2-Chloro-4-fluoro-phenyK 5-Fluoro-2-methyl-phenyl-, 5- Chloro-2-methoxy-phenyl-, 2,4,6-Trichloro-phenyl-, 2-Hydroxy-benzoic acid-5-y!-, 5-. (Di-n-propylaminoJ-naphth-l-yl-, 6-Methoxy-m-tolyK 2,5-Difluoro-phenyK 2,4- Dimethoxy-phenyl-, 2,5-Dibromo-phenyl-, 3,4-Dibromo-phenyl-, 2,2,5,7,8- Pentamethyl-chroman-6-yf-, 2-Methoxy-benzoic-acid-5-yl-, 5-Chloro-4-nitrothlophene- 2-yl-, 2,1,3-Benzothiadiazole-4-y[-, 1-Methyl-imidazole-4-yK Benzofurazan-4-yl-, 2-(Methoxycarbonyl)-thlophene-3-yl-, 5-(lsoxazol-3-yl)- thiophene-2-yl-, 2,4,5-Trifluoro-phenyl-, Biphenyl-4-yl-, Vinyl-phenyl-4-yl-, 2-Nitrobenzyl-, 5-Dichloro-methyl-furan-2-yl-, S-Bromo-thtophene-yl-, 5-(4- ChIorobenzamidomethyl)-thiophene-2-yl-, 2>6-Difluoro-phenyl-,2,5-Dimethoxy-4- nitro-phenyl-, DibenzoIb.cil-furan-2-yl-, 2,3,4-Trifluoro-phenyl-, 3-Nitro-p-tolyl-, 4- ' Methoxy-2-nitro-phenyl-, 3,4-CWfluoro-phenyI-, 4-(Bromoethyl)-phenyl-p 3,5-Dlchloro- 4-hydroxy-phenyl-, 4-n-Amyl-phenyi-, S-Chloro-S-methylbenzoIbJ-thiophene-yl-, 3- Methoxy-4-(methoxycarbonyl)-thiophene-2-yl, 4-n-Butyl-phenyl-, 2-Chlora-4-cyanophenyl-, 5-[2-(Methylthio)-pyrimidin-yl-]Jtnl6phene-2-jrt-,3>5-Dinitro-4-methoxyphenyl-, 4-BroTno-2-(trifluoromethoxy)-phenyl-, 4-Chloro-2,1 .S-Benzoxadlazole-T-yl-, 2-(1-Naphthyl)-ethyl-I 3-Cyano-phenyl-, S-Chloro.l.S-Benzoxadiazole-yl-, 3- Ch!oro-4-methyl-phenyl-, 4-Bromo-2-ethyl-phenyl-, 2,4-Dichloro-6-methyl-phenyl-6- Chloro-imidazo(2,1 -B)-thiazoIe-5-yl-, 3-Methyl-benzo[b3-thiophene-2-yl-t 4-Methylsulphonyl- phenyl-, 2-Methyl-suIphonyl-phenyl-, 4-Bromo-2-methyl-phenyl-l 2,6- Dichloro-4-(trifluoromethyl)-phenyl-, 4-[[3-Chloro-5-(trifluoromethyl)-2-pyridlnyl]oxy]- phenyl-, 5-Chloro-naphth1yl-, 5-Chloro-naphth-2-yl-, O.IO-Dlbromoanthracene-yl-, lsoquinoline-5-yl-, 4-Methoxy-2,3,6-trimethyl-phenyl-, 4'-Nltro-blphenyl-4-yl-, [(4- Phenoxy)-phenyl-, (1 .S-Dihydro-l-oxo^H-isoindoW-yl-H-Phenyl-, 4-Acetyl-phenyl-, 5-(2-Methyl-1 .S-thiazoleyiy-thiophene-yl-, 5-(1 -Methyl-3-{trifluoromethyl)pyrazoJ- 5-yl-]-thiophene-2-yl-, 5-[5-Trif)uoromethyl>-lsoxazol-3-yr!-thiophene-2-yI-,2-lodophenyl-, p-Dodecyl-phenyl-, 4-[(3-Cyano-4-methoxy-2-pyridinyl)oxy]-phenyl-, 4-(Nphthalimidtnyl)- phenyl-, 1,2,3,4-Tetrahydro-2-(trlfluoroacetylHsoquinollne-7-yl-, 4- Bromo-2-fluoro-phenyl-, 2-Fluoro-5- (trrfluoromethyl)-phenyl-, 4-Fluoro-3Ktrifluorornethyl)-phenyl-, 2,4,6-Trifluoro-phenyl-, 3-(Trffluoromethoxy)-phenyl-, 1,2-D!methylimldazote-4-yl-, Ethyl-4-CarboxyIate-3-yl-, 212,4,617-Pentamethyldihydrobenzofuran-5-yl-13-Bromo-2-chloropyridine-5-yl-, 3- Methoxy-phenyl-,2-Me»ioxy-4-methyl-phenyl-f 2-Chloro-4-fluorobenzoic-acld-5-yK 4-Chloro-naphth-1 -yl-, 2,5-Dichloro-4-nitix-thiophene-3-yl-, 4-(4-Methoxy-phenoxy)- phenyl-,4-(4-Chloro-phenoxy)-phenyK4-(315-Dichloro-phenoxyphenyl-I 4-(3,4-Dich!oro-phenoxy)-phenyl-l4-(4-Fluoro-phenoxy}-phenyK4-(4-Methylphgnoxyj- phenyl-, 4-[4-(Trifluo rmethyl)-phenoxy-phenyh 4-[3,5-Bis-(trffluorom9thyl)- phenoxyj-phenyl-, 3-(2-Methoxy-phenoxy)-ph9nyl-, [3-(2-Chloro-phenoxy)-phenyl-, 3- (2-Methyl-phenoxy)-phenyl-, 4-[2-(Trlfluoromethyl)-phenoxy]-phenyl-l 3-Phenylphenyl-, 3-(4-Methoxy-phenyl)-phenyI-, S--Chloro-phenylJ-phenyl-, 3-(3,5-Dichlorophenyl)- phenyK S-fS^-Dichloro-phenylJ-phenyl-, 3-(4-Fluorophenyl)-phenyl-r 3-{4- Methylphenyl)-phenyl-, a-^TrifluoromethylJ-phenylJ-phenyl-.S-IS.S-Bis- (Trifluoromethyl)-phenyl]-ph9nyl-14-(4-Pyridyloxy>-phenyI)-l4-(2-Methoxy-phenoxy)- pheny!-, 4-(2-Chloro-phenoxy)-phenyl-, 4-(2-Methyl-phenoxy)-phenyI-, 4-(4-Methoxyphenoxy)- phenyl-, 4-(4-Chlorophenyl)-phenyl-l 4-(3,5-Dichlorophenyl)-phenyl-, 4-(3,4- Dichlorophenyl)-ph9nyl-, 4-(4-Ruorophenyl)-phenyl-, 4-(4-Methylphenyl)-phenyl-r 4- [4-(Trifluormethyl)-ph9nyl]-phenyf-, 4-[3,5-Bis-(Trffluoromethyl)-phenyl]-phenyl-, [3- (Trifluoromethyl)-phenyl]-methyl-, (4-Chloraphenyl)-methyl-> (3,5-Dichlorophenyl)- methyl-, (3,5-Dichlorophenyl)-methyl-, (^FluorophenylVmethyl-, 4- Methylphenylmethyl-, [4-(Trifluonomethyl)-phenyl]-methyl-, Cydopropyl-, 2-(2- Chlorophenyl-Phenylethyl-TrifluoromethylphenylJ-phenylethyl-, 5-[4- Cyano-1 -methyl-5-(methylthio)-1 H-pyrazol-3-yI-thlophene-2-yl-f 3-Cyano-2,4-bis- (2J2,2-TrifJuorothoxy)-phenyl-, 4-[(2-Chloro-1,3-Thiazol-5-yl)-methoxy]-ph8nyl-f 3- Nitro-phenylmethyl-, 4-FormyIphenyl-, 2-(1,3-Dioxo-1 .S-dihydro-lsoindol^-ylJ-ethyl-, [3,5-Bis-(Trifluoromethyl)-phenylJ-methyl-, (4-(2-Pyridyloxy)-phenyl)-, (4-(3- Pyridyloxy)-phenyl)-, 5-lodo-naphth-1-yl-f Ethyl-2,5-d!methyl-1-ph9nylpyrrole-4- carboxylate-3-yl-, Ethyl-2-methyl-1,5-diphenyl-1 H-pyrrole-3-carboxytate-4-yl-, Ethyl-5- (4-chlorophenyl)-2-methyl-3-furoat9-4-yl>Ethyl-5- 3-carboxylate-4-yl-, Ethyl-2f5-dimethyl-3-furoate-4-yl-, 3-Chlono-4-(1,3-dioxo-2- Azaspiro[4,4]non-2-yl)-phenyl-, S-Bromolfluoro-phenyl-, 5-Chloro-2,4- dlfiuorophenyl-, Coumarin-6-yl, 2-Methoxy-phenyl, (3-Phenoxy)-phenyl-, 3-(4- Methoxy-ph9noxy)-phenyl-, 3-(4-Chlorophenoxy)-phenyl-, 3-(3,5Dichlorophenoxy)- phenyl-, 3-(3,4-Dichlorophenoxy)-phenyI-, 3-(4Fluoraphenoxy)-phenyl-, 3-(4- Methylphenoxy)-phenyl-, 3-[4-(Trlfluoromethyl)-phenoxy]-phenyl-, 3-[3,5- {Trif!uoromethyi)-phenoxy]-phenyl-, 3-[2-(TrifluoromethyI)-phenoxy]-phenyl-r 2,2- Dlphenytethyl-, 4-PhenyI-5-{trifluorom6thyl)-thiophen9-3-yl-, MethyI-4-Ph9nyl-5- (Trifluoromethyl)-thlophene-2-carboxylate-3-yl-, Methyl-IS-trimethylpyrrole-S- Carboxylate-4-yl-, 4-Fluoro-naphth-1-yl-, 3,5-DifluorophenyK 3-Fluoro-4-methoxyphenyl-, 4-Chloro-215-difluorophenyl-f 2-Chloro-4,5-difluoro-phenyh 5-Fluoro-3- methylbenzo[b]-thiophene-2-yl-, Methyl-3-phenylpropionate-4-ylI Dihydrocinnamic Acid-4-yl-, Methyl-2,5-dimethyl-3-furoate-4-yK Methyl-2-furoate-5-yK Methyl-2- methyl-3-furoate-5-yl-, Methyl-1 -methyl-1 H-pyrnofe-2-Carboxy]ate-5-yK 2- 1-Thiadiazol-S-ylHhiophene-S-yl-, 1,3,5-TrimethyI-l H-pyrazole-4-yl-, 3-Chloro-5- fluoro-2-methylphenyl-, Pentafluoroethoxytetrafluoroethyl-, 5-(5-lsoxazy!)-thiophene- 2-yl-, 5-(5-lsoxazol-yI)-2-furyl-l S-Methyl-I.S-benzothiadiazoleyK BlphenyI-2-yl-, 2,3-Dlhydro-l ,4-benzodloxine-6-yl-, 4-Methyl-Naphth-1 -yK 5-Methyl-2- (Trifluormethyl)-3-Furyl-, a.S-Dihydrobenzofblfuran-S-yl-, 1 -Benzothiophene-3-yl-, 4-Methyl-3,4-dlhydro-2H-1,4-Benzoxazine-7-y[-, 5-Methyl-1-phenyl-1 H-pyrazole-4-yl-, 6-Morpholino-3-PyridinyK 4-(1H-Pyrazol-1-yl-phenyl-, 6-Phenoxy-3-Pyridyl-, 3,4- Dihydro-2H-1,5-benzodioxepine-7-yK 5-(1,3-Oxazol-5-yl)-2-thienyl-, 4-(1,3-Oxazol-5- ylj-phenyl-, 5-Methyl-4-[soxazolyl, 2,1,3-Benzothiadiazole-5-yl-, 3-Thienyl-, 2-Methylbenzyl-, 3-Chloro-benzyl-, 5-Acetamido-naphth-1-yI-, 3-Methyl-8-Quinollnyl-, 4- Chloro-2-nitrophenyl-, 6-Quinolinyl-, 1,3-Benzothiazole-6-yl-, 2-Morpholino-3-Pyridyl-, 2,5-DimethyI-3-thienyl-, 5-[5-(Chloromethyl)-1 f2,4-oxadiazol-3-yl]-2-thienyl-, Ethyl-3- [5-yl-2-thienyl-]1 oxadiazole-S-carboxylate-, 3-{5-Methyl-1,3,4-oxadiazol-2-yl)- phenyl-, 4-lsoprapoxyphenyl-, 2,4-Dibromophenyl-, 3-Cyano-4-fluorophenyl-, 2,5-Bis- (TrifluoromethylJ-phenyl, 2-Bromo-4-fluoraphenyl-, 4-Bromo-3-fluorophenyl-, 4- (Dlfluoromethoxy)-phenyl-, S-tDrfluoromethoxyJ-phenyl-, 5-Chloro-2-fluoro-phenyl-, 3-Chloro-2-fluorophenyl-, 2-Fluoro-4-methylphenyl-t 4 Nitro-3-(trifluoromethyl)- phenyl-, 3-Fluoro-4-methylphenyl-1 4-Fluoro-2-methylphenyl-, 4-Bromo-3- (tjfluoromethylphenyl-, 4-Bromo-2-{trifluorom8thyI)-phenyl-, 3-Bromo-5- (trifluoromethyl)-phenyl-, 2-Bromo-(trlfluoromethyl)-phenyl-I 2-Bromo-5- (trifluoromethyl)-phenyl-,2,4-Dichloro-5-fluorophenyl-, 4,5-Dlchloro-2-fluorophenyl-, 3,4,5-Trifluorophenyl-, 4-Chloro-2-fluorophenyl-, 2-Bromo-4,6-Difluorophenyl-, 2- Ethylphenyl-, 4-Bromo-2-chlorophenyl-, 4-Bromo-2,6-dichlorophenyl-1 2H3romo-4,6- dichlora-phenyl-, 4-Bromo-2,6-dimethylphenyl-, 3,5-Dimethylphenyl-, 4-Bromo-3- methylpheny!-, 2-Methoxy-4-nltrophenyl-, 2,2-Dimettiyl-6-Chromanyl-, Ethyl-3,5- dlmethyl-1 H-pyrrole-2-carboxylate-4-yI-, lmldazo[1 -Alpyridine-S-yl-, 3-(1,3-Oxazol- S-ylJ-phenyl-.Ethyl-S-^yO-phenyq^-methyl-S-furoate, Methyl-3-{yl)-4- methoxybenzoate, 1-PyrrolidinylphenyIsulfony!-, MethyI-5-yl-4-methyl-2-thiophene- carboxylate, Methy]-3-yl-4-(isopropyisulfonyl)-2-thiophene, 2-PyrldyI-, 3-Fluoro-4- 'trophenyl-, 7-ChIorochromone-3-y]-, 4'-Bromobiphenyl-4-yl-, Acetyl-biphenyl-yl-'-Bromo'-fluoro-biphenyM-yl-.a-Chbro^-propyl- Ureido)-phenyl-, S-BromoacetyO-phenyl-, 2-Bromo-3-{trifluorornethyl)-phenyl-f 1- Methyl-S-isatinyl--lsopropyl-benzolo-acid-S-yl-, 2-Chloro-3-thiophenecarboxylioacid- 5-yl-, 3-Pyridyl-, Cyclohexyfmethyl-, 2-Methoxy-5-(N-phthalimidiny!}-phenyK 1- Benzothiophene-2-yl-, MorphollnophenylsulfonyhS^-Methyl-pyrimidinyO-phenyl-, and 2-Cyano-5-methylphenyl-l and R1a-R18a have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding soivates. Furthermore, the use of compounds of general formula (la) is preferred, wherein (Figure Removed) represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C1-6-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C3-8-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C1-6-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C1-6-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem, preferably H, a linear or branched C1-4-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably H, -CH3 -C2H5 or phenyl, and R1a-R9a, R12a-R18a and Wa have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates. Moreover, the use of compounds of general formula (la) is preferred, wherein (Figure Removed) represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C1-6-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C3-8-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C1-6-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C1-6alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem, preferably H, a linear or branched Cr4-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably H, -Ofo, -CzHg or phenyl, and R1a-R10a, R12a-R18a and Wa have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates. Preference is also given to the use of compounds of general formula (la), (Figure Removed) wherein R12a represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C1-6-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C1-6-cycloallphatic radical, which may be bonded via an optionally at least monosubstituted C1-6-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least monosubstituted, 5- or 6- membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C1-6-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably represents H, a linear or branched C1-4-alkyf radical, a cyclohexyl radical or a phenyl radical, more preferably H, -CH3> -CaHs or phenyl, and R1a-R11a, R13a-R18a and Wa have the meaning given above, optionally in form of one of their stereofsomers, preferably enantlomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates. Also preferred is the use of compounds of general formula (la), wherein R13a and R14a are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least monosubstituted C1-6-aliphatic radical, a saturated or unsaturated, optionally at least monosubstituted, optionally at least one heteroatom as ring member containing C3-8- cycloaliphatic radical, which may be bonded via an optionally at least monosubstituted Ci-e-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least monosubstituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C1-6-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably are each independently selected from the group consisting of H, a linear or branched Cr4-alkyl radical, a cyclohexyl radical and a phenyl radical, more preferably are each independently selected from the group consisting of H, CH3, -C2He and phenyl, and R1a-R12a, R15a-R18a and Wa have the meaning given above, optionally In form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or In form of a mixture of at least two of Its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates. Furthermore, the use of compounds of general formula (Ja) is preferred, wherein R13a and R14a together with the bridging nitrogen atom form a saturated, unsaturated or aromatic, 5- or 6-membered hetenocyclic ring, which may be at least monosubstituted and/or contain at least one further heteroatom as a ring member, preferably form an unsubstituted plperldin or morpholine group, and R1a-R12a, R15a-R1fla and Wa have the meaning given above, optionally In form of one of their stereoisomers, preferably enantlomers or diastereomers, their racemates or in form of a mixture of at least two of Its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates. Also preferred are compounds of general formula (la), wherein R15a represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C1-6-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing GMT cycloaliphatlc radical or an optionally at least mono-substituted, 5- or 6- membered aryl- or heteroaryl radical, which may be bonded via an optionally at least monosubstituted C1-6-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably represents H, a linear or branched C1-4-alkyl radical, a cydohexyl radical or a phenyl radical, more preferably represents H, -CHs, -C2Hs or phenyl, and R1a-R14a, R16a - R1fla and Wa have the meaning gfven above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mfxing ratio, or corresponding salts thereof, or corresponding solvates. Also preferred is the use of compounds of general formula (la), wherein R16a represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C1-6aliphatic radical, preferably an unbranched or branched.-saturated, unsubstituted C1-3 alkyl radical, more preferably a methyl radical, and R1a-R15a, R17a, R1fla and W* have the meaning given above, optionally in form of one of their stereoisomers, preferably enantlomers or diastereomers, their racemates or In form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates. Also preferred is the use of compounds of general formula (la), wherein R17a represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C1-6 aliphatic radical, preferably an unbranched or branched, saturated, unsubstituted C1-3 alkyl radical, more preferably a methyl radical, and R1a-R16a, R18a and Wa have the meaning given above, optionally In form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates. Also preferred are compounds of general formula (la), wherein R18a represents a phenyl radical, which is optionally at least mono-substituted by a C1-6 aliphatic radical, more preferably a phenyl radical, which Is optionally at least monosubstituted by a methyl group and R1a-R17a and Wa have the meaning given above, optionally in form of one of their stereoisomersj preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates. Particularly preferred is the use of one or more benzoxazinone-derived sulfonamide compound of general-formula (la) selected from the list A given above. More particularly preferred Is the use of one or more benzoxazinone-derived sulfonamide compound of general formula (la) selected from the group consisting of 1 -[1 -{NaphthyM -sulfonyi)-piperidine-4-yl]-1,4-dihydro-benzo[d][1 .SJoxazin-one, 1-(1 -Phenyteulfbnyl-piperidine-4-yl]-1,4-dihydro-benzo[d][1,3]-oxazin-2-one, 1 -[1 -(5-Chloro-3-methyl-benzo[b]thiophenyl-2-sutfonyl)-piperid]ne-4-yl]-1,4-dihydrobenzo[ d][1,3]oxazin-2-one, 8-Methyl-1-[1 -naphthyl-1-sulfonyl)-plperidine-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2- one, 1 -[1 -(Quinoline-8-suIfonyl)-piperWin-yl]-1,4-dihydro-benzo[d][1 .SJoxazin^-one, 8-Methyl-1-[1 -(quinollne-8-sulfonyl)-plperidin-4-yl]-1,4-dlhydro-benzo|[dJ[1,3]oxazin-2- one, 1 -[1 -(5-Dlmethylamino-naphthyM -sulfonyl)-piperidine-4-yll-8-methyJ-1,4- dlhydrobenzo[d][1,3]oxazln-2-one, 104 1-[1 -(5-Dimethylamino-naphthyl-1 -sutfonyl)-ptperidine-4-yf]-1,4-dihydrobenzo[ d][1,3]oxazin-2-one, 1 -[1 -(2,3-Dichloro-phenylsulfonyl)-pjperidine-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2- one, 1-[1 -{2,3-Dichloro-phenylsulfonyl)-piperidln-4-yl]-8-methyl-1,4-dihydrobenzo[ dJ[1,3]oxazin-2-one, and corresponding salts thereof, or corresponding solvates thereof. The compounds of general formula (la), their stereoisomers, corresponding salts and corresponding solvates may be obtained analogously by the methods described above for compounds of general formula (I). In another aspect the present invention relates to benzoxazinone-derived sulfonamide compounds of general formula (Ib), (Figure Removed) R , R , R3, R4b are each independently selected from the group consisting of hydrogen, halogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatjc radical, which may be bonded via an optionally at least monosubstituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least monosubstituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with ah optionally at least mono-substituted mono- or polycyclic ringsystem, a nltro group, a cyano group, - ORlob, -OC(=0)R11b, -(C=0)-OR11b, -SR12b, -SOR12b, -SO2R12b, -NH-SO2R12b, - S02NH2 and a -NR13bR14b moiety, R5b represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, R^, R7b, R8b, R* are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, a cyano group and a -COOR16b moiety, Wb represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least monosubstituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least monosubstftuted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, a NR16bR17b-moiety or a COR18bmoiety, R10b represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted.alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, R11b represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryt- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, R12b represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least monosubstituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least monosubstituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, R13b and R14b each are independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least monosubstituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least monosubstituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or R13b and R14b together with the bridging nitrogen atom form a saturated, unsaturated or aromatic heterocyclic ring, which may be at least mono-substituted and/or contain at least one further heteroatom as a ring member, R15b represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least monosubstituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or pofycyclic ring-system, R1eb represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, R17b represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, R18b represents an optionally at least mono-subsituted aryl radical, optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a soivate, respectively. If one or more of the residues R1b-R17band Wb represents an aliphatic radical, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, halogen, branched or unbranched C1-4-alkoxy, branched or unbranched C1-4-perfluoroaIkoxy, branched or unbranched C1-4-perfluoroalkyi, amino, carboxy, amido, cyano, nitro, -S02NH2, -CO-C1-4-alkyl, -SO-C1-4-alkyl, -SCfc-C1-4-alkyl, -NH-SO2-C1-4-afkyl, wherein the C1-4alkyl may in each case be branched or unbranched, an unsubstituted or at least mono-substituted phenyl or naphthyl radical and an unsubstituted or at least mono-substituted furanyl-, thienyl-, pyrrolyl-, imldazolyl-, pyrazolyl-, pyridinyl-, pyrimidinyl-, quinolinyf- and isoquinolinyl radical, more preferably be selected from the group consisting of hydroxy, F, Cl, Br, methoxy, ethoxy, CF3 and an unsubstituted phenyl radical. If any one of the above mentioned substitutents itself is at least mono-substituted, said substituents may preferably be selected from the group consisting of F, Cl, methyl and methoxy. If one or more of the residues R1b-R1sb represents or comprises a cycloaliphatic radical, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, halogen, branched or unbranched C1-4-alkyl, branched or unbranched C1-4- alkoxy, branched or unbranched C1-4-perfluqroalkoxy, phenoxy, benzoyl, cyclohexyl, branched or unbranched C1-4-perfluoroalkyl, -NRARB wherein RA, RB are each independently selected from the group consisting of H, a branched or unbranched Ci- 4-aikyl-radical, -Chk-CI-b-OH and phenyl, carboxy, keto, amido, cyano, nitro, - S02NH2, -CO-C1-4-alky), -CO-OC1-4-alkyl, -SO-C1-4-alky!, -SO2-C1-4-alkyl, -NH-SOa-C!. 4-alkyl, wherein CC1-4-alkyl may in each case be branched or unbranched, unsubstituted or at least mono-substituted phenyl or naphthyl and unsubstituted or at least mono-substituted furanyl-, thienyl-, pyrrolyl-, Imldazolyl-, pyrazolyl-, pyridinyl-, pyrimidinyl-, quinolinyl- and isoquinolinyl radical, more preferably be selected from the group consisting of hydroxy, F, Cl, Br, methyl, ethyl, methoxy, ethoxy, keto, benzoyl, phenoxy, cyclohexyl, -CF3, -CO-CH3, -CO-OCH3l -NRARB wherein RA, RB are each independently selected from the group consisting of H, a branched or unbranched v-alkyl-radical, -CH2-CHrOH and phenyl, and an unsubstituted phenyl radical. If any one of the above mentioned substitutents itself is at least mono- substituted, said substftuents may preferably be selected from the group consisting of F, Cl, methyl and methoxy. If one or more of the residues R1b-R4b and R10b-R15b and Wb comprises an alkylene group, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, halogen, branched or unbranched C1-4-alkoxy, branched or unbranched d. 4-alkyl, branched or unbranched C1-4-perfluoroalkoxy, branched or unbranched perfluoroalkyl, ammo, carboxy, amido,. cyano, nitro, -SO2NH2, -CO-C1-4-aJkyl, 4-alkyl, -SO2-C1-4-alkyl, -NH-SO2-C1-4-alkyl, wherein C1-4-alkyl may be branched or ' unbranched, an unsubstituted or at least mono-substituted phenyi or naphthyl radical and an unsubstituted or at least mono-substituted furanyl-, thienyl-, pyrrolyl-, imidazolyl-, pyrazolyl-, pyridinyl-, pyrimldlnyl-, quinolinyl- and Isoquinolinyl radical, more preferably be selected from the group consisting of hydroxy, F, Cl, Br, methyl, methoxy, ethoxy, CF3 and unsubstituted phenyl. If any one of the above mentioned substitutents itself is at least mono-substituted, said substituents may preferably be selected from the group consisting of F, Cl, methyl and methoxy. If one or more of the residues R1b-R4b and R10b-R15b comprises a mono- or polycyclic ringsystem, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, halogen, branched or unbranched C1-4-alkyl, branched or unbranched C1-4-alkoxy, branched or unbranchedC1-4-perfluoroalkoxy, branched or unbranched C1-4-perfluorocarbonyl, branched or unbranched C1-4-perfluoroalkyl, amino, carboxy, amido, cyano, keto, nitro, -SO2NH2, -CO-C1-4-alkyl, -SO-C1-4-alkyl, - SOz-C1-4-alkyl, -NH-SO2-C1-4-aIkyl, wherein C1-4-alkyl may be branched or unbranched, an unsubstituted or at least mono-substituted phenyl or naphthyl radical and unsubstituted or at least mono-substituted furanyl-, thienyl-, pyrrolyl-, imidazolyl-, pyrazolyh pyridinyl-, pyrimidinyl-, quinolinyl- and isoquinollnyl, more preferably from the group consisting of hydroxy, F, Cl, Br, methyl, ethyl, methoxy, ethoxy, CFs, -(C=O)-CF3, keto, cyano and an unsubstituted phenyf radical. If any one of the above mentioned substitutents itself is at least mono-substituted, said substituents may preferably be selected from the group consisting of F, Cl, methyi and methoxy. no If one or more of the residues R1b-R4b, R10b-R15b and R1flb represents or comprises an aryl radical, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, halogen, branched or unbranched C1-4-aJkoxy, branched or unbranched C1-4-alkyl, branched or unbranched C1-4-perfluOroalkoxy, unsubstftuted or at least mono-substituted phenoxy, unsubstituted or at least mono-substituted benzoyi, cyclohexyl, branched or unbranched C1-4-perfluoroalkyl, NRARB wherein R. RB are each independently selected from the group consisting of H, a branched or unbranched C1-4-alkyl-radical, -CH2-CH2rOH and phenyl, carboxy, amldo, cyano, -CH(OH)(phenyl), nitro, -SO2NH2, -CO-C1-4-alkyl, -CO-O-C1-4-alkyl, -SO-C1-4-alkyl, - S02-C1-4-alkyl, -NH-SOr-C1-4-alkyl, wherein C1-4-alkyl may bd branched or unbranched, an unsubstituted or at least mono-substituted phenyl or naphthyl radical and unsubstituted or at least mono-substituted furanyl-, thlenyl-, pyrrolyK Imidazolyl-, pyrazolyl-, pyridinyl-, pyrimidinyl-, quinolinyl- and Isoquinolinyl radical, more preferably be selected from the group consisting of hydroxy, F, Cl, Br, methyl, ethyl, cyano, nitro, -CH(OHXphenyl), methoxy, ethoxy, unsubstituted or at least monosubstituted benzoyi, unsubstituted oral least mono-substituted phenoxy, cyclohexyl, CF3, OCF3)-CO-CH3, -CO-OCHg, SO2-CH3, -NR*RB wherein R*. RB are each independently selected from the group consisting of H, a branched or unbranched O|. 4-alkyl-radical, -CHe-CH2-OH and phenyl, and an unsubstituted phenyl radical. If any of the above mentioned substitutents Itself Is at least mono-substituted, said substituents may preferably be selected from the group consisting of F, Cl, Br, CF3, OCFs, methyl and methoxy. If one or more of the residues R^-R45 and R10b-R16b represents or comprises a heteroaryl radical, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, halogen, branched or unbranched C1-4-alkoxy, branched or unbranched C1-4-alkyl, branched or unbranched C1-4-perfluoroalkoxy, unsubstituted or at least mono-substituted phenoxy, unsubstituted or at feast mono-substituted benzoyi, cyclohexyl, branched or unbranched C1-4-perfluoroaikyl, NRARB wherein RA, RB are each Independently selected from the group consisting of H, a branched or unbranched C1-4-alkyl-radical, -CHrCHrOH and phenyl, carboxy, amido, cyano, -CH(OH)(phenyl), nitro, -SO2NH2, -CO-C1-4-alkyl, -CO-OCC1-4-alkyl, -SO-C1-4-alkyl, - SOz-C1-4-alkyI, -NH-SOa-C1-4-alkyl, wherein C1-4-alky! may be branched or unbranched, an unsubstituted or at (east mono-substituted phenyl or naphthyi radical and unsubstituted or at least mono-substituted furanyl-, thienyK pyrrolyl-, imidazolyl-, pyrazolyi-, pyridinyK pyrimidinyl-, quinolinyl- and isoquinoiinyl radical, more preferably be selected from the group consisting of hydroxy, F, Cl, Br, methyl, ethyl, cyano, nitro, -CH(OH)(phenyl), methoxy, ethoxy, unsubstituted or at least monosubstituted benzoyl, unsubstituted or at feast mono-substituted phenoxy, cyclohexyl, CF3, OCF3l-CO-CH3l -CO-OCH3, SO2-CH3) -NRARB wherein RA F RB are each Independently selected from the group consisting of H, a branched or unbranched Ci- 4-alkyl-radical, -CHs-CKk-OH and phenyl, and an unsubstituted phenyl radical. If any of the above mentioned substituted itself is at least mono-substituted, said substltuents may preferably be selected from the group consisting of F, Cl, Br, CF3, OCF3) methyl and methoxy. If R13b and R14b form a heterocyclic ring, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, halogen, branched or unbranched C1-4-alkoxy, branched or unbranched C1-4-alkyi, branched or unbranched C1-4- perfJuoroalkoxy, branched or unbranched C1-4-perfJuoroalkyl, amlno, carboxy, amido, cyano, nitro, -SO2NH2, -CO-C1-4-alkyl, -SO-C1-4-alkyl, -SOz-C1-4-alkyl, -NH-SO2-C1-4-alkyl, wherein C1-4-alkyl may be branched or unbranched, an unsubstituted or at least mono-substituted phenyl or naphthyi radical and an unsubstituted or at Jeast mono-substituted furanyl-, thienyl-, pyrrolyl-, Imidazolyl-, pyrazolyi-, pyridinyl-, pyrimidinyl-, quinolinyl- and isoquinoiinyl radical, more preferably be selected from the group consisting of hydroxy, F, Cl, Br, methoxy, ethoxy, methyl, CF3 and an unsubstituted phenyl radical. If any of the above mentioned substitutents itself Is at least mono-substituted, said substituents may preferably be selected from the group consisting of F, Cl, methyl and methoxy. If R13b and R14b form a heterocyclic ring, which contains one or more further heteroatoms as ring members, unless defined otherwise, each of these heteroatoms may preferably be selected from the group consisting of N, O and S, more preferably from the group consisting of N and O. If one or more of the residues R1b-R15b and Wb represents or comprises a cycloaliphatic radical, which contains one or more heteroatoms as ring members, unless defined otherwise, each of these heteroatoms may preferably be selected from the group consisting of N, O, S and P, more preferably from the group consisting of N, O and S. If one or more of the residues R^-R45, R10b-R15b and Wb represents or comprises an heteroaryl radical,.which contains one or more heteroatoms as ring members, unless defined otherwise, each of these heteroatoms may preferably be selected from the group consisting of N, O, S and P, more preferably from the group consisting of N, O andS. If Wb represents or comprises a cycloaliphatic radical, a heteroaryl radical, an aryl radical and/or a mono- or polycyclic ring system, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, nitro, carboxy, cyano, keto, halogen, C1-20-alkyl, partially fluorinated C1-4alky], partially chlorinated C1-4-=alkyl, partially brominated C1-4 alkyl, C1-4-alkoxy, partially fluorinated CM alkoxy, partially chlorinated d^ alkoxy, partially brominated C1-4 alkoxy, C2-6-alkenylI S02-C1-4-alkyl, (C-0)-C1-5-alkyl, -(C=O)-O-C1.5-alkyl, -(C=OJ-Cl, -S-C1-4-alkyl-F -(OOJ-H, -NH- (C=O)-NH-C1.5-alkyl> -{C=O)-C1-4perfluoroalkyl. -NR^8, wherein RA and RB are independently selected from the group consisting of H, C1-4-alkyl and phenyl, NH- (C=O)-C1-5-alkyl, -C1-5-alkylen-(C=O)-C1-5-alkyl, (1,3-Dihydro-1-oxo-2H-isoindol-2-yl), N-Phthalimidinyl-, (1,3-Dioxo-2-azaspiro[4,4]-non-2-yl, substituted or unsubstituted phenyl, -SO2-phenyl, phenoxy, pyridinyl, pyridinyloxy, pyrazolyl, pyrimldinyl, pyrrolidinyl-, -SO2-pyrrolidinyl, morpholinyl, SO2-morpholinyK thiadiazolyl, oxadiazolyl, oxazolyl, thlazolyl, isoxazolyl, O-CH2-thiazolyl,-, NH-phenyl, and -C1-4- Alkylen-NH-(C=O)-phenyl, more preferably from the group consisting of hydroxy, nitro, carboxy, cyano, keto, F, Cl, Br, I, C1-12-alky!, CH2F, CHF2, CF3, CH2CI, CH2CI2, CCI3, CH2Br, CHBr2l CBr3, OCF3, OCHF2| OCH2F, O-CH2-CF3, vinyl, SOrCH3, - (C=O)-CH3, -(C=O)-C2H5, -(C=0)-0-CH3, -(C=OJ-O-CaCHa, -(C=O)-C1, -S-CH3-, - (C=0)-H, -NH-(C=O)-NH-CH3, -(C=O)-CF3| dimethylamino, diethylamino, di-npropylamino, di-lso-propylamino, di-n-butylamino, di-tert-butyamino, NH-(C=O)-CH3, - CH2-(C=0)-CH3l -CH2-(C=O)-C2H5) (1,3-Dihydro-1-oxo-2H-iso]ndoi-2-yi), NPhthallmidinyl-, (1,3-Dioxo-2-azaspiro[4,4]-non-2-yl, substituted or unsubstituted phenyl, -SO2-phenyl, phenoxy, pyridlnyl, pyridinyloxy, pyrazolyl, pyrimidlnyl, pyrrolidinyl-, -SO2-pyrrolidinyl, morpholinyl, SO2-morpholinyl-, thiadiazolyl, oxadiazolyi, oxazolyl, thlazolyl, isoxazolyl, O-CH2-thiazolyl,-, NH-phenyl, and - NH-(C=O)-phenyl. If any of the afore mentioned substituents itself is substituted by one or more substftuents, said substituents may preferably be selected from the group consisting of halogen, nitro, cyano, hydroxy, -(C=O)-CM-alkyl, C-alkyl, at least partially fiuorinated C1-4-alkyl, at least partially chlorinated C1-4-alkyl, at least partially bromlnated C1-4-alkyl. -S-C1-4-alkyl. -C(=O)-O-C1-4-alkyl, -(C=O)-CH2-F, -{C=O)-CHr Cl, -{C=O)-CH2-Br, preferably from the group consisting of F, Cl, Br, CH2F, CHF2, CF3, CH2CI, CHCI2, CCI3, CH2Br, CHBr2, CBr3l nitro, cyano, hydroxy, -(C=O)-CH3, CH3j C2H5, -S-CH3| -C(=O)-O-CH3, -C(=O)-0-C2H5l -(C=CHrF, -(C=OJ-CHrCI and -(C=O)-CH2-Br. Preferred are compounds of general formula (Ib) given above, wherein R1b, R2b, R3b, R4b are each independently selected from the group consisting of H, F, Cl, Br, an unbranched or branched, saturated or unsaturated, optionally at least monosubstituted C1-6-aliphatic radical, a saturated or unsaturated, optionally at least monosubstituted, optionally at least one heteroatom as ring member containing C3.8- cycloaliphatic radical, which may be bonded via an optionally at least monosubstituted C1-8-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycycllc ring-system, an optionally at least monosubstituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C1-6-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or poiycyclic ringsystem, a nitro group, a cyano group, -OR10b, -OC(=O)R11b, -SR12b, -SOR12b, -SO2R12b, -NHSO2R12b, -SO2NH2 and a -NR13bR14b moiety, preferably selected from the group consisting of H, F, Cl, Br, a saturated, branched or unbranched, optionally at least mono-substituted C1-3-aliphatic radical, a saturated, optionally at least monosubstituted, optionally at least one heteroatom as ring member containing C5- or C6- cycloaliphatic radical, which may be bonded via an optionally at least mono- ubstituted Cr or C2-alkylene group, a nitra group, a cyano group, -OR10b, - OC(=0)R11b, -SR12b and -NR13bR14b moiety, more preferably selected from the group consisting of H, F, Cl, Br, -CH3, -CH2CH3, -CF3i -CF2CF3, cyclopentyl, cyclohexyl, nltro, cyano and -OR10b, and R5b-RT8b and Wb have the meaning given above, optionally in form of one of their steneoisomers, preferably enantfomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiorners or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates. Also preferred are compounds of general formula (Ib) given above, wherein Rsb represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted Ci-e-aliphatic radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C1-4cycloalfphatic radical, preferably represents H or a branched or unbranched C1-3-alkyl radical, more preferably H, -CHa or -CH2CH3, most preferably a hydrogen atom, and R^-R45, Reb-R18b and Wb have the meaning given above, optionally in form of one of their stereoisomers, preferably enanttomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiorners or diastereomers, In any mixing ratio, or corresponding salts thereof, or corresponding solvates. Also preferred are compounds of general formula (Ib) given above, wherein R6", R76, R8", R are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least monosubstituted C1-6-aliphatic radical, a saturated or unsaturated, optionally at least monosubstituted, optionally at least one heteroatom as ring member containing C3.8- cycloalibhatic radical, a cyano group and a -COOR15b moiety, preferably selected from the group consisting of H, a branched or unbranched C1-3-alkyl radical, a cyano group and a COOR15b group, more preferably from the group consisting of H, -CH3, - CH2CH3 and a cyano moiety, most preferably each of R66, R7", R8b and Reb represent a hydrogen atom, and R1b-R5b, R10b-R18b and Wb have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiorners or diastereomers, their racemates or in form of a mixture of at least two of fts stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates. Also preferred are compounds of general formula (Ib) given above, wherein Wb represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C^o aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing Ca cycloaljphatic radical, which may be bonded vfa an optionally at least monosubstituted Ci-6-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least monosubstituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted d-e- alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem, a NR16bR17b-moiety or a COR18b-molety, preferably Wb represents a linear or branched C1-20-alkyl radical, preferably an alkyl radical selected from the group consisting of methyl, ethyl, n-propyl, Iso-propyl, n-butyl, Iso-butyl, sec-butyl, tert-butyl and 1,1-dimethyl-propyl; a linear or branched C2.2o-alkenyl radical; preferably a vinyl radical; -CF3; -CHF2; -CH2F; -CCI3; -CHCI2; -CH2CI; -CH2-CF3; CHjrCH2-CI; -CH2-CH2-CH2-CI; -CHy-S(Ofe-CHs; a cyclopropyl radical; a cydobutyl radical; a cyclopentyl radical; a cyclohexyl radical; -CH2-cyclopropyl; -CH2-cyclobutyl; -CH2-cyclopentyl; -CH2-cyclohexyl; -N(CH3)2; -N(C2H5)z; -N(n-CH2-bHrCH3)2; phenyl; benzyl; naphthyl; -CH=CH-phenyl; -(CF2HCF2)-O-phenyl; -{CH2)-naphtyi; - (CH2)-(CH2)-naphthyl; anthracenyl; -(C=O)-phenyf; thiophenyl; benzo[b]thiophenyl; furanyl; 2-oxo-2H-chromenyl; dibenzofuranyl; 2,3-dihydrobenzofuranyI; chromanyl; 2,3-dihydro~benzo[1,4]dioxinyI; 3,4-dlhydro-2H-1,5-benzo-dioxepinyl; chromonyl; 1HImidazolyl; pyridinyl; pyrrolidine-2,5-dionyl; pyrrolyl; 1H-pyrazolyl; IH-pyrimfdlne-2,4- dionyl; qulnolinyl; isoquinolinyl; 1 H-Benzolmldazolyl; 1,4-dihydro-quinoxaline-2,3- dionyl; 1,2,3,4-tetrahydro-isoquinolinyl; 1,4-dihydro-ben2D[bJ[1,4]diazepine-2,4-dionyf; 3-dihydro-1-oxo-2H-isoindoly.l; phthalimldinyl; 2-(1 ,3-dioxo-1 ,3-dihydro-isoindol-2- yl)-ethyl; lmidazo[1 ,2-a]pyridine; isatinyl; thiazolyl; 1,3-thiazolyl; 1,2,4-thiadiazolyl; imidazo[2,1-b]thiazolyl; 1 ,3-benzothiazolyl; benzo[1 ,2,5]thladiazolyl; 2-oxo-2,3- dihydro-benzothiazolyi; 2,1,3-benzothiadiazolyl; imidazo[2,1-b]thiazolyl; isoxazolyl; benzo[1 ,2,5]oxadiazolyl; benzo[d]isoxazolyl; benzofurazanyl; 2HDXO-2,3-dihydno-benzooxazolyl; 3,4-dihydro-2H-benzo[1 ,4]oxazinyl; or 2,1 ,3- benzoxadiazolyl; whereby each of .these afore mentioned cyclic moieties may optionally be substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of methyl; ethyl; n-propyl; iso-propyl; n-butyl; iso-butyl; sec-butyl; tert-butyf; 1,1- dimethyl-propyl; n-pentyl; vinyl; cyclopropyl; cyclobutyl; cyclopentyl; cyclohexyl; morpholino; methoxy; ethoxy; n-propoxy; iso-propoxy; n-propoxy; F; Cl; Br; I; -CN; - OH; -CF3; -CF2H; -CH2F; -CCl3; -CCIH2; -CHCI2; -CHa-F; -CHrCI;-CHrBn -(OO)- CH2-Br; -OCF3; -O-CH2-CF3; -O-CHF2; -NO2; -NH2; -N(CH3)2; -N(C2H5)2; -N(n-CHr CH2-CH3)2; -Nfn-CHrCHrCHrCHg-NHC-CHs; -NH-phenyl; -(C=O)-CF3; - (C=O)-OH; =O (oxo); -(C=O)-H; -Sf-Ofc-Chb; -S(=0)risopropyl; -S(=O)2-phenyl; - S(=O)2-pyrrolidinyl; -S(=O)rmorpholino; -(CH2)-(CH2HC=O)-O-CH3; -NH-(C=O)-NHCH2- CH2-CH3; -(C=O)-CH3; -{C=O)-O-CH3; -(C=O)-O-C2H5; -(CH2>-NH-(C=O)- phenyl; -CH2-C(H)(phenyl)(phenyl); -0-CHrthiazolyl; 1,3-dioxo-2-azaspiro[4.4]non-2- yl; phenyl; phenoxy; isoxazolyl; 1,3-oxazolyl; 1 ,2,4-oxadiazolyl; 1,3,4-oxadiazolyl; pyridinyl; pyridinyloxy; pyrazolyl; pyrimldinyl and phthalimidinyl; and whereby each of the cyclic moieties of these afore mentioned substituents may optionally be substituted with 1 , 2, 3, 4 or 5 substituents that are independently selected from the group consisting of methyl; ethyl; n-propyl; iso-propyl; F; Cl; Br; CN; -CH2-F; -CHrCCHBr; -CF3 and -S-CH3, more preferably Wb represents an alkyl radical selected from the group consisting of methyl; ethyl; n-propyl; isopropyl; n-butyl; sec.butyl; iso-butyl and tert-butyl; vinyl (CH2=CH-); -N(CH3)2; 1- naphthyl; benzyl; 2-naphtyl; phenyl; 2-methyl-phenyl; 3-methyl-phenyl; 4-methylphenyl; 2-ethyl-phenyl; 3-ethy!-phenyl; 4-ethyl-phenyi; 2-n-propyl-phenyl; 3-n-propyl- 117 phenyl; 4-n-propyl-phenyl; 2-isopropyl-phenyl; 3-isopropyl-phenyl; 4-lsopropyl-phenyl; 2-n-butyl-phenyl; 3-n-butyl-phenyl; 4-n-butyl-phenyl; 2-Iso-butyl-phenyl; 3-iso-butylphenyl; 4-iso-butyI-phenyl; 2-tert-butyl-phenyl; 3-tert-butyl-phenyl; 4-tert-butyl-phenyl; 1,1-dimethylpropyl-phenyl; 2-cyclopentyl-phenyl; 3-cyclopentyl-phenyl; 4-cyclopentylphenyl 2-cyclohexyl-phenyl; 3-cyclohexyl-phenyI; 4-cyclohexyl-phenyl; 2-methoxyphenyt; 3-methoxy-phenyl; 4-methoxy-phenyl; 2-ethoxy-phenyl; 3-ethoxy-phenyl; 4- ethoxy-phenyl; 2-n-propoxy-phenyl; 3-n-propoxy-phenyl; 4-n-propoxy-phenyl; 2-isopropoxy- phenyl; 3-iso-pnopoxy-phenyl; 4-isopropoxy-phenyl;2-f!uoro-phenyl; 3-fluorophenyl; 4-fluoro-phenyl; 2-chIora-phenyl; a-chloro-phenyl; 4-chloro-phenyl; 2-bromophenyl; 3-bromo-phenyl; 4-bromo-phenyl; 2-trifluoromethyl-phenyl; 3-trifluoromethylphenyl; 4-trifluoromethyl-phenyl; 2-trifluoromethoxy-phenyl; 3-trifluoromethoxyphenyl; 4-trifluoromethoxy-phenyl; 2-cartx)xy-phenyl; 3-carboxy-phenyl; 4-carboxyphenyl; 2-acetyl-phenyl; 3-acetyl-phenyl; 4-acetyl-phenyl; 2-(C=O)-0-CH3-phenyl; 3- (C=O)-O-CH3-phenyl; 4-(C=O)-O-CH3-phenyl; 2-(CH2HCH2)-(C=O)-O-CH3; 3-(CH2)- (CH2)-(C=O)-O-CH3; 4-(CH2)-(CH2)-(C=O)-O-CH3; 2-cyano-phenyl; 3-cyano-phenyl; 4-cyano-phenyl; 2-nitro-phenyl; 3-nltro-phenyl; 4-nitro-phenyl; 4-(4-bromophenoxy>- phenyl; 2-methylsulfonyl-phenyl; 3-methylsulfonyl-phenyl; 4-methylsulfbnyl-phenyl; 2- phenyl-phenyl (biphenyl-2-yl); 3-phenyl-phenyl (biphenyl-3-yl); 4-phenyl-phenyl (biphenyl-4-yt); 2-phenoxy-phenyl; 3-phenoxy-phenyl; 4-phenoxy-phenyl; 2,4- dimethyl-phenyl; 3,4-dimethyl-phenyl; 2,4,6-trimethyl-phenyl; 2,3,5,6-tetramethylphenyl; pentamethyl-phenyl; 2,5-dimethoxy-phenyl; 3,4-dlmethoxy-phenyl; 2,3- dichloro-phenyl; 2,4-dichloro-phenyl; 2,5-dichloro-phenyl; 3,4-dichloro-phenyl; 3,5- dichloro-phenyl; 2,6-dlchloro-phenyl; 2,4-dlfluoro-phenyl; 3,4-drfluoro-phenyl; 2,5- difluoro-phenyl; 2,6-dlfluoro-phenyl; 3-ch!oro-2-fluoro-phenyl; 3-chloro-4-fluorophenyl; 5-chloro-2-fluoro-phenyl; 2,3,4-trichloro-phenyl; 2,4,5-trichloro-phenyl; 2,4,6- trichloro-phenyl; 2,4,5-trlfluoro-phenyl; 2,3,4-trlfluoro-phenyl-; 2-chloro-4,5-dlfluorophenyl; 2-bromo-4-fluoro-phenyl; 2-bromo-4,6-difluoro-phenyl; 4-chloro-2l5-difluorophenyl; 5-ch!oro-2,4-difluoro-phenyi; 4-bromo-2,5-difluoro-phenyl; 5-bromo-2,4- dlfluoro-phenyl; pentafluoro-phenyl; 2,4-dinitro-phenyl; 4-chloro-3-nttro-phenyl; 2- methyl-5-nItro-phenyl; 5-bromo-2-methoxy-phenyl; 3-chloro-2-methyl-phenyl; 4- bromo-3-methyl-phenyl; 4-chloro-2,5-dimethyI-phenyl; 4-fluoro-3-methyl-phenyI; 5- fluoro-2-methyl-phenyI;2-nitro-4-trifluoromethyl-phenyl;2-methoxy-4-methyl-phenyl; 3,5-dichloro-2-hydroxy-phenyl;3,5-dichloro-4-hydroxy-phenyl;5-chloro-2,4-difluorophenyl; 3-chIoro-4-(NHHC=O)-CH3-phenyl; 2-chloro-6-metnyI-phenyl; 2-chloro-5- trifluoromethyl-phenyl; 2-chloro-5-trifluoromethoxy-phenyl; 4-bromo-2- trifluoromethoxy-phenyl;4-bromo-2-trifluoromethyl-phenyl;4-bromo-3-trifluorometn phenyl; 3-carboxy-4-fluoro-phenyl; 3-carboxy-4-chloro-6-fluoro-phenyl; 4-methoxy- 2,3,6-trimethyl-phenyl-; or one of the following groups: (Figure Removed) whereby in each case X denotes the position by which the respective substituent Wb is bonded to the -SO2 group of formula (Ib), and R1b-R18b have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or In form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates. Also preferred are compounds of general formula (Ib) given above, wherein R10b represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C1-8-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C3-8-cycloaiiphatic radical, which may be bonded via an optionally at least mono-substituted C1-6-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substftuted C1-6-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem, preferably H, a linear or branched C1-4-alkyl radical, a cyclohexyf radical or a phenyf radical, more preferably H, -CH3l -C2HS or phenyl, and R1b-R* Rm-R18b and Wb have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates. Also preferred are compounds of general formula (Ib) given above, wherein R11b represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C1-6aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C3-8-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C1-6-alkytene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C1-6-alkyiene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem, preferably H, a linear or branched Ci-4-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably H, -CH3, -QH5 or phenyl, and R1b-R10b, R12b-R18b and Wb have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates. Also preferred are compounds of general formula (Ib) given above, wherein R12b represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C1-6-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatorn as ring member containing C1-6- cycloaliphatic radical, which may be bonded via an optionally at least monosubstituted C1-6-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least monosubstituted, 5- or 6- membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted. Curalkytene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably represents H, a linear or branched C1-4-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably H, -CH3, -C2H5 or phenyl, and R1b-R11b, R13b-R18b and Wb have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates. Also preferred are compounds of general formula (Ib) given above, wherein R13b and R14b are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least monosubstituted Ci-6-aiiphatic radical, a saturated or unsaturated, optionally at least monosubstituted, optionally at least one heteroatorn as ring member containing CMcycloaliphatic radical, which may be bonded via an optionally at least monosubstituted C1-6alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least monosubstituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C1-6-aikylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably are each independently selected from the group consisting of H, a linear or branched Ci-4-alkyl radical, cyclohexyl and a phenyl radical, more preferably are each independently selected from the group consisting of H, -CH3, -C2Hs and phenyl, and R1b-R12b, R^-R1* and Wb have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or In form of a mixture of at least two of its stereolsomers, preferably enantlomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates. Also preferred are compounds of general formula (Ib) given above, wherein R13b and R14b together with the bridging nitrogen atom form a saturated, unsaturated or aromatic, 5- or 6-membered heterocyclic ring, which may be at least monosubstituted end/or contain at least one further heteroatom as a ring member, preferably form an unsubstituted piperidin or morpholine group, and R1b-R12b, R15b- R1fib and Wb have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereolsomere, preferably enantlomers or dlastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates. Also preferred are compounds of general formula (Ib) given above, wherein R15b represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C1-6-allphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C3-8-cycloaliphatic radical or an optionally at least monosubstituted, 5- or 6- membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C1-6-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably represents H, a linear or branched C1-4-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably represents H, -CH3, -csHs or phenyl, and R1b- R14b, R1eb-R18b and Wb have the meaning given above, optionally in form of one of their stereoisomers, preferably enantlomers or diastereomers, their racemates or in form of a mixture of at least two of its stereolsomers, preferably enantiomers or dlastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates. Also preferred are compounds of general formula (Ib) given above, wherein R16b represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C1-6 aliphatic radical, preferably an unbranched or branched, saturated, unsubstituted C1-3alkyl radical, more preferably a methyl radical, and R1b- R156, R17b and R18b and Wb have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates. . . Also preferred are compounds of general formula (Ib) given above, wherein R17b represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C1-6 aliphatic radical, preferably an unbranched or branched, saturated, unsubstituted C1-3 alkyl radical, more preferably a methyl radical, and R1b- R16b, R18b and W* have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of Its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates. Also preferred are compounds of general formula (Ib) given above, wherein R18b represents a phenyl radical, which is optionally at least mono-substituted by a C1-6 aliphatic radical, more preferably a phenyl radical, which Is optionally at least monosubstituted by a methyl group, and R1b-R17b and Wb have the meaning given above, optionally In form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or In form of a mixture of at least two of its stereoisbmers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates. More preferred are compounds of general formula (Ib) given above, wherein R , R , R , R are each Independently selected from the group consisting of a hydrogen atom; a fluorine atom; a chlorine atom; a bromine atom; a methyl group and a methoxy group; R6" represents a hydrogen atom; R6 bR7bReb R9b each represents hydrogen atom; \Nb represents an alkyl radical selected from the group consisting of methyl; ethyl; n-propyl; isopropyl; n-butyl; sec.butyl; iso-butyl and tert-butyl; vinyl (CH2=CH-); -N(CH3)2; 1- naphthyl; benzyl; 2-naphtyl; phenyl; 2-methyl-phenyl; 3-methyl-phenyl; 4-methylphenyl; 2-ethyl-phenyI; 3-ethyl-phenyl; 4-ethyl-phenyl; 2-n-propyl-phenyl; 3-n-propylphenyl; 4-n-propyl-phenyl; 2-isopropyl-phenyl; 3-isopropyl-phenyl; 4-isopropyl-phenyl; 2-n-butyl-phenyl; 3-n-butyl-phenyl; 4-n-butyl-phenyl; 2-iso-butyl-phenyl; 3-iso-butylphenyl; 4-iso-butyl-phenyl; 2-tert-butyl-phenyl; 3-tert-butyl-phenyl; 4-tert-butyl-phenyl; 1,1-dimethylpropyl-phenyl; 2-cyclopentyl-phenyl; 3-cyclopentyl-phenyl; 4-cyclopentylphenyl 2-cyclohexyl-phenyl; 3-cyclohexyl-phenyl; 4-cyclohexyl-phenyl; 2-methoxyphenyl; 3-methoxy-phenyl; 4-methoxy-phenyi; 2-ethoxy-phenyl; 3-ethoxy-phenyl; 4- ethoxy-phenyl; 2-n-propoxy-phenyl; 3-n-propoxy-phenyl; 4-n-propoxy-phenyl; 2-isopropoxy- phenyl; 3-lso-propoxy-phenyl; 4-lsopropoxy-phenyl;2-fluoro-phenyl; 3-fluorophenyl; 4-fluoro-phenyl; 2-chloro-phenyl; 3-chloro-phenyl; 4-chloro-phenyl; 2-bromophenyl; 3-bromo-phenyl; 4-brorno-phenyl; 2-trifluoromethyl-phenyl; 3-trifluoromethylphenyl; 4-trifluoromethyl-phenyl; 2-trifluoromethoxy-phenyl; 3-trifluorbmethoxyphenyl; 4-trifluoromethoxy-phenyl; 2-carboxy-phenyl; 3-carboxy-phenyl; 4-carboxyphenyl; 2-acetyl-phenyl; 3-acetyl-phenyl; 4-acetyl-phenyl; 2-(C=O)-O-CH3-phenyl; 3- (C=0)-O-CH3-phenyl; 4-{C=O)-O-CH3-phenyl; 2-(CH2)-(CH2)-(C=O)-O-CH3; 3-(CH2)- (CH2)-(C-O)-0-CH3; 4-{CH2MCH2MC=O)-O-CH3; 2-cyano-phenyl; 3-cyano-phenyl; 4-cyano-phenyl; 2-nitro-phenyl; 3-nltro-phenyl; 4-nitro-phenyl; 4-{4-bromophenoxy)- phenyl; 2-methylsuIfonyl-phenyl; 3-methylsulfonyl-phenyl; 4-methylsulfonyl-phenyl; 2- phenyl-phenyl (biphenyl-2-y[); 3-phenyl-phenyl (biphenyl-3-yl); 4-phenyl-phenyl (biphenyf-4-yl); 2-phenoxy-phenyl; 3-phenoxy-phenyl; 4-phenoxy-phenyl; 2,4- dimethyl-phenyl; 3,4-dimethyl-phenyI; 2,4,6-trimethyl-phenyl; 2,3,5,6-tetramethylphenyl; pentamethyl-phenyl; 2,5-dlmethoxy-phenyl; 3,4-dimethoxy-phenyl; 2,3- dlchloro-phenyl; 2,4-dichlono-phenyl; 2,5-dichloro-phenyl; 3,4-dichloro-phenyl; 3,5- dlchlora-phenyl; 2,6-dichloro-phenyl; 2,4-difluoro-phenyl; 3,4-difluoro-phenyl; 2,5- dlfluoro-phenyl; 2,6-dffluono-phenyl; 3-chloro-2-fluoro-phenyl; 3-chIoro-4-fluorophenyl; 5-chloro-2-fluoro-phenyl; 2,3,4-trichloro-phenyI; 2,4,5-trichloro-phenyl; 2,4,6- trichloro-phenyl; 2,4,5-trifluoro-phenyl; 2,3,4-trffluono-phenyl-; 2-chloro-4,5-difluorophenyl; 2.-bromo-4-fluoro-phenyl; 2rbromo-4l6-djfluoro-phenyl; 4-chloro-215-difluoraphehyl; 5-chloro-2,4-difluoro-phenyl; 4-bromo-2,5-dlfluoro-phenyl; 5-bromo~2,4- difluoro-phenyl; pentafluoro-phenyl; 2,4-dinitro-phenyl; 4-chloro-3-nitro-phenyl; 2- methyl-5-nitro-phenyl; 5-bromo-2-methoxy-phenyl; 3-chloro-2-methyl-phenyl; 4- bromo-3-methyl-phenyl; 4-chloro-216-dimethyl-phenyl; 4-fluoro-3-methyl-phenyl; 5- fluoro-2-methyl-phenyl;2-nitro-4-trifluoromethyl-phenyl;2-methoxy-4-methyl-phenyl; S.S-dlchloro-hydroxy-phenyl; 3,5-dichloro-4-hydroxy-phenyl; S-chloroAdifluorophenyl; 3-chloro-4-(NH)-C=O)-CH3-ph9nyl; 2-chloro-6-methyl-phenyl; 2-chloro-5- trifluoromethyl-phenyl; 2-chloro-5-trifluoromethoxy-phenyl; 4-bromo-2- trifluoromethoxy-phenyl;4-bromo-2-tiifluoromethyl-phenyl;4-bromo-3-trifluoromethylphenyl; 3-carboxy-4-fluoro-phenyl; 3-caitoxy-4-chloro-6-fluoro-phenyl; 4-methoxy- 2,3,6-trimethyl-phenyl-; or one of the following groups: (Figure Removed) whereby in each case X denotes the position by which the respective substituent Wb is bonded to the -SO2 group of formula (Ib), optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a solvate, respectively. Most particularly preferred are compounds of general formula (Ib) selected from the following group given in list B: List B: Compound 1-n-(Naphthalene-2-sulfonyl)-p|per[dln-vn-1.4-dihvdr(-ben2o[diri.3loxazin-2-one -[1 -fToluene-4-sulfonyl)-plperidln-4-vi1-1.4-dihvdro-benzofd]f1.31oxazin-2-one 1 -(1-Phenylmethanesulfonyl-pipef[dln-4-vl)-l .4-dlhvdro-ben2ordin .31oxa2in-2-one 1 -n-Benzenesutfonyl-piperidin-4-yl)-6-chloro-1.4-d[nvdro-penzo[d][1.3]oxazln-2-one 6-Chloro-1 -F1 -{toluene-4-smfonvl-plperidin>4-vn-1.4-dihydro-benzo{d3[1,3]oxazln-2-one 6-Chloro-1 -41 -phenylmethanesutfonvl-plDerldlnwt-vD-i .4-dihydro-benzoMTII .31oxazln-2-one 6-Chloro-1-n-(rTaphthalen&.1-sulfonviy-plperidln-4-vlV1.4-dihvdro-benzo[d]f1.3Ioxa2ln-2H)ne 6-Chloro-1 -fi -(naphthalene-2-sulfonvl>-piperfdin-4-vlT-1.4-dihydro-benzo[din .31oxazln-2-one 9 6-Chloro-1 -[1 -(Shloro-a-methyl-benzoIbJthiophene-BulfonylJ-piperldln-ylhl ,4-dihydrobenzofdin ,3]oxazin-2-one 10 1 -[1 -qhiophene-2-6Ulfonvl)-piperidin-4-vn-1.4-dihvdro-benzo[dlf1.3]oxazln-2-one 11 -[1 -(4-Acetvl-benzenesulfony>-plperidln-4-yl1.4-dihydro-benzord][1.31oxazln-2-one 12 2-[4-(2-Qxo4H-benzofd1[1.3loxazln-1 -vll-plperidlne-1 -sulfonyn-benzonitrile 13 1-[1-(2.4-Dimethyl-benzeneBulfbnyl)-plperidln-4-yl]-1.4-dlhydro-berizordK1.3]oxazin-2-one 14 -[1-(4/lethoxy-benzenesulfonyt)-plperfdin-4-yll-1,4-dihydro-benzo[d][1t3]oxazin-2-one 1S 1-[1-(2-Naphthalen-1-yl-ethanesulfonyl)-plperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazln-2- one 16 8-Melhvl-1 -[1 -(thiophene-2-sulfbnyl)-plperidin-4-yl3-1,4-dihydro-benzo[cn[1,3]oxazin-2-one 17 one 1 -[1 -(4-Acetyl-benzenesuKbnyl)-piper!din-4-yl^B-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2- 18 2-[4-{8-Metriv)-2-oxo4H-benzo[d][1,3loxazln-1 -yl)-piperldlne-1 -sulfonyll-benzonltrile 19 1 -[1 -(2,4-Dlmethyl-benzenesulfonyl-p!peridin-4-yl]-8-methyl-1,4-dihydrotenzofdlH ,3]oxazin-2-one 1 -[1 -(4-Methoxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin- 20 2-one 21 J-Methyl-1-[1-(2-naphtha!en-1-yl-ethanesulfonyl)-piperidir>-4-y!]-1J4-dihydro- 3enzofd][1,3]oxazln-2-one 22 4-(8-Methyl-2-oxo-4H-benzo[d][1,3loxazln-1-vD-piperidine-1-sulfonlc acid dimethylamide 23 2-I4-(2-Oxo-4H-benzord][1,3]oxazln-1-yl)-plperidlne-1-8ulfonvll-benzolc add methyl ester 24 one -[1 -(3-Trifluoromethyl-benzenesulfonyt)-plperidin-4-yl]-1,4-dihydro-benzo[d][1,3Joxazin-2- 2-[4-(8-MBthyi-2-oxo-4H-benzo[d3[1,3]oxazln-1 -yl)-piperidine-1 -sulfonyl]-benzoic acid methyl 25 ester 26 5-Methyl-1 -[1-(3-trifluoromethyI-benzenesulfonyl)-piperidin-4-ylI-1,4-dihydro- )enzo[d][1,3]oxazin-2-one 27 one 1 -[1 -(4Acetyl-benzenesu]fonyl)-piperldin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2- 28 2^4-(6-pliloro-2-oxo-4H-benzo[d]C1.3]oxazin-1-yl)-plperidine-1--8ulfonyl]-benzonltrile 2-one OA 2-[4-(6-Chloro-2-oxo-4H-benzo[d][1,3]oxazln-1-yl)-piperidine-1-sulfonyl]-benzoic acid methyl 30 ester 31 6-Chloro-1 -[1 -2,4-dimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydrobenzo[ d][1.31oxazin-2K)ne 32 3-Chloro-1 -[1 -(3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dlhydrobenzo[ d1[1,3]oxazin-2-one ' 33 1 -[1 -(5-Chloro-3-methyl-benzo[b]thlophene-2-sulfonyl)-piperidin-4-y]]-8-methyl-1,4-dihydro- enzo[d][1,3]oxazin-2-one 34 1 -{1 -[4-(4-Bromo-phenoxy>-benzenesuIfonyl]-plperidin-4-yl}-8-methyt-1,4-dihydrobenzord][ 1,3]oxazin-2-one 35 one .[1 .(4-Fluoro-benzenesulfonyl)-p]peridin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazln-2- 36 eridin-4-vO-1,4-dlhydro-benzofdiri ,3Ioxazln-2- 38 one 39 Ch[oro-1-[1.(4-methanesutfonyl-benzenesuffonyI)-piPerid!iv4-yl]-1,4-dihydrobenzofdin .3]oxazln-2-QnB 40 41 one 42 1 -[1-(4-Methanesulfonyl-benzenesulfonyl)-piperidin-4-srt-methyl-1,4-dihydrobenzofcnn ,31oxazin-2-one 43 H1 -{Butane-1 -sulfonv-p!Derldlrv4-vll-8-methyl-1,4-dihvdrbenzo[d][1.3]oxazln-2-one 44 6-Chloro-1 -[1 -(2-nttro-benzenesulfonyi)-plperidir4-yl]-1,4-dJhydro-benz:oldS1,3]oxazIn-2- one 45 ona 6-Chloro1 -[1 -3-nltro-benzenesuIfonyl)-piperldin-4-ylJ-1,4-dihydrp-benzo[d][1,3]oxazIn-2- 46 14HBlphenyl-4-sutfonvll-Dlperldii4-vll-chlort.1.4lihydn-bergo[dl[1.3Ioxazin-2-one 47 one 8-MethyM -[1 -(2-nilro-benzenesulfbny!)-piperidin'4-yl]-1Ihydro-benzoldjfl ,3]oxazln-2- 48 one [-[1 Biphenyl8utfonyl)-plpertdln-4-yll-8-iTiethyl-1,4-dlhydro-benzoId][1.31oxazin-2-one 8-Methyl-1-lH4-nltro-beriMnesu[fonyl-p1perldin-4-yi]r1,4-dlhydro-ben2o[d][1,3]oxazin-2- one 51 one 6hloro-1-[14tro-beiizenesulfonylhpiper[dh-4]-1,4-dihydro-benzo[d][1I3loxazln-2- 52 I -(1-EthanesuHbnylp{per[dln-4l)-1.4-dihydro-ben2o[dlH .3]oxazin-2-one 53 l-[1-(Propane-1-sutfonylplperldln-4-ylH ,4-dlhydro-benzo[d][1.3]oxazln-2-one 54 I -[1 -(Propane-2-8utfonyl)-plperldln-4-ylH .4-dihydro-benzo[dl[1.3]oxazin-2-one 6-Chloro-1-(1 -ethan98utfonyl-.piperidln-4-yt)-1,4 57 58 6ihloro-1-t1-qulnoHn6-8-auifonvti-plperidlfHt-vlV1.4-dlhydro-benzoId][1.31oxa2in-2-one 59 -n-f4-Nltro-benzenesuKbnyl)-plperidlr>4-yiH .4-dlhvdro-benzordlH .31oxazln-2^ne 60 6ethvl-141QulnoBne-8-eutfonvl)-plperldln-4-vl1-1.4-dthvdrD-benzQ[d3[1.31oxazin-2-one 61 e-Methyl-ll-ta-naphthalen-l-yl-ethanesuffonyli-plperidlnyll-lihydro- nzoldiri .31oxazin-2-one 6-Methv-1-n-(toluene-4ufonvi-p[perldln-4-yn-1.4-dlhvdro-benzordTn .3Toxazln-2-one 83 one 64ethv1-1-IHnaphthalene-1tfonvlVplperidlnvl1.4-d!hvdro-benzo[dl[1.3loxazin-2-one 65a00n HbenzoLfd-lJHk J,3-Jloxazln -2-:o ne,4-dlhydro-benzo[d]t1,3]oxazin 67 one N 68 1 -f 1-Benzene8utfonv-pip9fid[n-4-vi-methvH ,4-dihvdro-benzordTri .31oxazln-2-one 1-11 4-Chlon3-n!tro-benzenesutfonyl)-piDeridirv4-y1]-6-methyl-1,4-dihydro- benzoin ,31oxaz}n-2-one HH5-Dlmethytem!no-naph 70 benzordin .31oxazln-2-one 1-[1-(4-Chloro^3-nHro-benzenesulfonyl)-plperidin-4-yll-8-methyl-1,4-dihydro- 71 benzotdiri ,3]oxazln-2-one ' 1.(4hloroltro-benzenesulfonyl)-plpBrfdlrv4-yl1,4Kiihydro-bBnzo[dK1,3]oxazin-2- one 6-Chloro-1-[1 .(4-ch[oro-3-nitro-benzenesulfbnyl)-piperidin-4-yll-1,4-dihydrobenzofdin .3toxazln-2-one 6-Chloro-1 -[1 -5-dimethylamlno-naphthalene-1 -sulfbnyl)-plperidin-4-yl]-1,4-dihydro- 74 benzoldl[1,31oxazln-2-one 136 75 1-[1-(4-Methoxy-2,3,6-triinethyl-benzenesulfonyl)-piperidin-4-yl1,4-dihydrobenzo[ d][1.3]oxazln-2-one 76 1 -[1 -(4-Methoxy-2,3,6-trimethyl-benzenesu[fonyl)-piperidin-4-y!]-8-methyl-1,4-dlhydrobenzo[ d][1,3]oxazin-2-one 77 B-Chloro-l-II^-methoxy-S.e-trlmethyl-benzenesulfonylJ-piperidinyll-l-dihydrobenzo[ d][1,3]oxazin-2one 78 1-[1-(4-Methoxy-2,3,6-trimethyl-benzenesuifonyl)-plperidln-4]-&-methyl-1,4-dihydrobenzoM[ 1,3]oxazin-2-onB 79 -[1 -2-Broma-benzenesutfonv»-DlDeridln-4-vl1-1,4-d!hydro-benzo[d]ri .31oxazin-2-one 80 1-[1 -2-Bromo-benzenesulfonyt)-piperldin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2- one 81 one 1-[1-(2-Bromo-benzenesulfonylH)iperidin-4-yl]-6-chIoro-1I4-dlhydro-benzo[d|[1>3]oxazin-2- „ 1 -[1-(2-Bromo-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[dl[1,3]oxazin-2- one 6-Chloro-1-[1-(2l3-dich[oro-benzenesutfbnyl)-piperidin-4-yl]-1l4-dihydro-benzo[d][1,3]oxazin- 2-one H1 -2,3-DichlorD-benzenesulfonyl)-piperidln-4-yl]-8-methyl-1,4-dlhydrobenzo[ d][1,31o3cazin-2-one 85 1-[1-(2.4.5-Trlchloro-benzenesulfonyl)-piperldin-4-ylM.4-dlhvdro-benzo[d]f1.31oxazin-2-one 86 8-Methyl-1-[1 -{2,4,5-trlchlofo-benzene8utfonyl)-plper1dln-4-yl]-1,4-dihydrobenzo[ d][1,3]oxazln-2-one 87 6-Chloro-1 -[1-(2(4,5-trichloro-benzenesulfonyl)-piperidln-4-yl]-1,4-dihydrobenzo[ d][1,3]oxazin-2-one 88 6-Methyl-1 -[1-(2,4.5-trlchloro-benzenesulfonyl)-piperidIn-4-y!]-1,4-dihydrobenzo[ d][1,3]oxazfn-2-one 89 1 -[1-{5-Bromo-2-methoxy-benzenBsulfonyl)-piperidin-4-yt]-1,4-dlhydro-benzo[d][1,3]oxazln- 2-one 1-[1 -(5-Bromo-2-methoxy-benzenesulfonyl}-piperidin-4-yl]-8-methyl-1,4-dlhydrobenzofdlfl ,3]oxazin-2-one 91 1 -[1 -(5-Bromo-2-methoxy-benzenesulfonyl)-piperidl5-4-yl]-6-chloro-1,4-dihydrobenzo[ d][1,3]oxazln-2-one ' 92 1 -[1 -{5-Bromo-2-methoxy-benzenesulfonyf)-plperidin-4-yI]-6-rne{hyl-1,4-dihydrobenzofd][ 1,3]oxazln-2-one 93 -M -(2,6-Pimethoxy-benzenesulfonyl)-plperldln-4-yll-1.4-dfhydro-benzo[dH1,3]oxazln-2-one 94 1-[1 -(2,6-Dimethoxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dlhydro- 3enzo[dI1,3]oxazin-2-one 6-CNoro-1 -[1-(2,5-dimethoxy-benzenesu{fonyl)-plperldln-4-yl3-1,4-dlhydrobenzofdlM ,3]oxazin-2-one 96 l-tl-S-Dimethoxy-benzenesutfonylJ-ptperidin-yll-e-methyl-l^-dlhydrobenzofdin ,3]oxazin-2-one 97 1-(1-Pentamethyfbenzenesulfonyl-plperldin-4-ylH.4-dlhydro-benzo[d][1.3]oxazin-2-one J-Methyl-1-(1-pentamethylbenzenesulfony(-plperidln-4-yl)-1,4-dihydro-benzo[d][1,33oxazin- 2-one 5-Chloro-1 -(1 -pentamethylbenzenesulfonyl-plperidln-4-yl)-1,4-dihydro-benzo[d][1,3]oxazln- 2-one 100 6-Methyl-1 -(1 "pentamethylbenzenesulfonyl-p!per!din-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin- 2-one 101 1 "{1"I2-(2-2.2-Trlfluoro-acetyl)-1 S-tetrahydro-lsoquinoline-y-sulfonyq-piperidlnylH ,4- dlhydro-benzo[d][1,3]oxazin-2-one 102 S-Methyl-HI-ptrifluoro-acetylJ-I.S-tetrahydro-isoquinofln-sulfonylj-pfperfdin- ,4-dihydro-benzo[d]n .31oxa2ln-2-one 103 6-Chloro-1 -{1 -I2-(2,2,2-lrifluoro-acetyl)-112,3I4-tetrahydro-i8oquinollne-7-sulfonyl]-plperidIn- 4-yl}-1,4-dlhydro-benzordlH ,3]oxazIn-2-one 104 6-Methyl-H1-t2-(2l2,2-trifluoro-acatyl)-1,2I3l4-tetrahydro-isoqulnollne-7-sulfonyl]-plperidin- ,4-dlhydro-benzord][1,3]oxazin-2-one 105 1 -[1 -{2-Methyl-5-nltro-benzenesu!fonyl)-plperidln-4-yIJ-1,4-dihydro-benzo[d][1,3]oxazin-2- one 106 J-Melhyi-1 -[1 -(2-methyl-5-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydrobenzoMH ,3]oxazin-2-one 137 107 e-Chloro-1 -[1 -(2-methyl-5-nitro-benzenesu!fonyl)-piperidin-4-yl]-1,4-dIhydrobenzo[ d]f1,3]oxazin-2-one 108 8-MethyM -[1 -(2-methyl-5-nitro-b6nzenesulfonyl)-p!peridin-4-yl]-1,4-dlhydrobenzo[ dl[1,31oxazin-2-one 1 no H1 -(4-Bromo-2,5-difluoro-benzenesulfonyl)-piperid!n-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin- 2-one 110 H1-(4-Bromo-2,5-difluoro-benzene3Ulfonyl)-p!peridin-4-yl]-8-methyl-1l4-dIhydrobenzofdlfl, 3]oxazln-2-one 111 1 -t1-(4-Bromo-2,5-difIuoro-benzene8ulfonyl)-plperidin-4-yl]-6-chlort>-1,4-dihydrobenzo[ d][1,3]oxazln-2-one 112 1 -[1 -(4-Bramo-2,5-dffiuoro-benzene3ulfonyI)-plperidin-4-yI]-e-methyl-1,4-dihydrobenzo[ d][1,3]oxazin-2-one 113 1 -I1-(4-Chloro-2l5-dimethyl-benz6nesu[fonyl)-pIperidln-4-yl]-l ,4-dihydrobenzo[ d][1,3]oxazJn-2-one 114 1 -[1 -(4-Chloro-2,5-dimethyl-benzenesulfonyl)-plper!d[n-4-yl]:8-methyl-1,4-dihydrobenzo[ d][1,3]bxazin-2-6ne 115 8-Chloro-1 -{1 -{4-chloro-2,5-dimethyl-benzenesuHbnyl)-plperldln-4-ylH ,4-dihydrobenzo[ d][1,3]oxazin-2-one 116 1 -[1 -(4-Ch loro-2,5-dimethyl-benze nesulfonyl)-piperld ln-4-yl]-6-methyl-1,4-dihydrobenzo[ d][1,3]oxazin-2-one 117 1 -[1 -(4-Methoxy-benzenesutfonyI)-piperldin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazln- 2-one 118 -[1-(4-lsopropyl-benzen9SUtfonyl>-piperidin-4-vn-1.4-dlhydro-benzo[d][1,3]oxazln-2-one -[1-(4-lsopropyl-benzenesulfonyl)-piperidin-4-yl]-8-nriethyl-1,4-dihydro-benzo[d][1,3]oxazin- 2-one 120 6-Chloro-1 -{1 -(4-isopropyl-benzenesuttbnyl)-piperidin-4-yl]-1,4-d!hydro-benzo[d][1,3]oxazin- 2-one 1-[1-(4-l8opropyl-45enzenesulfonyl)-plperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazfn- 2-one 22 1-[H3-Chloro-4-fluoro-benzenesutfonyl)-piperldin-4-yll-1,4-dihydro-benzo[d][1,3]oxazin-2- one 123 H[3benzenesu[tbnyl)-piperidin-4-yI]-8-mathyl-1,4-dihydrobenzo[ din .31oxazln-2-one 124 3-Chloro-1 -[1 -(3"Chloro-4-fluoro-benzenesulfonyl)-plperidin-4-yl]-1,4-dihydroi) enzo[d][1,3]oxazin-2-one . 125 1 -[1-3-Chloro-4-fluoro-benzene8ulfonyl-pipei1dln-4-yl]-6-methyl-1,4-dihydrot> anzo[dlf1,31oxazin-2-one 1 26 -1 ,4-dihydro-benzo[d][1 ,3]oxazin-2- 127 one 6-MethyM -[1 -(3-nitro-benzenesutfonyi)-piperld!n-4-y[]-1,4-dihydro-benzo[d][1,3]oxazin-2- 128 3-Methyl-1 -[1-(3-trifIuoromethyl-benzenesu[fonyl)-plperidin-4-yr|-1,4-dihydro- nzo[d}[1,3]oxazin-2-one HI -(4-Trifluoromethoxy-benzene3Ulfonyl)-piperidin-4-yl]-1,4-dihydro-benzoId][1,3Ioxazin-2- one 130 l-II-Nftrotrifluoromethyl-benzenesulfonylJ-plperldin-ylH.ihydro- 3enzo[d]I1,3]oxazin-2-one 131 H1 -(3-Fluoro-benzenesutfonyl)-plperldln-4-yl]-1,4-dlhvdtx-benzord][1,3]oxazln-2-one 132 1 -11 -(2.4-Dichloro-benzene8ulfony[)-plperidln-4-yO-1,4-dlhydro-benzo[d][1,3]oxazln-2-one 133 I -H -f 2,4.6-Trimethvl-benzenesulfonyl)H3lperidln-4-yl]-1,4-Jihydro-benzo[d][1,3]oxazln-2-pne 134 H1 -(2-Trifluoromethy)-benzenesulfonyl}-piperidin-4-y]]-1,4-dihydro-benzo[d][1,3]oxazEn-2- one 135 5-Methyl-1 -[1 -(4-trlfluoromethoxy-benzenesulfonyl)-plperidin-4-yl]-1,4-dihydro- enzo[d][1,3]oxazin-2-one 136 5-Methyl-1 -[1-2-nltro-4-tr]fluoromethy!-benzenesulfonyl)-ptperldin'4-yl]-1,4-dihydro- enzo[d][1,3]oxazln-2-one 11-(3-Fluoro-benzenesulfonyl)-plperldIn-4]-8-methyl-1,4-dlhydro-benzoId][1,3]oxazin-2- one 138 l-IIDichloro-benzenesulfonylJ-plpertdin-^yll-S-methyl-l^dihydro- enzo[d1[1,3]oxazln-2-one " 138 139 8-Methyl-1-[1 -(2,4,6-trimethyl-benzenesuffony1)-piperidin-4-yl]-1,4-dihydrobenzo[ d]pl ,3]oxazfn-2-one 140 8-MethyI-1-t1-(2-trtfluoromethy]-benzenesulfonyI)-piperidin-4-yl]-1 1,3]oxazJn-2-one 141 1 -ri-(4-Fluoro-benzene8Ulfonyl)-p|perldin-4-yl3-1.4-dihydro-benzordlf 1.37oxazin-2-one 142 1 -fi -f4-Bromo-benzenesu[fonvl)-p|peridfn-4-y|]-1.4-dlhydro-b9nzo[d1f1.31oxazin-2-one 143 1-[H3-NHro-benzenesulfonvi)-piperld[n^t-yl1-1.4-dihvdro-benzofdiri.3loxaz!n-2-one 144 1 -{1 -[4-(4-Bromo-phenoxy)-b9nzenesutfonyl]-pfperld!n-4-yl}-1,4-dihydro-benzo[d][1,3]oxazin- 2-one 14b 1-[1-(3-Methoxv-benzen9sulfonvlVDiDerldin-4-yll-1,4-dfhydro-benzo[d]ri,31oxazin-2-one 146 8-Methvl-1 -[1 -(toluene-4-su{fonyl-Dfperidin-4-yl]-1 ,4-dlhydro-benzordlM ,3Toxazin-2-one 1471-[1-(2-Nrtro-benzenesulfonvl)-plDer!din-4-yl]-1,4-dihvdro-benzord]ri.3]oxazln-2-one 148 1 -(1-BenzenesulfonyHjJperidin-4-yl)-8-methyl-1 ,4-dihvdro-benzoWin , 3]oxazln-2-one 149 1 -[1 -{3-Methoxy-benzenesulfonyl)-piperidin-4-ylJ-8-rnethyM ,4-dihydro-benzo[d]ri ,3]oxazln- 2-one 150 1-[1-(2,4-Dlmethy[-benzenesulfbnyl)-p]perldin-4-yl]-6-melhyl-1,4-l]hydrobenzofdin 3]oxazJn-2-one 151 1-{1-[4-(4-Bromo-phenoxy)-benzenesulfonyl]-piperidin-4-yl}-0-meBiyl-1,4-dihydrobenzo[ d][1,3]oxazln-2-one 152 6-Methyl-1-[1 -(thlophene-2-sulfonyi)-p|peridin-4-yl]-1.4-dihydro-benzordlM ,3joxazin-2-one 153 1 -[1 -(Toluene-3-8utfbnyl)-plperidin~4-yl]-1,4-dlhydro-benzo[dI[1,31oxazin-2-one -(1 -(5-Fluoro-2-methyl-benzene5Ulfonyl)-piperidin-4-ylJ-1,4-dihydro-benzofdHI ,3]oxazin-2- one 155 1-[1-(4-[8opropoxy-benzenesulfonyl-piper[dirv4-ylM.4-dihydrD-benzo[d][1.3]oxazln-2-one 156 1 -t1 -3-Ch[oro-benzene8ulfQnyl)-plperklin-4l]-1,4-3ihydro-benzo[d]ri. 31oxazln-2-one 157 1 -11 -(3.4-Dimethoxy-benzenesulfonyl)-ptperldin-4-^l-1.4-dlhydro-benzo[dTf1.3]oxazin-2-one 158 1-(1 -Pentafluorobenzenesulfonyl-plperldin-4-yn-1,4-dlhydro-benzoMn ,3]oxazin-2-one 159 8-Methyl-1-[1-ftoluene-3-sulfonv[)-p|p9ridln-4-1-1.4-dihvdro-benzofdlf1,31oxazin-2-one 160 oxarln-2-one 161 1 1 -(4-l8opropoxy-benzenesulfbnyl)-p)per!d!n-4-yl]-8-methyl-1,4-dihydro-benzo[dI|:i ,3] oxazfn-2-on9 1-[1-(3-Chloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2- one 1 f1 -{3.4-Dimethoxy-benzBnesuIfonyl}-plperidin-4-yl8-methyl-1,4-dihydro-benzo[dJ|;i ,3] oxazin-2-one .. 8-Methyl-1-(1 -pentafluorobenzenesulfbnyl-pIperidln-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2- 104 one . 165 -Methvl-1-[1-(toluene-3sulfonyl)-plperld[n-4-vn-1.4-dlhvdro-benzord1f1.31oxazln-2-one 166 1.[1.(5.Fluoro-2-methyl-benzenesulfonyl)-plp9rldin-4-yl]-fl-methy!-1l4-dihydro- )enzo[dlf1,31oxazin-2-one 167 1 .[1 -{4-lsopropoxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dlhydro- enzo[d][1,3]oxazin-2-one A oo 1 -[1 -(3-Chloro-benzenesulfonyl)-plperidln-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2- 168 one . 169 1 -[1-(3,4-Dimethoxy-benzenesu{fonyl-piperldin-4-yrHB-methyl-1,4-dihydro- 3enzo[dK1,3]oxazln-2-one e-Methyl-1 -(1 -pentafluorobenzenesulfonyl-p[perldln-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2- one 171 6-MethyM--[1-(4-trlfluoromethoxy-benzenesulfonyl)-plperidin-4-yl]-1,4-dihydro- enzo[d][1.31oxazln-2-one 6-Melhyl-1 -[1 -{2-nitro-4-trifluoromethyl4)enzenesulfonyl)-piperldin-4-yl]-1,4-dihydrobenzofcflU ,31oxazin-2-one A -70 1 -I1 -{3-Fluoro-benzenesulfbny])-plperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxaz!n-2- 173 one 174 1 -[1 -(2,4-Dichloro-benzenesulfonyl)-plperldlrH-yl]-6-methyl-1,4-dihydrobenzo[ d][1,31oxazin-2-one 175 6-MethyM -{1e-trimethyl-benzenesulfonytj-plperidinyll-l ,4-dihydrojenzoCdlh ,31oxazln-2-one 176 6-Methvl-1-f1-f2-{rifluoromethyl-b9nzene8Utfonyl)-plperldln-4-vl]-1.4-dlhydro- benzo[d][1,3]oxazin-2-one 177 l-fHS-Melhoxy-benzenesulfonylpiperldinyq-e-methyl-^ihydro-benzoIdll.SJoxazin- 2-one e-Methyl-1 -[1 -(2-nrtrc-benzenesuffonyl)-piperidin-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2- one 179 -n-(4-Acetyi-benzenesulfonyl)-piperidin-4-y&-methyl-1,4-dihydro-benzo[d][1,3joxazin-2- one 180 1-[1-(4-MethanesuHbnyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dfhydrobenzo[ d1M .31oxazin-2-one 181 6-Methyl-1 -(1-phenylmethanesulfonvl-plper[dln-4)-1.4-dihydro-benzo[d][1,3]oxazln-2-one 182 2-[4-(6-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperid[ne-1 -sulfonyQbenzoic acid methy ester 183 6-Methyl-1 -[1 -{2-oxo-2H-chromene-6-sulfonyl)-piperidin-4-yl]-1,4-dihydrobenzo[ d][1,3]oxazln-2-one 184 one e-Chloro-1 -[1 K4-fiuorp-benzenesulfbnyl)-ptp.eridin-4-yl]-1,4-dlhydro7benzQ[d][1 . 185 6-Chlort-1 -{1 -{3,5-dichloro-benzene8ulfonyl)-piperldln-4-yl]-1,4-dlhydro-benzo[d][1,3]oxazin- 2-one 186 1 -{1 -[4-(4-Bromo-phenoxy)-benzenesulfonyl]-plperidin-4-yl}-6-chlora-1,4-dihydrobenzo[ d][1,3loxazin-2-one 187 e-Chlpro-l -f 1 -(thIophene-2-sulfon vl)-plperid!n-4-ylH .4-dihydro-benzo[d]f1.3]oxazin-2-one 188 6-Chloro-1 -{3-methoxy-benzenesulfonyl)-plperid[n-4-yl]-1,4-dIhydro-benzo[d][1,31oxazin- 2-one 189 6-Chloro-1 -{1 -{2-oxo-2H-chromene-6-sulfbnylHjiperidin-4-yI]-1,4-dihydrobenzo[ d][1,31oxazin-2-one 190 6-Chloro-1 -H -(toluene-3-sulfonyl)-plperidlrHl-vlM Adihydro-benzoWiri ,3]oxazin-2-one 191 B-Chloro-1 -{1 5-fluoro-2-methyl-benzenesulfbnyl)-piperidin-4-yl]-1,4-dihydrobehzotd][ 1,3Ioxazin-2-one 192 6-Chloro-1 -[1 -(4-isopropoxy-benzenesutfonyl)-piperldin-4-yI]-1,4-dihydro-benzo[d][1,3] oxazin-2-one 6-Chlora-1 -[1 -(3-chloro-benzene8Ulfonyl)-piperidin-4-yt]-1,4-dihydro-benzo[d][1,3]oxazin-2- one 194 KJhloro-1 -[1 -(S-dimethoxy-benzenesulfonylJ-piperidin-yQ-l ,4-dihydrobenzold][ 1,3]oxazIn-2-one 4Qc B-Chloro-1-(1-pentafluorobenzenesulfony[-plperldin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2- 100 one 196 3-Chloro-1-[1-(4-trKluoromethoxy-benzenesulfonyl)-plperldin-4-yl]-1p4-dihydro- 3enzo[d][1,3]oxazln-2-one . 197 3hloro-1-[1-(2-nltro-4-tnfluoromethyl-benzenesulfonyl)-piperIdin-4-yl]-1t4-dihydrobenzofdl[ 1.31oxazin-2-one 6-Chloro-1 -[1 -(3-fluoro-benzenesuIfonyl)-piperldln-4-yl]-1.4-dIhydro-benzo[d][1,3]oxazJn-2- 198 one 199 5-Chloro-1 -[1 -(2,4-dichloro-benzene8Ulfonyl)-plperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin- 2-one 200 6-Chloro-1 -[1 -{2,4t6-trimethyl-benzene8ulfonyl)-piperidin-4-ylJ-1,4-dihydro- )enzo[d][1,3]oxazin-2-one 201 i-Chloro-1-[1-{2-trlfluoromethy]-benzenesulfonyl)-piperidln-4-yI]-1,4-dihydrobenzp[ d][1,3]oxazln-2-one 202 1-[1-(2-Oxo-2H-chromene-6-3utfonyl)-plperldln-4-vll-1.4-dlhvdro-benzordlf1.3loxazin-2-one 203 I -11 -(3,5-Dichloro-benzenesufonyl)-plperidIn-4-yll-1,4-dlhydro-benzo[d][1,31oxazin-2-one 204 1-f1-f2.5-Dichloro-benzenesulfonv-p|perldln-4-vn-1.4-dihydro'benzo[d1[1.3]oxazln-2-one 205 -(5-Brom°-6-ch'oro-pyridine-3-sulfbnyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazln- 2-one 206 1 -M -(4-Chlofo-benzenesatfonyl)-plperldln-4-yll-1.4-dihydro-benzo[diri.31oxaz1n-2-one 207 1 -[1 -(2,6-Dichloro-benzenesulfony»)-pIperldin-4-yn-1,4-dlhydro-benzordlf 1.31oxazln-2-one 208 J-Methyl-1 -[1 -(2-oxo-2H-chromene-6-sulfonyl)-piperidin-4-yl]-1,4-dihydrobenzoFdiri, 31oxaz!n-2-one 209 1-[1-(3.5-Dichloro-benzenesuIfonyI)-piperidin-4-yf|-8-methyl-1l4-dihydrobenzo[ d][1,3]oxazin-2-one 210 1 -f 1 -(2.5-Dlch[oro-benzenesulfony!)-plperfdln-4-vl1-8-methyl-1,4-dlhvdro- 140 benzoldlfl ,3]oxazln-2-one 9-11 1 benzoMFI ,3]oxazin-2-one 212 one -(4-Chloro-benzenesulfonyl)-piperidin^-yl]-8-mBthyl-1,4-dihydro-benzo[d][1,3]oxazin-2- 213 1-I12,e-DidiJoro-benzenesulfonyi)-piperid[n-4-yl]-8H7i6thyl-1,4-dihydn>- benzo[d][1.3]oxazin-2-one 214 i-[1 -(Biphenvl-4-sutfon^]-ploerldin-4-vlVl .4-dlhydro-benzord]n .31oxazln-2-one 215 6-Chloro-11-(2,5xJiforo-benzenesulfony[)-piperidlny!Hf4H3lhydro-benzoIeO[1,3]oxazin- 2-one 216 1 -11 -5-Bromo-6-chlQro-pyrkiine-3-sulfonyl)-p!peridin-4-yl]-6-chloro-1,4-dihydrobenzotctfll. 3]oxazln-2-on& 217 one e-Chloro-1-[1 -(4-ch!oro-benzenesulfonyl)-plperldln-4-ylH f4-dihydro-benzo[d][1,3]oxaz!n-2- 218 6hloro-1-[1-(2te-dlchlpro-benzenesulfbny[)-plperldirv4-yl]-1,4-dlhydro-benzo[d][1l3]oxazin- 2-one 219 1 -f1 - Biphenvl-4-sulfonvlVp]peridln-4-vn-6-mefliy!-1.4-dlhydro-benzoId][1.3]oxazln-2-one 220 2-r4-(6-Methyl-2-oxo-4H-benzordiri .31oxazin~1 wD-Plperldlne-1-sutfonvq-benzonttrlle 221 1-[1-(2,5-DIchloro-benzenesulfonyl)-p]perldln-4-yt]-6-/nelhyi-1,4-dihydrobenzoldin ,33oxazln~2-one 222 1-[1^6^omo^-chloro-pyridlne-3-®uifonyl)-piperidin-4-yl]-6-rnethyl-1,4-dfhydrobenzoldlll ,3]oxazln-2-one 1'P -{4-Chloro-benzenesulfonyl)-plperldin-4-yl]-6-mettiyM ,4- one 224 1-[1-2,e-DicWafo-benzenesulfonyi}-pIperIdin-4-yt]-6-methyl-1,4-dlhydrobenzo[ dl[1,3]oxazin-2-one 225 1-[1 -{S.S-Dlchloro-benzenesuIfonylJ-piperldfri-yll-e-methyl-l ,4-dlhydrobenzoCdlH ,3loxazin-2-one 226 6-Methyl-1 -11 -(1 -methyl-1 H-lmldazola-4-sulfonyl)-plperldIn-4-yrj-1,4-dlhydrobenzo[ dHl ,3loxazin-2-one 227 1-[H5-&x>mo-2,4ifIuoro-benzeneBUlfonylHlparldin-4-yll-8-rnethyl-1,4-dlhydrobenzo[ cTlI1,31oxazln-2-onfl -[1 -(4-Methanesulfonyl-benzenesulfonyI)-plperldin-4-yt]-1,4-dihydro-benzo[dl[1,33oxaztn-2- 228 one 228 one [1 -(5-Bromo-2,4-dinuorQ-benzene8ulfony1-plperid!n-4-yll"1,4-dlhydro-benzo[dl[1,3]oxazln- 230 2-one 231 H1-(8)h!oro-lmldazot2J-b]ihiazole-6-sutfonylHiper]dln-4-yl]-1,4-dlhydrobenzo[ dl[1.3loxazln-2-one 232 1-n-(4-Ethvl-benzenesulfony)Vp|peridlrv4-vn-1.4-dlhvdro-benzotdH1.3loxaz]n-2-one 233 1-ri-(Benzotbfthtophene-3utfonviVplperldlrv4-vl1-1.4-llhydro-benzo(dlt1,3toxazin-2-one 1-[1-(6-Chloro-!midazot2,1-b]thiazole-5-8UlfonyI)-p1peridin-4-yl]-8-melhyl-1,4-dihydrobenzo[ dl[1,3]oxazln-2-one 1-[1-(4-Ethy)-benzenesulfonyl)-plperidin-4-yll-8-methyl-1,4-dihydro-benzo[d][1,3]oxazln-2- 235 one y. 236 benzoldin .3]oxazln-2-one 237 benzotd][1.3]oxazln-2-one 6-Chloro-1-[1-{4-«thyl-benzene8ulfonyl)-piperidin-4^!l-1T4- 238 one a 1-[1 -{BenzoIb]th1ophene-3-su!fony1)-plperid1rK4-yl]-6-chloro-1,4-dihydro-benzoldlII ,3Joxazin- 239 2-one 1-[1 -6-Chloro-imidazo[2,1 -b]thiazo!e-5-sulfonyl)-plperldin-4-yl3-6-m&thyl-1,4-dihydrobenzo[ d][1.31oxazin-2-one 241 one 242 1-[1 -(Benzo[blthiophene-3-BuIfony!)-pIperidln-4-yl]-6-methy!-1,4-dihydrobenzo[ d][1.31oxazin-2-one 243 1 -[1-(7-Chloro-benzo[1 .a.SJoxadiazole-sulfonyn-piperidin-ylpl ,4-dihydrobenzofcfin .3]oxazin-2-one 244 1 -[1 -{2-Methoxy-4-methy!-benzenesulfonyl)-piperldin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin- 2-one 245 3-{4-[4-(2-Oxo-4H-benzo[d][1,3Joxa2in-1-yJ)-p|perldine-1 -sutfonyl]-pheny1}-propSonic acid methyl ester 246 1-[1-(2.4-Dinitro-ben2enesuifonyl)-Diperidin-4-vn-1.4-dihydro-benzord1f1.3]oxazin-2-one 247 1 -[1-(7-Chloro-benzo[1,2,5]oxadiazole-4-suffonyl)-piperidin-4-ylJ-8-methyl-1,4-dihydrobenzo[ dl[1,3]oxa2ln-2-one 248 1-[1-(2-Methoxy-4-methyl-benzenesulfony[)-p!perldin-4-yl]-8-methyHl4-dihydrobenzo[ d][1.3]oxazltv2-one 249 3-{4-[4-(8-Methy]-2-oxo-4H-benzo[d][1,3]oxarin-1-yl)-piper/dine-1-sulfonyr!-phenyl}-proplonic acid methyl ester 250 1 -[1 -{2,4-Dinftro-benzenesulfonyl)-piperidin-4-yl]-8-niethyl-1,4-dihydno-benzo[d][1,3]oxazln- 2-one 251 benzofdlM,3]oxazin-2-one 252 -[1 -(2-Methoxy-4-methyl-benzenesuffonyl)-piperidln-4-yl]-6-methyl-1,4-dihydro- 3enzd[d][1,3]oxazin-2-one 253 Se-Methyl^-oxo^H-benzotdlP.SJoxazln-l-ylJ-piperidlne-l-sulfonyQ-phenylJ-proplonic acid methyl ester 254 1 -[1 -{2l4-Dfnitro-benzenesu[fonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin- 2-one 255 }-Chloro-1-[1 -{7-chloro-benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4^l]-1,4-dlhydro- enzofd][1,3]oxazin-2-one 256 J-Chloro-1 -[1-(2-methoxy-4-methyl-benzenesulfonyl)-piperldln-4-yl]-1,4-dlhydro- »enzo[d]t1,3]oxazin-2-one 257 3-{4-[4-{6-Chloro-2-oxo-4H-benzo[dH1,3]oxazin-1 -yl)-plperidine-1 -sulfonyi]-phenyl}-proplonic acid methyl ester 258 one 6-Chloro-1-[1 -2,4-dinltro-benzenesutfonyl)-piperidln-4-yl]-1,4-daiydro-benzo[d][1,3]oxazin-2- 259 }-Chloro-1 -[1 -(1-methyl-1 H-imidazole-4-3uffonyl>-piperidin-4-yl]-1,4-dihydro- enzo[d][1,3]oxazin-2-one 260 -[1-(5-Bromo-2,4-dtfluoro-benzenesuifonyl)-piperidin-4-y!]-6-chloro-1,4-dihydro- enzo[d][1.3]oxazin-2-one 261 i-Methyl-1-[1-{1-methyl-1H-imidazole-4-sulfonyl)-p!peridin-4-yl]-1- enzofd][1.3]oxaz[n-2-one 262 -[1 -{5-Broma-2,4-dlfluoro-benz6nesutfonyf)-piperidirv4-yl]-8-methyl-1,4-dihydro- enzofd1[1,3]oxazln-2-one 263 -[l-fBenzoIblthiophene-sulfonylJ-piperidirv-ylJ-B-methyl-l^dihydro- 3anzo[dK1,3]oxazin-2-one 264 -[1-(Benzo[blthlophene-2-sulfbnyl)-piperldln-4-yl]-1.4-dihvdro-benzo[dl[1.3]oxazln-2-Qne 265 -[1-(Benzo[b]thiophene-2-su]fony])-piperidin^4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin- 2-one 266 "t1 -(Benzo[b]thiophene-2-sulfonyl)-plperldin-4-yl]-6-methyl-1,4-dihydrouenzo[ din ,3]oxazln-3-one 267 -0 -(2.5-Dtfluoro-benzenesulfonyl)-plperidin-4-yl1-1,4-dlhydro-benzordl[1,31oxazln-2-one 268 -one 1K2,5-Drfluoro-benzenesuffonyl)-pipeldJn-4-yl8-methyl-1l4-dihydro-benzo[d][1>3]oxazlnoco -Chloro-1 -[1 -(2,5-dffluoro-benzenesulfonyl}-plperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazln- 269 -one 270 -[1 -2,5-Difluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin- 271 -one -[1 -(4-Chloro-2,5-difluoro-benzenesulfonyl)-plperidin-4-y)]-1,4-dihydro-benzo[d][1,3]oxazin- 272 -[1-(4-Chloro-2,5-dlfluoro-benzenesulfony-plperidln-4-yl]-ft-methyl-1l4-dihydroenzordlfl. Sloxazin^-one 273 -Chloro-1 -[1 -{4-chloro-2,5-difluoro-benzenesulfbnyl)-piperidin-4-yl3-1,4-dihydro- jenzord][1,3]oxazln-2-one 274J -[1-(4-CNoro-2.5-dlfluoro-benzenesuH'onyl)-plper[dln-4-yll-6-methyM,4-dihydro- benzo[d1[1.3]oxazin-2-one 275 -[1 -(2.4.S-Trifluoro-benzenesu[fonvl)-piperidin-4-vn-1.4-dihvdro-benzo[din ,31oxazln-2-one 276 8-Methyl-1 -[1 -{2,4,5-frifluoro-benzenesulfonyl)-p!peridln-4-yl]-1?4-dihydrobenzordlfljSloxazin- g-one 277 e-Chloro-1 -{1 -2,4,5-trinuoro-benzene8ulfonyl)-piperidin-4-yl]-1,4-dIhydrobenzofdin ,3]oxazin-2-one 278 6-MethyM -[1 -(2,4,5-trtfluoro-benzenesulfonyl)-piper!din-4-yl]-1,4-dihydrobenzordld .3]oxazin-2-one 279 1 -[1 -(3,5-Dichloro-2-hydroxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydrobenzordin ,31oxazln-2-one 280 1-[1-(2.6-Difluoro-benzenesulfbnyl-plp6rldln-4-yn-1 (4-dihydro-benzo[dI[1,31oxaz!n-2-one 281 -[1 -(2,6-Dinuoro-benzenesulfonyl}-plperldin-4-yl]-8-methyI-1,4-dihydrt-benzo[d][1,3]oxazin- 2-one 282 e-Chloro-1 -{1 -(2f6-dffluoro-benzeneaulfonyl)-piperldin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin- 2-one 283 1 -[1 -(2,6Difluoro-benzene8Uffonyl)-p!perld!n4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin- 2-one 284 1 -[1-(5-Chloro-2,4-d[fluoro-benzenesuifonyl>-pIperidln-4-y]]-1,4-dihydro-benzo[dJ[1,3]oxazin- 2-one 285 1 -[1 -(5-Chloro-2,4-dlfIuoro-benzenesulfonyl)-piperldln-4-yl]-8-methyl-1,4-dihydrobenzofdin .3]oxazln-2-one 286 B-Chloro-1 -[1 -(5-chloro-2,4-difluoro-benzene8Ulfonyl)-plpBrid!n-4-yl]-1,4-dlhydrobenzo[ d][1,31oxazin-2-one . 287 1-[1 -{5-Chloro-2,4-difluoro-benzenesulfonyl)-plperldln-4-yl]-6-methyM ,4-dihydrobenzo[ dl[1.31oxazln-2-one 288 1 -[1 -(2-Chtoro-benzene8u[fonvl)-plperidin-4-yn-1.4-dlhydro-benzo[cflriJ3]oxazin-2-one 289 one 6-Chloro-1-[1-(2-chloro-benzenesulfonyl)-pIperidin-4-yl]-T,4-dihydro-benzo[d][1I3]oxazin-2- one 291 " -Chloro-benzenesulfonyl)-plperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazln-2- one . 292 6-Chloro-1 -[1 -(2-naphthalen-1 -yl-ethanesulfonyl)-piperidin-4-yl]-1,4-dihydrobenzofdlM ,31oxazin-2-one 6-Bromo-1 -[1 -{4-bromo-benzenesuifonyf)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3Joxazliv2- 293 one 294 6-Bromo-1 -f1 -(toluene-4-sulfonyl)-plperidln-4-vll-1,4-dihydr o-benzord1[1.31oxazln-2-one 295 J-Bromo-1-[1 -(2,4-dimBthyl-benzenesulfonyl)-plperldin-4-yI]-1,4-dlhydrobenzo[ d][1,3]oxazlrv2-one 6-Bromo-1-[1-(2-naphthaten-1 -yl-ethan6sulfonyl)-plperidin-4-yl]-1,4-dihydrobenzofdlfl ,3loxazin-2-one 297 -Bromo-1 -[1 -(quinollne-8-sulfonyl)-plperidfn-4-yH-1,4-dlhydro-benzo[diri ,31oxazln-2-one 298 }-Bromo-1 -[1 -(5-chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-piperid!n-4-yl]-1,4-dihydro- 3enzo[d1f1. 3|oxazln-2-one OOQ 6-Bromo-1 -[1 -3-nltro-benzenesulfbnyl)-piperidin-4-yi1,4-dihydro-benzo[d][1,3]oxazln-2- 299 one 300 }-Bromo-1-[1-(naphthalen&-1-sulfbnyl)-plperldln-4-vl1.4-dihydro-ben2o[din.3]Qxazln-2-one 301 6-Bromo-1-ri -(naphthalene-2-suIfonyl)-pipefidln-4-yl1.4-d!hydro-benzo[dI[1.31oxazln-2-ona 302 I -(1 -Benzeneaulfonyl-plperldin-4-yl6-bromo-1.4-dthydro-benzoJd]|'1,3]oxazin-2-one 303 Brotno-1-{1-[4-(4-bromo-phenoxy)-benz8nesu]fonyl]-piparld!n-4-yl}-1,4-dihydro- enzo[d][1,3]oxazin-2-one 304 6-Bromo-1 -[1 -(thiophene-2-sulfonyl)-piperidin-4-vll-1.4-dihvdro-benzo[dl[1,37oxaz]n-2-one 6-Bromo-1-[1-{2-methyl-5-nltro4jenzenesulfonyl)-plperidln-4-yl]-1>4-dlhydrobenzo[ d][1,3]oxazin-2-pne 306 6-Bromo-1-[1-(4-bromo-2I5-difluoro-benzenesulfonyl)-piperidln-4-yl]-1,4-dlhydro- enzo[d][1,31oxazin-2-one 307 6-Brofno-1-[1-(toluen6-3-3utfonylVplperldln4-yl]-1.4-dlhydro-benzord][1.3]oxazin-2-one 308 e-Bromo-l-II-JS-fluoro^-methyl-benzenesulfonylJ-piperldln^-yll-l.^dihydrobenzofd][ 1,31oxazin-2-one 309 6-Brqmo-1 -[1 -(4-isopropoxv-benzenesufonyl)-plperidln-4-ylH ,4-dlhydro^ 143 benzord][1,3]oxazln-2-one 6-Bromo-1-[1 -(3-chlon-benzene8Uffonyl)-piperIdin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazln-2- one 311 6-Bronao-11-(3l4-dimethoxy-benzenesutfonyI)-pIperidin-4-yi]-1,4-dihydrobenzotcfiri. 31oxazin-2-one 6-Bromo-1-{1-pentafluorob8nzenesulfonyi-piperklin-4-yl)-1,4-dihydro-benzo[d][1T3]oxazln-2- 0 one 313 e-Sromo-l-CHhloroS-dimethyl-benzenesulfonylJ-piperidin^-ylJ-l^-dihydrt)- benzo[d][1,3]oxazin-2-one 314 6^romo-1-[H3-methoxy-faenzenesulfony])-pJperidin-yl]-1,4-dihydro-benzo[d][1,3]oxazin- 2-one 315 e-Bromo-l-IHisopropyl-benzenesulfonylJ-piperidin--ylJ-l-dihydnxbenzoIdJIl.SJoxazin- 2-one 6-Bromo-1 -[1 -(4-fluoro-benzenesulfonyI)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2- one 317 6-Bromo-1-[1-(3-chloro-4-fluoro-b8nzenesulfonyl)-piperidin-4-yl]-1,4-dihydrobenzo[ dlf1,3]oxazln-2-one 318 6-Bromo-1-(1 -pentamethyfbenzenesulfonyl-piperidin-4-yf)-1,4-dihydro-benzo[d][1,3]oxazin- 2-one 6-Bromo-1-[1-(2-nltro-benzene8ulfonyl>plperidin-y]-1,4ihydrcbenzo[dl[1,3]oxazln-2- one 320 6-Bromo-1 -1 -(4-chloro-3-nifro-benzenesulfonyJ)-plperidin-4-yl]-1,4-dihydrobenzo[ d][1,3]oxazin-2-one 321 6-Bromo-1 -[1 -(5-dimethylamino-naphthalene-1 -8Ulfbnyl)-piperid!n-4-yl]-1,4-dihydrobenzofdTTI ,3]oxazln-2-one 6-Bromo-1 -[1 -(4-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2- one 323 4 - d i h y d r o - b e n z o [ d ] t 1 , 3 ] o x a z i n - 2 - one 324 6-Bromo-1 -[1 -(4-melhanesutfonyl"benzen9sulfony[)-piperidin-4-yr|-1,4-dihydrobenzotd][ 1.3]oxazin-2-one 325 1-[1-(Blphefiyl-4-sutfonvl)-piperidin-4-yll-6-bfomo-1,4-dihydro-benzo[d1[1,3]oxazin-2-onB 326 6-Bromo-1 -d-phenylmgthanesutfony 327 6-Bromo-1-[1-(2,6-dimethoxy-benzenesulfonyl)-plper[d!n-4-yI]-1,4-dlhydro- ,3]oxazin-2-one 328 6-Bromo-H1-[2-{2,2I2-ttfIuoro-acetyl1I2,3,4-tetrahydrcHsoquinoline-7-8ulfonyl]-piperidinyl}- 1,4-dihydr(-benzo[d][1,3]oxazin-2-one 329 6-Bromo-1 -[1-{2,3-dichlon-benzene8ulfonyl)-piperidin-4-ylJ-1 r4-dihydro-benzo[d][1,3]oxazin- 2-one 330 3-Bromo-1 -[1-(2)4,5-trichloro-benzene8ulfonyl)-piperid3n-4-yl]-1,4-dihydro- 3enzofd][1,3]oxazin-2-one . 331 3-Bromo-1-[1-{5-bromo-2-rnethoxy-benzene8Ulfnyl)-piperidin-4-yl]-1,4-dihydroaenzoWlH ,3]oxazin-2-one 332 6-Bromo-1 -[1-(4-trifluoromethoxy-benzene8ulfonyl)-p!p9rIdln-4-yl]-1,4-dihydrobenzordiri, 31oxazln-2-one 333 6-Bromo-1-[1^2-nhro^trlfluoromethyl-benzene8Ulfonyl)-plperidiiv4-yl]-1,4-d]hydrol_ 3]oxazin-2-one 6-Bromo-1-[1-(3-fluoro-benzene8utfonylH)lperIdln-4-yf]-1,4-dlhydro-benzo[d][1,3]oxazirv-2- 334 one 335 6-Bromo-1-[1-(2,4-dlchloro^enzenesulfonyl)-p!p9rldIn-4-y!]-1,4-dihydro-benzo[d][1,3]oxazin- 2-one e-Bromo-H.e-trlmethyt-benzenesulfonyiJ-pJperldin-yll-l ,4-dihydrobenzo[ d][1.3]oxazin-2-one 337 6-Bromo-1-[1-(2-trtfluoromethyl-benzenesulfonyl)-plpBrid[n-4-ylJ-1l4-dihydrobenzord][ 1.3]pxazJn-2-one 338 one 339 >Bromo-1-[1-(4-methoxy-2,3,6-Wmethyl-benzenesu)fonyl)-plperidin-4-yl]-1,4-d!hydrobenzo[ cri[1,3loxazln-2-one 340 1j1-(3,S-P!dilon>4-hydroxy-benzenesuIfonyl)'plpgr]dln-4-yll-1,4-d[hydro- benzo[d][1.3loxazin-2-one 341 1 -[1 -(3,5-Dichloro-4-hydroxy-benzenesulfonyl)-pipBridin-4-yl]-8-methyl-1,4-d!hydrobenzo[ cflf 1,3]oxazin-2-one 342 e-Chloro-l-p-CS.S-dichloro^-hydroxy-benzenesulfonylJ-plperldln^ylj-l^dihydrobenzo[ d][1,3]oxazin-2-one 343 1-[1-(3,5-DicWoro-4-hydroxy-benzenesu[fonyl)-piperldin-4-yl3-&-methyl-1,4-dihydrobenzo[ d][1 ,3]oxazin-2-one 344 6-Bromo-1-[1-(3,5-d[chloro-4-hydroxy-benzenesu[fonyl)-piperldin-4-yl]-1,4-dihydrobenzo[ d][1,3]oxazin-2-one 345 8-Chloro-1-[1-(3,5-dichlora-2-hydroxy-benzenesulfonyI)-plperldin-4-yl]-1)4-dihydrobenzo[ d]n. 3]oxazin-2-one 346 6-Bromo-1-[1-(3,5-dichloro-2-hydroxy-benzene8Ulfonyl)-plperldIn-4-1,4-dihydrobenzofdlfl 3]oxazin-2-one 347 2-[4-(6-Bromo-2-oxo-4H-benzo[d][1,3]oxazln-1-yl)-piperid[ne-1-sutfonyl]-benzonitriie 348 e-BrDmo-l-II-methoxy-benzenesulfonylJ-plperidln--yll-l-dihydro-benzoIdltl.Sloxazin- 2-one 2-[4-{6-Bromo-2-oxo-4H-benzo[d][1,3]oxazln-1-yl)-plperidine-1-8ulf6nyl3-benzoic acid methyl ester 350 6-Bromo-1 -[1 -(3-trifluoromethyl-benzenesulfonyl)-piper[din-4-yl]-1,4-dihydrobenzoMn ,3loxazin-2-one 351 6-Bromo-1 -[l-(2-oxo-2H-chromene-6-8uIfonyl)-plperldln-4-yf]-1,4-dihydrobenzo[ d][1,3]oxazln-2-one 6-Bromo-1 -[1 -(3,5-d!chloro-benzenesulfonyl)-piperIdIn-4-yrj-1,4-dlhydro-benzo[d][1,3]oxazin- 2-one 6-8romo-1 -[1 -{2,5-dichloro-benzenesutfonylplperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin- 353 2-one 354 6-Bromo-1 -[1 -(5-bromo-6-chloro-pyr[dine-3-6ulfbnyl-pfperfdln-4-yJ]-1,4-dihydrobenzofdin .3]oxazin-2-one 6-Bromo-1 -t1-(4-chtoro-benzenesulfbnyl)-piperidin-4-yl]-1,4-dlhydro-benzo[dH1,3]oxazin-2- 355 one 356 6-Bromo-1-[1 -(2,6-dichloro-benzenesutfonyl)-i}iperidin-4-yl]-1,4-dlhydro-benzo[d][1,3]oxazin- 2-one 6-Bromo-1-[1-(1-methyl-1H-imidazole-4-3ulfonyl)-piperidin-4-yl]-1,4-dlhydrobenzotdin ,3]oxazln-2-one 358 S-Bromo-1-[1-(5-bromo-2,4-difluoro-benzenesulfonyl)-piperldin-4-y[]-1,4-dihydn> jenzo[d][1,31oxazln-2-one -(4-ethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2- one 360 6-Bromo-1-[1-{6-chloro-imidazo[2,1-bIthiazole-6-Buifony[)-plperldin-4-yl]-1,4-dihydriobenzofdin .3]oxazln-2-one 361 1-[1 -(Benzo[b]thlophene-3-sulfonyl)-piperidin-4-yl]-6-bromo-1,4-dihydro-benzo[d][1,3]oxazin- 2-one 362 >Bromo-1 -[1-(7-chloro-benzo[1,2,5]oxadlazole-4-sulfbnyl)-plperldln-4-yl]-1,4-dihydrobenzofd][ 1.31oxazin-2-one 6-Bromo-1-[1 -(2-methoxy-4-methyl-benzenesu[fonyl)-piperidin-4-yl]-1,4-dihydrobenzo[ d][1.3]oxazin-2-one 3-{4-[4-(6-Bromo-2-xo-4H-benzo[d][1,3]oxazin-1-yl)-plperidlne-1-sulfonyl]-phenyl}-proplonic acid methyl ester • 6-Bromo-1 -[1-(2,4-dinitro-benzene8ulfonyl)-piperidln-4-yl]-1,4-dlhydro-benzo[d]|;i,3]oxazin-2- 365 one 366 I -[1 -(Benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-8-bromo-1,4-dlhydro-benzo[d][1,3]oxazin- 2-one 6-Bromo-1-[1 -(2,5-difluoro-benzenesulfonyl)-plperidln-4-yl]-1,4-d!hydro-benzo[d][1,3Joxazind67 2-one 368 J-Bromo-1 -[1 --chloro-2,5-difluoro-benzenesulfonyl)-plperldin-4-yl]-1,4-dihydrobenzo[ d][1,31oxazln-2-one 369 6-Bromo-1 -[1 -(2,4l5-trifluoro-benzene8ulfonyl)-piperidln-4-yl]-1,4-dihydro- >enzo[d]ri .3]oxaz!n-2-one 370 6-Bromo-1-[1 -(2,6-difluoro-benzenesulfonyl)-piperldin-4-yl]-1,4-dihydro-berizordJP ,3]oxazin- 2-one 371 6-Bromo-1-[1-(5-chloro-2,4-drfluoro-benzenesulfonyl)-pip6ridin-4-yl]-1,4-dlhydr6- benzoMM .3]oxazin-2-one 372 e-Brorno-l-II^-chloro-benzenesuIfonyO-piperidirM-ylM^-dlhydro-benzofdJp.S^oxazln^- one 373 374 37fa 376 6-Bromo-l -[1 ^2 A4-trifluoro-benzenesulfonyl)-piperidin-4-yl]-1 ,4-dihydrobenzofdKt , 3]oxazin-2-one N-{4-[4-(6-Bromo2-oxo-4H-benzo[d][1 ,3]oxazin-1 -yl-p!perldine-1 -sulfonyl]-2-ch!oro-phenyl}- acetamide 1 -[1-(2.3,4-Trifluoro-benzen9sulfonvlVDiDeridin-4-yl]-1 ,4-dihvdro-benzoTdin ,3loxazln-2-one 8-MetnyM -[1 -(213]4-trtfiuoro-benzenesulfonyl)-piperidin-4-yl]-l ,4-dihydrobenzo[ d][1 ,3]oxazin-2-one 377 6-Chloro-1 -[1 2,3trffluoro-benzenesulfonyf)iperidin-4-yl]-1 ,4-dihydrobenzo[ d][1,3]oxazin-2-one 378 6-MethyM -[1 2,3,4-tn1luoro-benzenesulfonyl)-piperidin-4-y[]-1 ,4-dihydrobenzo[ d][1,3]oxazin-2-one 379 N-{2-ChlorcHH4-(e-methyl-2-oxa4H-benzo|;d]t1,3]oxazln-1 -yl)-piperldine-1 -8uffonyl> phenylVacetamlde 380 1-[H3.4-Dtfluoro-benzene8ulfonyn-plperidln-yl]-1,4-dlhydrD-benzofd]f1.3]oxazln-2-one 381 l-IHS-Dlfluoro-benzenesulfonylJ-piperidln-yll-a-methyl-l^-dihydro-benzofdJtl.SloxazIn- 2-one 382 6-Chloro-1 -[1 -(3,4-difluoro-benzenesutfonyl>-piperldln-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin- 2-one 383 1 -[1 -(3,4-Difluoro-benzenesulfonyl)-plperidln-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin- 2-one 6-Bromo-1-[1 -(3,4-difluoro-benzene8Ulfbnyl)-plper[dln-4-yl]-1,4-dlhydro-benzo[d][1,3]oxazin- 2-one 385 N-{2-Chloro-4-[4-(8-methyl-2-oxo-4H-benzo[d][1,3]oxazln-1 -yl)-pfperidine-1 -eulfonyl]- phenyl)-acetamlde 2-one 387 1 -[1 -(2-Chloro-4,5-d{fluoro-benzenesu[fonyl)-p[perldIn-4-yl]-8-methyl-1,4-dihydrobenzokflfl ,3]oxaz1n-2-one 6-Chlorc>-1 -[1 -{2-chloro-4,5-difluoro-benzenesulfony[)-p[peridln-4-yl]-1,4-dihydrobenzo[ d][1,3]oxaz8n-2-one 1 -[1 -{2-Chloro-4>5-difluoro-benzenesulfbnyl)-plpBrldln-4-yl]-6-methyt-1,4-dihydrobenzoMM ,3]oxazin-2-one 390 J-Bromo-1 -[1- Sloxazin-one N-{2-Chloro-4-[4-{2-oxo-4H-benzo[d][1,3]oxazin-1 -yl)-plperldlne-1 -sulfonyQ-phenyl}- acetamlde ^QO 1 -[1-(Benzo[1,2,5]oxadlazole-4-8ulfonyl)-plperidln-4-yl]-1,4-dlhydro-benzo[d][1,3]oxazln-2- 392 one 393 1 "{1-(Benzo[1,2l5]oxadlazole-4-6ulfonyl)-p!perldln-4-ylH-fnethyl-1,4-dihydrobenzo[ d][1.3]oxazin-2-one 394 1 -[1 -(Benzo[1,2,5]oxadiazole-4-8ulfonyI)-piper[din-4-yl]-6-cWoro-1,4-dIhydro- enzofd1f1,3]oxazin-2-one 395 1 -[1 -{Benzo[1,2,5]oxadtazole-4-sulfonyl)-plDeridin-4-yl]-6-methyl-1,4-dihydro- enzo[d][1.3loxazln-2-one 398 1 "I1 "(Benz°I1,2,5]oxadiazole-4-8ulfonyl)-plperldin-4-yl]-e-bromo-1,4-dihydrobenzo[ d]f1,31oxazln-2-one N-{2-Chloro-4-[4-{6-chlon>2-oxo-4H43enzo[d]f1l3]oxazIn-1-yl)-plperidine-1-«ulfonyl]-phenyl}- acetamide 1 -[1 -(Benzo[1,2,5Jthiadiazole-4-sLilfonyl)-plperIdin-4-yl]-1,4-dlhydro-benzo[d][1,3]oxazin-2- 398 one 399 1 -{1 -{Benzofl ,2,5]thiadiazole-4-sulfonyl)-p[peridln-4-ylI-8-methyl-1,4-dihydro- enzo[d][1.31oxazin-2-one 400 1-[1 -enzo[1,2,5]th!adiazole-4-sulfonyl)-plperidln-4-yl]--chloro-l ,4-dihydrojenzo[ d][1,3]oxazln-2-one 1-[1 -(Benzo[112,5]thladiazole-4-8uIfonyl)-plperldin-4-yl]-6-methy|-1,4-dihydrobenzo[ dTI1,31oxazln-2-one 402 1-[1-{Benzo[1,2,5]thiadiazole4-su!fonyl)-piper1dlrHl-y!]-6-bromo-1,4-dihydrobenzofdin .31oxazin-2-one 403 H1-Ethanesulfonvt-pIperidin-4-v-8-m9thvl-1.4-dlhvdro-benzo[d]ri.3]oxaz{n-2-one 404 -[1 -(2.4-Difluoro-benzenesulfonvl Vp|per[dirv4-vn-1.4-dlhydro-benzo[d1[1.3]oxazln-2-one 405 1 -[1-{2J4-Difluoro-benzenesulfonyl)-p|pertdin-4-yl]-8-{nethyl-1,4-dihydro-benzo[d][1,3]oxazin- 2-one 406 6-Chloro-1-[1 -(2,4-difIuoro-benzene8u[fonyl)-pfper!din-4-yI]-1,4-dihydro-benzo[d][1,3]oxazin- 2-one 407 1-[1-(2r4-Difluoro-benzenesulfonyl)-plperidln-4-yl]-6Tiethyl-14-dihydro-benzo[d][1l3)oxazln- 2-one 408 6-Bromo-1 -[1 -(2,4-difluoro-benzene8ulfonyl)-plper!din-4-yl]-1,4-d!hydro-benzo[d][1,3]oxazin- 2-one 409 ft-Methyl-1 -T1 -(propane-2-sulfony|)-plperidln-4-vll-1.4-dlhvdro-benzofdlf 1.31oxazln-2-one 410 1-[1-(3,4-DicNoro-benzenesulfonvl)-plperldln-4-yll-1.4-dlhydro-benzord][1.31oxazln-2-one 411 1 -[1 -(3,4-D!cWora-benzenesulfonylH)iperidin-4-yl]-8-methyl-1,4-dlhydropenzo[ d][1,3]oxazln-2-one 412 6-Chloro-1 -[1 -(3,4-dichloro-benzene8ulfonyl)-piperidin-4-]-1,4-dihydro-benzoIdJI ,3]oxazin- 2-one 413 1 -[1 -(3,4-DlchIoro-benzenesulfonyl-p|peridffi-4-yl]-6-methyl-1,4-dihydrobenzotdlf 1,31oxazln-2-one 414 6-Bromo-1-[1 -(3,4-dlchloro-benzenesulfony[)-piperidin-4-yi]-1,4-dihydro-benzo[d][1,3]oxazin- 2-one 415 8-Methyl-1-[1-(propane-1-sulfonyl)-plperldln-4-yll-1.4-dlhvdro-benzofd1[1,3]oxazin-2-one 1 P -(2-Chloro-6-methyl-benzenesulfonyl)-plperidln-4-yl]-1,4-dlhydro-benzo[d][1,3]oxazin-2- one 417 1 -[1 -(2-Chloro-6-methyl-benzenesulfonyl)-plperldin-4-yl]-8-methyl-1,4- 1,3]oxazln-2-one 418 3-Chloro-1 -[1-(2-chIoro-6-methyl-benzene8Ulfonyl)-plperldln-4-yl]-1,4-dlhydro- 3enzo[d]f 1,3]oxazln-2-one 419 1 -[1 -(2-Chloro-6-methyl-benzenesulfonyl)-piperldln-4-yl]-6-methyl-1,4-dlhydrobenzo[ dl[1,3Ioxazln-2-one 420 1 -[1 -(2-Chloro-6-methyl-benzenesulfbnyl)-piperld!n-4-yl]-6~methy]-1,4-dihydrobenzo[ d][1,3]oxazln-2-one 421 8-MethyH-[1-(2,3I6I6-tetramethy[-benzenesulfonyl)-plperldin-4-yl]-1l4-dihydrobenzofdiri ,3]oxazln-2-one 422 1 -[1 -(2.3,4-Trlchloro-benzenesulfonyl>-plperldln-4-ylM ,4-dihydro-benzo[d][1,3]oxazln-2-one B-Methyl-1-[1-(2,3,4-trichloro-benzene8Ulfonyl)-plperidin-4-yl]-1l4-dihydrobenzofdin ,3]oxazin-2-one 424 e-Chloro-l-IISAtrichloro-benzenesulfonylJ-piperidinylJ-lhydrobenzo[ d][1,3]oxazln-2-one 425 benzofdlh ,3]oxazln-2-one 6-Bromo-1-[1 -(2,3,4-trichloro-benzene8ulfonyl-piperidin-4-yl]-1,4-dJhydrobenzofdiri ,31oxazin-2-one HH^S.S.e-Tetramethyl-benzenesulfonyljhpiperidin-yll-l-dihydro-benzoMEI.Sjoxazin- 2-one 428 I -[1 Thlophene-3-6utfonyl-piperidIn-4-vn-1,4-dlhydro-benzo[dlf 1,31oxazln-2-one 429 8-Methyl-1-[1-(thiophene-3-8ulfonyl)-plperidin-4-vll-1.4-dlhvdro-benzord1f1.31oxazln-2-one 430 )-Chloro-1-[1-(thiophene-3-sulfonyl)-plperidln-4-yl]-1.4-dlhydro-benzo[d][1.3]oxazin-2-pne 431 6-Methyl-1-[1-(thiophene-3-sulfonyl)-p|peridin-4-yl]-1.4-d]hydro-benzo[d][1.3loxazin-2-one 432 6-Bromo-1-[1^thiophene-3-sulfonyl-p|perldln-4-yl3-1.4-dlhvdro-benzord][1.31oxazin-2-one 6-Chloro-1-[1 -(S.S.e-tetramethyf-benzenesulfonylJ-piperidirh-yll-l ,4-dihydrobenzo[ d][1,3]oxazin-2-one 434 1 -T1-(2.4.6-Trichlor(-benzenesulfonvl)-plperIdln-4-vl1-1.4-dlhydro-benzo[d][1,31oxazln-2-one 435 benzo[dl[1,3]oxazin-2-one 436 6-Chloro-1 -[1 -(2,4,6-trichloro-benzenesulfony])-plperldin-4-yl]-1,4-dihydrobenzo[ d][1,3]oxazin-2-one 6-Methy!-1 -[1 -(2,4,6-trichloro-benzenesulfonyl}-piperidin-4-yl]-1,4-dihydrobenzo[ d][1.3]oxazin-2-one 438 6-Bromo-1-[1-(2,4>6-trichloro-benzenesulfonyl)-pip6ridin-4-yl]-1,4-dihydrobenzordTI .3]oxazln-2-one 439 6-Methyl-1-[1-(2,3,5,e-tetrametiiyl-benzenesulfonyl>-piperidin-4-yl]-1I4-d!hydrobenzoldlfl ,31oxaztn-2-one 440 1 -[1 -2-Bromo-4,6-dffluoro-benzenesulfonyl}-plperldln-4-yl]-8-methy]-1,4-dihydrobenzo[ din ,3]oxaztn-2-one 441 1 -[1 -(2^romo-4,6-dffluoro-benzenesulfonyl)-plperldln-4-yJ]-6-chlort>-1,4-dlhydrobenzordlf 1,3]oxazln-2-one 442 1 -[1 -C2-Bromo-4,6-dHluoro-benzenesulfonyl)-plperldln-4-yl]-6-methyM ,4-dlhydrobenzofdlfl ,3]oxazin-2-one 443 6-Bromo-1-[1-(2-broino-4,6-difluoro-benzenesu!fonyl)-pipBridin-4-yl3-1,4-dlhydrobenzofdin .3]oxazin-2-one 444 6-Bromo-1-[1 -2,3,5,6-tetramethyl-benzenesulfonyl)-plperidin-4-yl]-1,4-dihydrobenzotdin .3]oxazln-2-one 445 1 -[1 -(4-Bromo-2-trlf|uoromethoxy-benzenesulfbnyl)-plperidin-4-yl]-1,4-dihydrobenzo[ d][1,3]oxazln-2-one 446 1 -[1 -(4-Bromo-2-trifluoromethoxy-benzenesulfonyf )-plperldin-4-yl]-8-methyl-1,4-dihydrobenzofdlfl ,3]oxazln-2-one 447 1-[1-(4-Bromo-2-trifluoromethoxy-benzene8ulfonyl)-piperidin-4-yf]-8-cliiort-1,4-dihydrobenzo[ d][1,3]oxazln-2-one 448 1-[1-(4-Bromo-2-trrfluoromethoxy-benzene8Utfonyi)-piperidin-4-yl]-6-methyl-1,4Hdihydrobenzo[ d][1,31oxazin-2-one 449 6-Bromo-1 -{1 -(4-bromo-2-trlfIuoromethoxy-benzenesulfonyl)^lperidin-4-yl]-1,4-dihydrobenzo[ d][1,3]oxazln-2-one 450 1 -[1-(4-Phenoxy-benzen«sutfonyl)-piperidiiv4-yl]-1,4-dihydro-benzord][1,31oxazln-2-one 451 1 -[1 -(3-Bromo-benzenesulfonyl)-plperldliv4-yl]-1,4-dlhydro-benzord][1,3]oxazln-2-one 1 -[1 -(3-Bromo-benzene8ulfonyl)-plperidin-4-yl]-8-methyl-1,4~dihydro-benzo[d][1,3]oxazin-2- one 453 "(3-Bromo-benzenesulfony))-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2- one AKA H1 -(3-Bromo-benzenesulfonyl)-piperldin-4-yl]-6-methy[-1,4-dihydro-benzo[d][1,3]oxazln-2- 404 one 6-Bromo-1 -[1-(3-bromo-benzenesuIfonyl)-pIperidin-4-y]]-1,4-dihydro-benzo[d][1,3]oxaz!n-2- one 8-MethyH -{1 -(4-phenoxy-benzenesulfbnyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazln- 2-one 457 1 -[1 -{4-tert-Butvl-benzenesuifonyi)-plperldln-4-vll-1,4-dlhydro-benzordlM ,31oxazln-2-one 1 "C1 -4-tert-Butyl-benzenesulfonyl)-plperldin-4-yl]-8-methyl-1,4-dlhydro-benzo[d][1,3]oxazln- 2-one l-f-tert-Butyl-benzenesulfonylJ-piperldinyll-e-chloro-IAdihydro-benzoIdlll.Sloxazln- 2-one 430 1 -[1 -4-tert-Butyl-ben2enesulfonyl)-piperldin-4-yl]-&-methyl-1,4-dihydro-benzo[d][1,3]oxazin- 2-one 481 J-Bromo-1 -[1 -(4-tert-butyl-benzenesuIfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazln- 2-one 2-one AM 1-[1-(2-Bromo-4,6-dlfluoro-benzenesulfbnyl)-pIperidln-4-yl]-1,4-dihydro-ben2X)[d][1,3]oxazin- 483 2-one 464 H1-(2-MeUianesulfonyl-benzenesulfonyl)-pIperklln-4-yl]-8-methyl-1,4-dihydrojenzofdin 6-Chloro-1-[1 -(2-methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-1,4-d!hydrobenzoMM ,31oxazln-2-one -[1-(2-Methanesulfonyl-benzene3ulfonyl)-piperIdin-4-yl]-6-rnethyl-1,4-dihydrobenzo[ d][1,3loxazin-2-one 6-Bromo-1 -[1 -{2-methanesulfonyl-benzenesulfonyl)-pipertdln-4-yl]-1,4-dlhydrobenzo[ d]f1,31oxazln-2-one one 469 6-Chloro-1-n -(4-propyl-ben2enesulfonv1)-plperidln-4-yl1-1.4-dihydro-ben2o[d][1,3loxazln-2- 470 one e-Methyl-l-f^propyl-benzenesutfonyO-piperidlnylJ-l.dlhydro-benzoIdJfl.SJoxazin- one e-Bromo-1 -[1 -{4-propyl-benzenesulfonyl)-piperid]n-4-yl]-1,4-dihydro-benzo[d]1,3]oxazin-2- one 472 1-[1-(3-Chloro-2-methyl-benzenssulfonyl)-plperidin-4-yl]-8-methy]-1,4-dihydrobenzofdin ,3]oxazin-2-one 473 6-Chloro-1-[1-(3-chloro-2-methyl-benzenesulfonyi)-p]perldln-4-yl]-1I4-dihydrobenzo[ dl[1,3joxazin-2-one 474 1 -[1 -{3-Chloro-2-methyf-benzene8ulfonyl)-piperidin-4-yl]-6-m6thy|-1,4-d[hydrobenzo[ d][1,3]oxazln-2-one 475 6-Bromo-1-[1-{3-diloro-2-methyl-benzenesu[fonyl)-plperidin-4-yl]-1,4-dihydrobenzordin ,3]oxazlrv2-one 478 1-I1-(ButylnzenesuKbnyl)-piper!dlrK4-yI]-8-rTiethyl-1,4-dihydro-benzo[dJ[1,3]oxazin-2- one A77 1 -[1-(4-Butyl-benzenesulfonyl)-piperidin-4-yl]-6-chJofo-1,4-dihydro-benzo[d]t1,3Joxazin-2- one 478,4-dihydro-benzotd][1,3]oxazJn-2- one e-Bromo-1 -[1 -(4-butyl-benzene8uffony()-plperldln-4-yl]-1,4-dihydro-benzo[d]f 1,3]oxazin-2- 478 one 1-[H4^romo-3-methyl-bQnzenesulfonyl-piperJdin-4-ylJ-8-rnethyl-1,4-dihydrobenzoFdin .3]oxazin-2-one benzordl[1,3loxazln-2-one 482 benzo[d][1,31oxa2ln-2-one 6-Bromo-1-[1 -(4-bromo-3-methyl-benzene8ulfonyl)-plperldfn-4-yl]-1,4-dihydrobenzo[ dl[1.33oxazJn-2-one 484 benzo[d][1.3]oxazin-2-one 485 6^hloro-H1Wt1-dimethyl-propyJ)-benz8nesulfonyl>lPerid]n-4-yl}-1,4-dihydrobenzo[ d][1,3]oxaztn-2-one 486 1 -{1 -[4-(1,1 -DimethyI-propyl)-benzene8u(fonyl]-piperidin-4-yl)-6-methyl-1,4-dihydrobenzofdin ,31oxazin-2-one 487 benzo[d][1,31oxazin-2-one 488 EthenesuHbnvl-plperidin-4-yl)-8-methyl-1.4-dlhvdro-benzord1f1.3Toxazln-2-one 489 3-W8-Methyl-2-oxfr4H-bBnzofd1M .37oxazJn~1-vl)-plperldine-1 -sutfonvll-benzolc add 490 344-(e-Me&iyl-2-oxo~4H-bBnzo[din.3]oxazln-1-vl)-plperidlne-1-sulfonvn-benzolcacld 491 3-r4-f6-Bromo-2-oxo-4H-b6nzordin ,3]oxazln-1 -vD-plperkllne-l-sutfbnvH-benzofc add 492 1 -[1 -(3-Chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yr|-8-methy]-1,4-dihydrobenzotdin ,31oxazln-2-one 493 5-Chloro-1-[1-(3-chloro-2-fluoro-benzene8Ulfonyl)-piperidin-4-yl]-1,4-dihydrobenzo[ d][1,31oxazln-2-one 494 1 -[1 -(3-Chloro-2-fIuoro-benzenesu(fonyl)-piperidin-4-yl]-6-methyl-1,4-dihydrobenzo[ d][1.3]oxazln-2-one 495 3-Bromo-1-[1-3-chloro-2-fluoro-benzene8ulfonyl)-plperidin-4-yl]-1,4-dihydrobenzord][ 1,31oxazln-2-one 496 M-{4-Methyl-5-[4-(8-methy!-2-oxo-4H-benzo[cl][1,3]oxazin-1-y!)-piperidine-1-8Ulfonyri-thlazol- 2-yfl-acetamide 497 M-{5-[4-(6-Chloro-2-oxo-4H-benzo[d][1,3]oxazln-1-yl)-piperidine-1-sulfony]]-4-methyl-thiazol- 2-yl}-acetamlde 498 N-{4-Methyl-5-[4- 2-yl}-acetamlde 499 N5-[4-(6-Brt)mo-2^xo^H-benzo[d][1,3]oxazin-1-yl)-pIperidine-1-sulfonylH-methyl-thiazol- 2-yl}-acetamide 500 1 -[1 -(2-Bromo-4-fluoro-benzenesulfonyl)-piperldin-4-yl]-8-methyl-1,4-dihydrobenzo[ d][1,31oxazln-2-one 501 1 -[1 -f 2-Bromo-4-fluoro-benz6nesutfonyn-piperidin-4-vll-6-Ghloro-1,4-dlhvdro- benzo[cfln .3]oxazin-2-one 502 1 -[1 -(2-Bromo-4-f!uoro-benzenesulfony|)-pfp6ridin-4-yl]-6-methyl-1,4-dihydrobenzo[ d]f1,3]oxazin-2-one 503 6-Bromo-1 -[1 -2-bromo-4-f[uoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydrobenzo[ d]ri ,3]oxazln-2-one 504 1 -[1 -{5-Chloro-2-fluoro-benzenesulfony|)-piperidin-4-yl]-8-methyl-1,4-dihydrobenzo[ d][1,3]oxazin-2-one 505 6-Chloro-l -[1 -(5-chloro-2-fluoro-benzenesulfbnyl)-piperidin-4-yl]-1,4-dihydrobenzo[ d][1,3]oxazin-2-one 506 1 -[1 - ,31oxazfn-2-one 507 6-Bromo-1 -[1 -(5-chloro-2-fiuoro-benzenesulfonyl)-piperid ln-4-ylJ-1,4-dihydrobenzofdiri ,3]oxazin-2-one 508 1 -[1 -{4-Bromo-3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydrobenzofd][ 1,3]oxazin-2-one 509 1 -[1 -{4-Bromo-3-trifIuoromethyl-benzenesulfony!)-pipBridin-4-yl]-6-chloro-1,4-dihydrobenzo[ d][1,3]oxazin-2-one 510 1 -[1 -(4-Bromo-3-trifluoromethyl-benzenesulfonyl)-plperidin-4-yl]-6-methyl-1,4-dihydroben20[ d][1.3]oxazin-2-one 511 e-Bromo-1 -{1 -(4-bromo-3-trlfIuoromelhyl-benzene8ulfonyl)-piperIdfn-4-yl]-1,4-dihydro- ,3]oxazin-2-one 512 - one 513 1 -f 1-(4-Propyl-benzenesutfonyl)-pipei1din-4-yn-1.4-dihvdro-benzo[d][1,3]oxazin-2-one 1-[1-(3-Chloro-2-methyl-benzenesuffonyl)-piperldln-4-yl]-1,4-dihydro-benzo[d][1,3]oxazln-2- one 515 1-[1-(4-Butyl-benzenesulfonyl)-piperidin-4-ylH.4-dlhydro-benzo[d][1,3]oxazin-2-one 516 •(4"Bromo-3H7iethy!-benzenesulfonyi)-piperldin-4-yl]-1,4-dihydro-benzo[d][1,3]oxaz1n-2- one ' ,1 -Dimethyl-propyl)-benzenesulfony)]-plperidin-4-yl}-1,4-dihydrt>- benzo[d][1,3]oxazin-2-one N-{4-Methyl-5-[4-{2-oxo-4H-benzoId][1,3]oxa2in-1 -yt)-piperidine-1-sulfony!3-thlazol-2-yl}- acetamlde ft 1 -I1 -{3-Chloro-2-fluoro-benz0nesulfonyl)-plperldin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazln-2- 510 one con 1 -E1 -(2-Bromo-4-fluoro-benz8ne8Ulfonyl)-plperidln-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2- 520 one 521 1 -[1-(4-Bramo-3-trrfluoromethyl-benzenesulfonyl)-piperidin-4-ylI-1,4-dihydrobenzo[ d][1,3]oxazin-2-one 522. 4 - d t h y d r o - b e n z o [ d ] [ 1 , 3 ] o x a z i n - 2 - 523 1 -[1 -(l8oquinoline-5-sulfonyi)-piperidin-4-vl1-1,4xllhvdro-benzo[dl[1.3]oxazin-2-one 524 6-Fluoro-H1-(2-methanesulfonyl"benzenesulfony[)-piperidln-4-yl]-1l4-dlhydro- enzo[d][1.3]oxazin-2-one B-Fluoro-1-[1-(4-propyl-benzene8ulfonyl)-plpei1dln-4-ylJ-1f4-dihydro-benzo[d]t1,3]oxazin-2- &Z5 one 526 1 "f1 - dl[1.3]oxazin-2-one 527 1 -f1 -f 4-Butvl-benzenesulfonvl)-plpBridin-4-vl1-6-fluoro-1,4-dlhydro-benzordiri ,3]oxazin-2-one 1 -[1 -(4-Bromo-3-methyl-benzen88Ulfonyl)-plperldin-4-yf]-6-fluoro-1,4-d!hydrobenzo[ d][1,3]oxaz!n-2-one 529 4-(i, 1 -Dlmethyl-propyl>-benzenesulfonyl]-plpeTiarn-4--yt}-fr-fJuoro-1,4-dihydro- enzofd][1.3]oxazin-2-one 530 g.{5_[4-(6-Fluoro-2-oxo-4H-benzo[d][1,3]oxazln-1 -yl)-piperidine-1 -sulfonylH-methyl-thlazol- 2-y(}-acetamide 531 1 "1 -(3-Ch!oro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-6-fIuoro-1,4-dihydrobenzo[ d][1,3]oxazin-2-one 532 1-[1-(2-Bromo-4-fluoro-benzenesulfonyl)-plperldin-4-yi]-6-fluoro-1l4-dihydro- enzo[d][1,3]oxaztn-2-one 533 1 -[1 -(4-Bromo-3-trifluoromethyl->enzenesulfonyl)-plperldin-4-yll-6-fluoro-1,4-dihydro- benzofdlH,3]oxazin-2-one 534 1 -lH5-Chloro-2-fluoro-benzenesulfonyl)-pIper1din-4-yl]-e-fluoro-1,4-dihydropenzo[ d][1 .33oxaztn-2-one 635 6-Fluonxl -f 1 -flsoqulnoHne-5-sulfonyi-plDerldin-4-vi]-1,4-dihydro-benzo[cnf 1.3Ioxazin-2-one 636 6-RUQTO-1 -[1 ^guinollne-8-sulfonvn-plperldin~4-vn-'l.4-dlhydro-benzofdlf 1.3]oxa2in-2-one 537 1 -[1 -(5-Chloro-3-meihyl-benzo[b]thlophene-2-sulfonyf)-piperklIn-4-yi]-6-fluoro-1,4-dihydrobenzoWlp ,3]oxazln-2-one 538 6-Huoro.Hl-(naphthalene-lulfonyl)-Diperldiri-viT-1.4-dihvdro-benzordlf1.3]oxaz[n-2-one 530 8-Ruoro-1-[1-fnaphthalene~2uffonylVDlDerMin^4-vl1-1.4-dihydn-benzordiri.3lQxazin-2-one 540 2-one 541 1 -[1 -(Benzo[b]thtophene-3-suffony])-plperidin-4-y[]-e-fIuoro-1,4-dihydro-benzo[dJ[1,3]oxazln- 2-one 542 8athoxy-1 -n-fguinoltne-8-8ulfonv[)-pip6rldln-yl]-1,4-dihydro-benzordl[1,31oxazfn-2-one 643 1 -{1 K5hioro-3eftyt-benzo[b]thiophene-2-sutfony1)-pfperidin-4-yf]-8-methoxy-1,4- dihydro-benzo[d7[1,3]oxazlrv-2-one 544 one 8-Methoxy-1-(Hnaphthalene-l-3ulfony!)-plperldin-4-yl]-1l4-dihydro-benzo[d]t1,3]oxazln-2- 545 one 8-Methoxy-1 -[1 -(naphthalene-2-«ulfonyl)-piperldin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazln-2- 546 1 -[1 -(Benzo[b]thtophen6-2-«ulfonyl)-plperidirv4-yl]-8-inethoxy-1,4-dihydroaenzo[ dl[1,3]oxazin-2-one 547 1 -{1-{Benzolb]thiophene-3-sutfbnyJpfperldfn-4l]-a-methoxy-1,4-dlhydro- 548 j-Ghloro-l-n^-methanesuIfonyl-benzenesutfonyl^piperldln-^ylJ-l^-dihydrojenzofcflf 1,3]oxazin-2-one KAO 5-Chloro-1 -[1 -{4-propyJ-benzenesutfonyl)-piperldln-4-ylh1,4-dihydro-benzo[d][1,3]oxazin-2- 548 one 550 5"Chloro-1 -[1 -(3-ch!oro-2-methyl-benzBnesulfonyl)-plperidtn-i-yQ-1,4-dihydronzofdlfl ,3]oxaztn-2-one 1 -[1-(4-Butyl-benzenesulfonyl)-p!peridin-4-v1>5-chloro-1,4-dihydro-benzoIdKI ,3]oxaz!n-2- one 552 1 -{1 -(4-Bromo-3-methyl~b6nzene8Utfonyl)-plperldln-4-yl]-5-ch!oro-1,4-dlhydro- enzo[d]|"1,3]oxazin-2-one 553 5-Chioro-1 -{1 -[4-(1,1 -dimethyl-propy()-benzene8uJfonyl]-piperklin-4-y!}-1,4-dihydrozcrfdH1,3] oxazln-2-Qne N-{5-[4-(5-Chloro-2-oxcK4H-benzo[d3[1,3]oxazin-1 -yl-plp6ridine-1 -sulfonyl]-4-methyI-thlazol- '.-vO-acetamida 555 5-Chloro-1 -[1 -3-chtoro-2-fluoro-benzenesulfonyl)-p!p6rIdln-4-ylh1,4-dlhydrobenzofdin ,3]oxazln-2-one 556 benzo[dl[1 .31oxazln-2-one 557 141-(4-Bromo-34rifluoromethy!-benzanesulfonyl)ipertdln-4-yl]-5-chlcjro-1,4-dihydro- enzojd][1,3]oxazln-2-one "Chloro-1 -[1 -{5-chloro-2-fIuoro-benzenesulfonyl)-p!peridln-4-ylH ,4-dihydrojertzojdin. 31oxazin-2-one 5SO 5-Chloro-1-n -flsoqulnol!ne-5^ulfonvl)-plperidliv4-vn-1,4-d[hvdro-benzof(nH .31oxazin-2-one 560 1 -{1 -(2-Methanesulfonyl-benzenesulfonyl)-plperidin-4-yll-8-niethoxy-1,4-dIhydro- enzo[d][1,3]oxazln-2-one 561 i -[1 -(2-Methanesutfonyl-benzenesulfonyt)-piperidirv4-yl]-&^ethoxy-1,4-dihydroienzo[ dl[1.3]oxa2ln-2-Qne 562 1 -[1 -{3-Chloro-2-methyi-benzene8uffonyI)-plper]d!n-4-yl]-8-methoxy-1 ,4-dfhydrobenzo[ d]f1 ,3]oxazln-2-one 1.[1.(4-Butyl-benzenesulfony!)-piperIdifv4-yl]-8-methoxy-1l4^ihydro-benzoId][1,3]oxazln-2- 563 one 564 1 -[1 -{4-Bromo-3-methyI-benzene8ulfonyl)-pIperidln-4-yl]-8-melhoxy-1,4-dihydro- >enzo[d][1.31oxazln-2-on6 penzoIdlH .3]oxazln-2-one 566 I N-(5-[4-f8-Methoxy-2-oxo-4H-bBnzord][1,3]oxazlr>-1-vl)-plperidine-1-sulfonvi]-4-methyl- 1S1 thlazol-2-y[)-acetarn ide 567 1 -fl -{3-Ch[oro-2-fIuoro-benzenesutfonyl)-plperidin-4-y[]-8-methoxy-1,4-dfhydrobenzofdin ,3]oxazin-2-one 568 1 -{1 -2-Bromo-4-fluoro-benzenesulfonyl)-piperidln-4-yl]-fl-methoxy-1,4-dfhydrobenzo[ d][1,33oxazln-2-one 569 1 -[1 H[4-Bromo-3-trlfluorometiiyl-benzene3ulfonyf)-pIperldln-4-yI]-8-m«hoxy-1,4-dihydrobenzo[ d][1,3]oxazin-2-one 670 1 -[1 -(5-Chloro-2-fluoro-benzenesulfonyl)-plperidln-4-yl]-8-mBthoxy-1,4-dihydrobenzo[ d][1,3]oxazln-2-one 571 1 -[1 -(!soquinoline-5-6ulfonyl}-p!peridfn-4-yl]-8-methoxy-1,4-dlhydro-benzo[d][1,3]oxazln-2- one; hydrochloride 572 1 -[1 -(4-Methyl-naphthafene-l -sulfonvl)-ptperldln-4-vl]-1.4-dlhydro-benzo[d]n ,3]oxazln-2-one 573 6-Chlora-1 -[1 -(4-methy[-naphthalene-1-suHbnyl)-plperidin-4-yl]-1,4-dihydrobenzo[ d][1.3]oxazln-2-one 574 6-Methy1-1 -[1 -{4-methy[-naphthalene-1-sulfonyl)-pIperidirv-4-yl]-1 benzo[d]{1,3]oxazin-2-one 575 8-Methyl-1-[1-{4-methyl-naphthalene-1-aulfonyl)-ptperidin-4-yl]-1p4-dihydrobenzo[ d][1.3]oxazin-2-one 576 6-Fluoro-1 -[1 -(4-methy[-naphthatene-1 -sulfonyl)-piperidin-4-yl]-1,4-dihydrobenzo[ d]M ,3]oxazln-2-one 577 8-Methoxy-1 -[1 -(4-methyl-naphtha!ene-1 -sulfonyl)-plperid!n-4-y1]-1,4-dfhydrobenzofdiri ,3]oxazin-2-one 578 5-ChIoro-1-[1-(4-methyl-naphtha[ene-1-3ulfonyl)-p!perfdln-4-yl]-1,4-dlhydrobenzofdlM ,3]oxazin-2-one 579 5-Chtoro-1-[1 -(naphthalene-1-sutfonyl)-plperidln-4-yn-1.4-dlhydro-benzo[dlf1,3loxazln-2-one 580 5-Chtoro-1 -[1 -(naphthalene-2Hsutfonyl>-plperidln-4-v^-1,4-dlhydfD-benzo[d][1,3]oxazln-2-one 581 S-Chtoro-1 -[1 -fquinoline-8-sulfonyl)-plperidln-4-yl]-1,4-dihvdro-ben2ordlf1.3]oxaz»n-2-one 582 5-Chloro-1 -[1 -(5-chloro-3-methyl-benzo[b]thlophene-2-«ulfonyl)-piperid1n-4-yl]-1,4-dihydrobenzo[ d]f1,3]oxazin-2-one 583 1-[1-(Benzo[b]thiophene-2-8Ulfonyl)-piperidin^-yl]-5^hloro-1,4Kl!hydro-benzo[d][1,3]oxazin- 2-one 584 1-0 -{BenzoIb]thiophene-BUlfonyl-piperldir4-yI]-5-chloro-1,4-dihydr&-benzQ[d]l1,3]oxazin- 2-one 585 6-Bromo-1-[1 -4-methyl-naphthalene-1 -suifonyl-piperfdin-4-yl]-1,4-dlhydroaenzo[ d][1,3]oxazin-2-one 586 2-Chloro-4-fIuoro-5-[4-(8-methy[-2-oxo4H-benzo[d][1,3]oxazin-1-yl)-piperidlne-1-«ulfonyI]- benzole acid 587 2Jhlon5-[4-{6loro-2xo-4H-benzo£d][1,33oxazin-1-yl)-piperidine-1-su»fonyl]-4-fluorobenzole acid 588 2-Chlorofluoro-5-[4-(6-methy[-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-«ulfonyqsenzoic acid 589 2-Chloro-4-fluoro-5-4-(2-oxo-4H-benzold3[1,3]oxazin-1 -yl)-piperidine-1 -sulfonylj-benzolc acid 590 2-Chloro-fluoro-5-{4-(8-methoxy-2-oxo-4H-benzo[d][1l3]oxazin-1-yl)-piperidine-1-8ulfony!]- tienzoic acid 591 2^h!oro-5-[4-(5K;hlorD-2K)xo-4H-benzo[d][1,3]oxazi1-yl)peridine-1-8ulfonyH-fluorobenzolc acid 592 3-[4-(2-Oxo-4H-benzo[dlf1.31oxaz1n-1-vn-plperidlne-1 -sulfonvll-benzolc acid 593 3-[4-(8-Methoxv-2-oxo-4H-benzo[d]n.3loxazin-1-vl-plperidlne-1-sutfonvlT-ben2olcacld 594 3-[4-(S-Chloro-2-oxo-4H-benzord]ri .3loxazln--1 -vDnalperidina-l -sulfonvll-benz'oic acid 595 1 -[1 -l8oquinoline-5-sulf6ny])-plperidin-4-y18-methyl-1,4-dihydro-benzo[d][1,3]oxazIn-2-one; hydrochloride 596 6-Chloro-1 -{1 -(isoquinoline-5-su[fonyl)-piperidin-4-y1]-1,4-dihydro-benzo[d][1,3]oxazin-2-one; hydrochloride 597 -[1-(l3oquinoline-6-sulfonyl-p[peridin-4-yl3-6-methy1-1,4-dIhydro-benzo[d][1l3]oxazln-2- oneihydrochtoride 598 6.7-Difluon141 -(au inollne-8-sulfonvl-plperldln-4-vn-1,4-dlhvdro-benzordin .31oxazfn-2-one 599 1 -[1 -5-Chloro-3-methyl-benzo[b]thioph8ne-2ulfonyl)-piperidln-4-y]J-6,7-difIuoro-1,4- dlhydro-benzordin ,31oxazln-2-one 600 6.7-Ptfluoro-1 -n ^naphthalene-1-sulfonvn-piperldln-yl]-1.4-dihydro-benzordlfl ,3]oxazln-2- 601 one 6,7-Dffluoro-l -[1 -{naphtha!ene-2-sulfonyl)-piperidin-4-ylJ-1,4- one 602 1-[1-{Benzo[b]thiophane-2-sulfbnyl)-piperidln-4-yO-8l7-difluoro-1,4-dihydrobenzo[ d][1.3]oxazln-2-one 603 1-[1-(Benzo[b]thiophene-sulfonyl)-piperldln-4-yl]-6,7-dlfluoro-1,4-dihydrobenzo[ dl[1 ,3]oxazln-2-one 604 H1-(5-Dimethylamino-naphthalene-1-sulfonyl)-plperidin-4-yl]-6,7-dif)uoro-1,4-dihydrobenzo[ d][1.3]oxazin-2-one 605 1-fHBIphenyl-4-sulfbnvl)-piperidln-4-ylI-e.7-dlfluoro-1.4-dlhydro-benzord]ri.3loxazln-2-on9 606 1-[1 -{Benzo[112,5]thladiazole-4-8ulfony])-plperidin-4-ylh6,7-difluoro-1,4 benzo[d]{1,3]oxaz?n-2-one 607 1 -[1 -(Benzo[1.SJoxadlazole-sulfonylJ-plpeildin-ylJ-e, 7-dffluoro-1,4-dihydrobenzo[ d][1,3]oxazin-2-one 608 1-[H7-Chloro:benzp{1,2l6]oxadiazol6-4ulfonyf)H3lperidln74-yJh6,7-difluoro-1I4- benzofdlf 1,3]oxazln-2-one 609 8,7-Difluoro-1 -{1 -(4-methyl-naphthalene-1-8ulfonyl)-plperidin-4-yl]-1,4-dihydrobenzo[ d7[1,3]oxazin-2-one 610 1 -[1-(4-Chloro-naphthal9ne-1-8u[fonyl)-plperidin-4-yl]-1,4-dihydro-benzo[d]f1,3loxazln-2-one 611 1 -11 -(4-Fluoro-naphthalene-1 -sulfonyl)-plperldin-4-ylH ,4-dlhydro-benzord]f 1,31oxazln-2-one 612 1-f1-(D[benzofuran-2-sulfonyl)-plperldin-4-yl]-1,4-dlhydro-benzo[d][1.3]oxazln-2-one H1 -(2,3-Dihydro-benzofuran-6-8ulfonyl)-piper!din-4-yl]-1,4-dlhydro-benzo[d][1,3]oxazin-2- 613 one 614 1 -[HBIphenyl-2^utfonyQ-plperldlfHl.-yfM ,4-dlhydro-benzordlM .3]oxazln-2-one K 1-[1-{5-lsoxazol-5-yl-thlophene-2-8ulfbnyl)-piper?d[n-4-yl]-1l4-dlhydro-benzo[d][1,3]oxazln-2- 615 one . 61 e " -(4-Chloro-naphthal6ne-1 -sutfonyl)-plper!dfn-4-ylh8-methyM ,4-dlhydrobenzofd] ri,3]oxazin-2-one 617 1 -[l-(4-Fluoro-naphthalene-1 -sulfonyl)-piperidin-4-ylJ-6-methyl-1,4-dihydrobenzo[ d]f1,3]oxazln-2-one 1-[1-(Dibenzofuran-2-sulfonyf)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxaz!n-2- one . 618 1 -[1 -(2,3-Dihydro-benzofuran-5-sulfonyl)-plperidin-4-y[J-8-methyl-1,4-dihydrobenzo[ d][1,3]oxazln-2-one 620 1-[1- 621 1 -[1 -(5-lsoxazol-5-yl-thtophen9-2-«ulfonyl)-piperldin-4-yl]-8-mBthyl-1,4-dihydrobenzo[ d][1.3]oxazJn-2-one B22 5-Chloro-1-[H4-ohloro-naphtha!ene-1-sulfbnyl)-plperidin-4-yl]-1,4-d!hydrobenzoMM .31oxazln-2-one 623 5-Chloro-1-[1-(4-fluoro-naphthalene-1-sulfonyl)-piperidin-ylM,4-cf!hydrobenzo[ diri .3]oxazln-2-onB 5-Chloro-1-[Hdibenzofuran-2-sulfonyl)-plperidin-4-yl]-1,4-dlhydro-benzo[d][1,3]oxazln-2- one 5-ChlorD-1-[1-(2,3-dihydro-benzofuran-5-sulfonyl)-plperidin-4-yl>1,4-dihydrobenzofdlfl ,3]oxazln-2-one 626 1 -f1 -fBlphenyl-2-sulfonyl)-plperidinH4-vll-.5-chloro-1.4-dih vdro-benzord][1.3]oxazin-2-one 627 5-Chloro-1 -[1 -(5-isoxazol-5-yl-thiophene-2-sulfbnyl)-piperidfn-4-yl]-1,4-d!hydrob9nzo[ d][1,3Toxazln-2-one 628 1-[1-{4-Chloro-naphthalene-1-sulfonyl)-piper!din-4-yl]-8-methoxy-1,4-d]hydrobenzofdin ,3]oxazln-2-one 629 1 .[1 -(4-Fluoro-naphthalene-1 -sulfonyl)-plperidin-4-yl]-8-methoxy-1,4-dihydrobenzo[ d][1,3Ioxazln-2-one 1 -[1 -(Dibenzofuran-2-3ulfonyt)-piperidin-4-yl]-8-methoxy-1,4-d[hydro-benzo[d][1,3]oxazii>2- ona 631 l-fHS-Dihydro-benzofuran-S-sulfonyO-piperidin^yq-B-methoxy-l^-dihydrabenzo[ d][1,3]oxazln-2-one 632 1-ri-fBlph6nyl-2utfonylVpiperidliT-4-yll-6-methoxy-1.4-dihydro-benzord]ri.3]oxazln-2'One 633 1-[1-(5-lsoxazol-5-yl-thtophene-2-sulfonyl)-pfperidin-4l]-8-methoxy-1,4-d[hydrobenzofdlH ,31oxazin-2-one 634 6-Chloro-1 -f1 -(4-chloro-naphthalene-1-8Utfonvl)-ptperidln-4-vl]-1,4-dihydro- 153 benzofd][1.3]oxazin-2-one 635 6-Chloro-1-[1-(4-fluoro-naphthalene-1-8u!fonyl)-piperidln-4-yl]-1l4-dihydrobenzo[ diri .3]oxazin-2-one 638 6-Chloro-1 -[1 -(dibenzofuran-2-sulfonyI)-pIperWin-4-ylJ-1,4-dihydro-benzo[d][1,3]oxazin-2- one 637 e-CMoro-1 -[1 -(2,3-dlhydroenzofuran-5-sulfonyl)-piperidin-4-y!]-1,4-dihydrobenzofd][ 1.3]oxazin-2-one 638 1-n-(Biphenyl-2-sulfonvlVpiperldln-4-y[]-6-chloro-1T4-dihvdro-benzord]ri.31oxazin-2-one 639 benzold][1,3]oxazin-2-one 640 1 -[1 -{4-Chloro-naphthalene-1 utfonyO-pfperidin-4-y[]-6-methyl-1,4-dihydrobenzofdTM, 3]oxazin-2-one 641 1-[1-4-Fluoro-naphthalene-1-sulfonyl)-plperidin-4-yl]-6-methyH,4-dihydrobenzo[ d]f 1,3]oxazin-2-one 642 one ,4-dihydro-benzo[d][1 ,3]oxazin-2-. 643 1 -{1 -{2,3-Dlhydro-benzofuran-5-8Ulfonyl)-piperidin-4-yl]-6-methyl-1,4-dlhydrobenzordff 1,3]oxazin-2-one 644 1 -11 -Biph6nyl-2-su]fonyl-piperldln-4-yn--methyM .4-dihydro-benzord][1,3]oxazin-2-one 645 1 -[1-(5-l30xazol-5-yl-thtophene-2-sulfonyl)-pfper!din-4-yI]-6-methyH ,4-dihydrobenzo[ d][1,31oxazin-2-one 646 1 -[1 -(4-Oiloro-naphthalene-1 -sulfonyI)-plper]din-4-yl>6,7-difluoro-1,4-dihydrobenzo[ d][1 . 647 B,7-Dlfluoro-1 -[1 -(4-fluoro-naphthatene-1 -sulfonyl)-piperldin-4-yI]-1,4-dlhydrobenzofdlfl ,31oxazJn-2-one (Dlbenzofuran-2-8ulfonyl-piperidin-4-yl]-6,7-difIuoro-1,4-dihydro4»nzo[d][1,3]oxazin-2- one 649 4 -[1 -(2l3-Dihydro-benzofuran-5-6Ulfonyl)-plperidin-4-yl]-6,7-difluoro-1,4-dfhydrojenzo[ d]f1,3]oxazin-2-one 650 -[1 -{Biphenyl-2-BUlfonyl)-plperidiiv4-yll-6.7-dlfluoro-1.4-dlhydro-benzo[diri .3Ioxazln-2-one 651 3,7-Difluoro-1 -[1 -(5-isoxazof-5-yl-thlophene-2-sulfonyl}-pipericfln-4-yl]-1,4-dihydrobenzofdlM 3]oxaz!n-2-one 1-[1-(1,2-Dimethyl-1H-im!dazole-4-sutfonyl)-piperidin-4-yl]-1l4-dihydro-benzoIdK1,3Joxazin- 2-one 653 HH5-Mathyl-benzo[1 .Sjthfadlazole'SUlfonylJ-piperidin-yl]-! ,4-dihydrobenzordiri ,3bxazin-2-one Ocx -[1-(3,5-Dlmethyl-isoxazole-4-sulfonyl)-piperidin-4-yl]-1,4-dlhydro-benzo[d][1,3]oxazin-2- 654 one ess bercoCdin ,3]oxazin-2-one 8-Methyl-1 -[1 -(5-methyl-benzo[1,2,5|thiadiazore-4^ulfonyl>.piperidin-4-yl]-1,4-dihydrobenzordTH ,3]oxazin-2-one 1 -[1-(3,5-Dlm0thyl-l80xazole-4-lfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydrobenzo[ dltL31oxazin-2-one . 6-Chloro-1-[1 -1,2-dimethyl-1 H-lmldazolB-4-8Ulfony!)-piperidln-4-ylh1,4-dihydro benzo[djri,31oxazin-2-one . 6-Chloro-1-[1 -(5-methyl-benzo[1,2,5lthtadiazofe-4-sulfonyl)-piperidin-4-yri-1,4-dihydrobenzofd] f1,3]oxazln-2-one 660 5-Chloro-1 -[1-(3,5-dimethyl-lsoxazole-4-autfonyl)-p!peridin-4-yl]-1,4-dihydro- enzo[d][131oxazin-2-one 661 1-IH1,2-Dlmethyl-1H-imkJazole-4-sulfonyl)-piperidin-4-yl]-8-nnethoxy-1r4-dihydrobenzord] ri,31oxazin-2-one 662 8-Methoxy-1 -[1 -{5-methyl-benzo[1,2,5]{hiadiazole-4-sulfonyl)-piperid!n-4-y!]-1,4-dihydrobenzord][ 1.31oxazin-2-one . 663 1 -[HS.S-Dlmethyl-lsoxazole-sulfonylJ-piperidin-rhe-methoxy-l ,4-dihydrobenzo[ dl[1,3]oxazin-2-one 5-Ch!oro-1-[1 -(1,2-dlmethyl-1 H-lmidazole-4-6ulfonyl)-pperidln-4-yl]-1,4-dihydrobenzordlflStoxazi^- one 665 5^hloro-H1-(5-melhyl-benzoE1,2,5]lh1ad]azole-4-sulfonyl)-piperId&T-4-yl]-1l4-dihydrojenzc^ dlll ,3loxaz-2-one 666 5-Chtoro-1 -[1 3,5-dimethyMsoxazole-sulfony])lperidin-4-yi]-1 ,4-dlhydro- " ,3]oxazin-2-one 667 1 -[1 -{1,2-DimethyM H-lmldazofe-4-sulfonyl)-plperldfn1-yi]-6-methyl-1,4-dlhydrobenzo[ d][1,3]oxazin-2-one 668 6-Methyl-1-[1-(5-m6thyl-benzo[1,2p5]thiad!azoJe-4-sulfonyl)-plperidin-4-yl]-1,4-dihydrobenzofd][ 1,3Ioxazin-2-one 669 l-fl-fS.S-Dimethyl-isoxazole-aulfonylJ-pfperldln-ylJ-e-methyl-l-dihydrobenzotd][ 1,3]oxazin-2-one 670 ,2-Dimethyl-1 H-!midazole-4-su!fonyl)-piperldin-4-y]]-8-fluoro-1,4-dihydrobenzojd][ 1,3]oxazin-2-one 671 benzofd]f1,31oxazin-2one 672 1-[1-(3,5-Dimethyl-isoxazolesulfbnyl}-piperldin-4-yl]-6-fIuoro-1,4-dihydrobenzo[ d][1,3]oxazln-2-one 673 benzordiri ,3l6xazln-2-orie R74 benzofdin .31oxaztn-2-one 675 1-[1-(3l5lmethyl-isoxazole4-sulfonyl)-Piperid!n-4-yl]-6,7-difluoro-1,4-dihydrobenzo[ d][1,3]oxazin-2-one 676 677 M1 -r5-Chloro-naphtfiaIene-1 -sulfonyl)-pp9rldln-4-yl] 1-[H5-Chloro-naphthaIene-2.sulfony)-piperJdin-4-yl -1 ,4-dihydro-benzo[d][1 ,3]oxazin-2-one 1-1 ,4-dihydro-benzo[d][1 ,3]oxazin-2-one 678 N-{5-[4-(2-Oxo-4H-benzo[d][1,3]oxazin-1 -yl)-plper[dine-1 -«ulfonylj-naphthaten-1 -yl}- acetamide 679 1-[1-5-Chloro-naphthalene-1-sulfonyl)-p!peridln-4-yl]-8-methyl-1,4-dlhydrobenzofdlfl ,3]oxazin-2-one 680 1 -[1 -{5-ChJoro-naphthalen&-2-sulfony[)-piperldin-4-yI]-8-methyl-1,4-dihydrobenzo[ d]f1.3]oxazin-2-one 681 NKM4 acetamide 682 5-Chloro-1 -[1 -(5-chloro-naphthalene-1-suIfonyl)-piperidin-4-yf]-1,4-dlhydrobenzo[ d][1,3]oxazln-2-one 683 5-Chloro-1-[1-(5-chloro-naphthalene-2-3ulfonyl)-piperidin-4-yl]-1,4-cfihydrobenzofd][ 1,3]oxazin-2-one 684 N^-[45hlort-2-oxo^H-benzo[d][1,3]oxazin-1-yl)-plperidine-1-sulfonyl]-naPhtha]en-1-yl}- acetamide 685 1-[1-(5-Chloro-naphftalene-1-suifonyl-plperidirv4-yl]-8-methoxy-1,4Kllhydrobenzofdin ,3]oxa2in-2-one 1 -f 1 -(5-Chloro-naphtha!ene-2-3Ulfonyl)-plperidin-4-yl]-8-methoxy-1,4-dihydrt- benzofdl[1,31oxazin-2-one 687 N-[5-[4-(8-Methoxy-2-oxo-4H-benzo[d][1,3]oxazin-1 -ylperfdine-1 -sulfonyl]rnaPhthaleiv1 - yl}-aoetarnide 2,5-Dimethyl-[4-(8-methyl-2-oxcMH-benzoId][1,3]oxazIn-1-yl)-PiPeridlne-1-Bulfonyll-fUran- 3-carboxylic acid methyl ester . 689 J-Methyl-HH2-ox-2,3ihydro-benzothiazole-6ulfonyl)-Piperldln-4-yl]-1,4-dihydroienzo[ d][1,3]oxazln-2-one 690 1 -[1 -(4-Fluoro-3-methyl-benzenesulfonyl)-piperidin-4-ylJ-8-methyl-1,4-dlhydroienzo[ dl[1,3]oxazin-2-one 8-Methyl-1 -[1-(2-oxo-2,3-dfhydro-benzooxazole-6-sulfony[)-plperidin-4-yl]-1,4-dlhydro~ benzo[d][1.3]oxazIn-2-one 692 1 -[1-(4-Cyclohexyl-benzene8Ulftnyl-piPeridin-4-yl]-8-niethyl-1,4-dIhydrobenzord][ 1,31oxaln-2-ona 2,5-Dimethyl-4-[4-(2"Oxo-4H-benzo[d][1l3]oxazln-1-ylpiperIdlne-1-sulfbnyl]-furan-3- carboxic acid methyl ester 1-[1-(4-Fluoro-3-methyl-bianzenesu!fonyl)-pfperidin-4-yl]-1,4-dlhydro-benzoj;d][1I3]oxazln-2- one 695 1"1 -(2-Oxc-2,3ihydro-benzooxazole-6sunbnyl}-piPeridln-4-yl]-1,4-dIhydrobenzo[ dlf1,3]oxazin-2-one 1 .[1 -(4-Cyclohexyl-benzenesulfonyl)-plpei1din-4-yn-1,4-dihydro-benzo[d][1.31oxazln-2-one 697 2-Fluoro^-[4-(8-methyl-2K)xo^H-benzorcnC1.3loxazln-1-yt)-piperid{ne-1-sutfQnyl]-benzolc 698 acid 2-Fluoro-5-[4-(2-oxo-4H-benzofdiri .31oxazin-1 -vl-p|peridine-1 -sutfbnyll-benzoic acid 699 1 -[1 -{a-Oxo.S-dihydro-benzothlazole-e-sulfbnylJ-piperidin^yll-l ,4-dihydrobenzo[ d][1,3]oxazin-2-one 700 1 -[1-(5-Pyridin-2-yl-thiophene-2ulfonyl-piperrdin-4-y|]-1,4-dihydro -benzo[d][1,31oxazin-2-one 701 3-r4-(2-Oxo-4H-benzo[diri.3]oxazin-1-vl)-plperidine~1-sulfonvn-benzonitrile 702 3-[4-(2-Oxo-4H-benzo[d][1,3]oxazin-1 -yl)-piperidlne-1 -sulfonylJ-thiophene-2-carboxylic add methyl ester 703 H5-[4-(2-Oxo-4H-benzo[d][1,3]oxazin-1-yl)-p!perldine-1-8ulfbnyl]-napMhalen-1-yI}- pyrrolidine-2,5-dione 704 1 -[1 -(2-Chloro-5-trifIuoromethyl-benzenesulfonyl)-plperidln-4-y]]-1,4-dihydrobenzo[ d][1,3]oxazin-2-one 705 -(3.4-Dlmethyl-benzenesulfonyl>-plperidln-4-yl3-1,4-dlhydro-benzord][1,3]oxaz!n-2-one 708 8-Methyl-1 -{1 -(5-pyridin-2-yl-thiophene-2-«u[fonyl)-piper!d in-4-yl]-1,4-dihydrobenzo[ d][1,3]oxazin-2-one 707 3-f4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-vl)-plperldine-1-sulfonyl]-benzonitrile 708 carboxyllc acid methyl ester 709 H5-[4-(B-Methyl-2-oxo-4H43enzo[d][1,3]oxazln-1-yl)-piperidine-1-siJ(fonyl]-naphthaler»-1-yl)- Pvrrolldine-2,S-dione 710 1 -[1 -(2-Chloro-5-trffluoromethyl-benzBnesulfbnyl)-plperldin-4-yl]-8-niethyl-1,4-dihydrobenzo[ d][1.3]oxazin-2-one 711 1 -[1-(3.4-Dimethyl-benzenesulfonyl)-plperidln-4-yl]-8-methyl-1,4-dihydrobenzo[ d]f1,3]oxazin-2-one 712 5-Chloro-1-[1-(5-pyridln-2-yl-thiophene-2-sulfonyl)-piperidir-4-yl]-1,4-dihydrobenzo[ d][1,3]oxazin-2-one 713 3-[4-(5-Chloro-2-oxo~4H-benzo[d]f1.3loxazln-1-yl-plperidin6-1-8ulfonyi]-benzonltrBe 714 3-[4-(5-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-plperidine-1-sulfonyl]-thiophene-2- carboxylic acid methyl ester 1-{5-{4-{5-Chloro-2-oxo-4H-benzo[d]I1,3]oxazin-1 -yl)-plperidine-1 -«ulfonyl]-naph&ialen-1-yl}- pyrrolldine-2,5-dione 5-Chlon-1 -[1 -(2-chloro-5-trif1uoromethyl-benzenesulfonyl)-piperldin-4-yl]-1,4-dihydrobenzord][ 1,3loxazin-2-one 717 S-CNoro-1 -[1 -3J4-dlmethyl-benzene8Ulfonyl)-piperfdin-4-yl]-1,4-dihydrobenzo[ d][1,3]oxazln-2-one 718 6-Methyl-1-[1-(5-pyridin-2-yl-thiophene-2-6ulfonyl)-piperidin-4-yl]-1l4-dihydroaenzo[ d][1.3]oxazin-2-one 719 3-f4-f6-Methyi-2-oxo-4H-benzord1f1.31oxazliv1-vl-piperidme-1-sulfonvl]-benzonltrile 720 3-[4-{6-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-y!-piperidine-1-su!fonyl]-thiophene-2- carboxylfc acid methyl ester H5-[4-(8-Methy!-2-oxo-4H-benzo[d][1,3]oxazln-1-yl)-piperidine-1-sulfonyl]-naphthalen-1-yl}- pyrrolldine-2.5-dione 722 1 -[1 -(2-Chloro-5-trlfluoromethyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dlhydrojenzo[ d][1,3]oxaz]n-2-one 723l-II-tSDimethyl-benzenesulfonyplperidin-yll-e-methyl-IAdihydrojenzord][ 1.3]oxazln-2-one 724 6-Chloro-1 -[1 -{5-pyridin-2-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro- 3enzo[d][1,3]oxazln-2-one 725 3-[4-(6-Chloro-2-oxo-4H-benzo[cr|[1.3]oxazln-1-yl)-Plperidine-1-su[f6n^]-benzonltrlle 726 3.[4-(6-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-plperidine-1-sulfonylHhiophene-2- carboxyllc acid methyl ester 1-{5-[4-(6-Chloro-2-oxo-4H-benzo[d3[13]oxazln-1-yl)-plperidine-1-sulfonyl]-naphthalen-1-yl}- pyrrolldlne-2,5-dione 728 6-Chloro-1 -[1 -{2-chloro-5-trifluoromethyl-benzenesulfony[)-pIperidir>4-yl3-1,4-dlhydro- 3enzo[d][1,3]oxazln-2-onB 729 6-Chloro-1 -[1-(3,4-dimethy[-benzenesulfonyl)-piperidin-4-ylI-1,4-dihydro- enzo[dK1,31oxazIn-2-one 730 1 -t1 -(S-Methyl-l3oxazole-4-sulfonyl)-plperldlrv4-ylM .4-dlhydro-benzo[din ,3]oxazln-2-one 731 1 -[1 -2,2-Dlmeth^-chroman-e-6uifonyl)-plpBridin-4-yl]-1,4-dFhvdro-benzordiri ,3]oxazln-2-one 732 1 -[1 -(4-Methyl-314-d ihydro-2H-benzo[1,4]oxazine-7-sulfonyl)-piperidin-4-yl]-1,4-dihydrobenzofdin. 31oxazin-2-one 733 1 -[1 -(2,3-Dihydro-benzo[1 ,4]dioxlne-6-sulfonyl)-pipBridin-4-yl]-1 ,4-dihydrobenzo[ d][1 ,3loxazin-2-one 734 -[1 -(1 ,3,5-Trimethy]-1 H-pyrazo[e-4-sulfonyl)-piperidin-4-yl]-1 ,4-dihydro-benzo[d][1 ,3]oxazln- 2-one 735 1 -[1 -(S-Methyl-oxo- 3-dihydro-benzooxazole-6-sulfonyl)-piperklin-4-yl]-1 ,4-dihydrobenzo[ d]f1 ,3Joxazin-2-one 736 S-Methyl-Hl-IS-methyl-isoxazole-ulfonyllperidin-yll-ldihydrobenzo[ d][1.3]oxazln-2-one 737 1 -[1 -(2,2-Dimethy[-chronrian-6-Bulfonyl)-piperidin-4-y[]-8-methyl-1,4-dlhydrobenzo[ d][1.31oxazin-2-one 738 8-Methyl-1 -[1 -(4-methyl-3,4-dihydro-2H-benzoI1,4]oxazlne-7-su1fony])-piperidin-4-yl]-1 ,4- d|hydro-benzo{d3[1,3]oxazln-2-one 739 1 -[1 -(2,3-Dihydro:benzo[1,4]diqxine-6-su|fqnyl)-piperldln-4-yl]-8-methyM ,4-dlhydrabenzo[ d][1,31oxazJn-2-one 740 S-Methyl-l-III.S.S-trimethyl-IH-pyrazole-ulfonylJ-piperldlnylHdfhydrobenzo[ d][1,3]oxazin-2-one 741 8-Methyl-1-I1-(3-methy[-2-oxo-2,3-dihydro-benzooxazole-8-sulfonyl)-p[peridln-4-yl]-1t4- dihydro-benzord][1,3]oxazin-2-one 742 8-Methoxy-1-[1 -1,3,5-trimethyl-1 H-pyrazole-4-8ulfonyl)-p!peridin-4-yl]-1,4-dihydix>- benzo[d][1,31oxazIn-2-one 743 8-Methoxy-1 -[1 -{3-meUiyl-2-oxo-2l3-dihydro-benzooxazole-6-suIfonyl)-piperidin-4-yl]-1,4- dihydro-benzo[d1f 1.3]oxazln-2-one 744 1-[1-(Benzo[d]isoxazol-3-ylmethanesulfonyl)-plperidin-4-ylJ-1,4-dihydro-benzo[d][1J3]oxazin- 2-one 745 1'[^"(2'2'4.6J-Pentamethyl-2I3-dthydro-benzofuran-5-8ulfonyl)-piperidin-4-yl]-1l4-dihydrobenzo[ d][1,31oxazin-2-one 7,R 6-Methyl-5-[4-(2-oxo-4H-benzo[d3[1,3]oxazin-1-yl)-piperidine-1 -sulfonyl}-1 H-pyrimidine-2,4- 740 dione 747 1 -[1 -(3-Methyl-quinollne-8-sulfonyl)-plperldin-4-yll-1,4-dihydro-benzo[d][1,3]oxazin-2-one 748 1 -[1 -(2,2,5,7,8-Pentamethyl-chroman-6-8ulfonyl)-piperidin-4-yl]-1,4-dlhydrobenzo[ d][1,31oxazin-2-one 749 1,4-Dimethyl-6-[4-{2-oxo-4H-benzo[d][1,3]oxazin-1-y!)-piperidine-1-sulfony1}-1,4-dihydroqulnoxaline- 2.3-dlone , 760 1-n-(1 H-lmldazole-4-sulfonyl)-piperidln-4-yl]-1,4-d[hydro-benzo[d]f1,3]oxazin-2-one 751 1 -[1 -{2-Oxo-1,2,3,4-tetrahydro-qulnoI]ne^-sulfonyl)-plperld!n-4-yl]-1,4-dlhydro- 3enzo[d][1,31oxazin-2-one 7-[4-(2-Oxo-4H-benzo[d][1,3]oxazln-1-yl)-piperldine-1-sulfonyl}-1,5-dlhydrobenzo[ blTL4]diazepine-2,4-dlone 8-Methyl-1 -[1 -(3-methyl-qulnol!ne-8-sulfonyl)-plperldin-4-yl]-1,4-dlhydro-benzo[d][1,3]oxazln- 763 2-one 8-Chloro-1 -[1 -(3-methyl-quInoltne-8-aulfonyl)-plperldln-4-yl]-1,4-dlhydro-benzo[d][1,3]oxazin- 2-one 5-Chloro-1 -[1 -(3-methyi-quinol]ne-8-sulfonyl)-plperldln-4-yt]-1,4-dihydro-benzo[d][1,3]oxazln- 2-one 756 J-Methoxy-1 -[1 -(3-methyl-quinollne-8-8Ul{bnyl)-plperldln-4-y]]-1,4-dlhydro- enzo[d][1,31oxazin-2-one 757 1 -[1 -(Pyridine-2-su!fonyI)-p]peridln-4-yll-1.4-dlhydro-benzo[d][1,3]oxaz!n-2-one 758 -[1 -{6,7-Dihydroxy-naphthalene-1 -sulfonyl-piper!din-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin- 2-one 75g Acetic acid 3-acetDxy-5-[4-(2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-plperidine-1-sulfonyl]- naphthalen-2-yl ester 760 1 -f1 -f 1 H-Benzoimidazole-2-8utfonvl)-plperldln-4-vl]-1.4-dihydro-benzorcn[1.3]oxazln-2-one 761 1 -[1 -{1 H-Benzoimidazole-2-sulfbnyl)-piperldin-4-yl]-8-methoxy-1,4-dlhydrobenzo[ d][1,3]oxazln-2-one 762 1-J1 -1 H-Benzo!mldazole-2-suIfonyl)-plperldin-4-yl]-5-chloro-1,4-dlhydrobenzo[ d][1.3]oxazin-2-one 763 1-[H2,5-Dimethoxy-benzenesulfbnyl)-piperidin-4-yl]-e-fluoro-1,4-dihydrobenzofd][ 1,31oxaztn-2-one 764 1 -[1-(2,5-Dimethoxy-benzenesu[fonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydrobenzo[ d][1. 3IoxazJn-2-one 765 1-[1-(2,5-Dimethoxy-benzenesulfonyl)-piperidln-4-yl]-6,7-dffluoro-1,4-dihydrobenzo[ d][1.3]oxazin-2-one 766 5-Chloro-1-[1-(2,5-dimethoxy-benzenesuifonyl)-piper1dIn-4-yI]-1,4-dihydrobenzofdin 3]oxazin-2-one 767 1 -[1 -{5-Dimethylamino-naphthalene-1 -ulfonyl)-plperldfn-4-yl]-8-methoxy-1,4-drhydrt>- benzotdiri .3]oxazin-2-one 5-Chloro-1-[1-(5Jimethylarnino-naphthalene-1-sulfonyl)-plperidin-4-yfI-1,4-dihydrc>- benzo[d][1.3]oxazin-2-one 768 769 6-Chloro-1 -[1-5-chloro-naphthalene-1-uffonyl)-plperldln-4-y[]-1,4-dihydrobenzo[ d][1.3]oxazln-2-one 770 1-[1-(5-Chloro-naphthalene-1-sutfonyl)-piperidin-4-yl]-e-methyl-1,4-dihydrobenzo[ d][1,3]oxazln-2-one 771 1 -[1 -(5-Chloro-naphthalene-1 -su[fony])-piperldin-4-yI]-6-fluon>-1,4-dlhydrobenzordlfl. 31oxa2in-2-orie 772 6-Chloro-1-[1-(5-chloro-naphthalene-2-8U]fony!)-plperldln-4-yl]-1,4-dihydrobenzo[ d][1,3]oxazin-2-one 773 1 -[1 -{5-Chloro-naphthalene-2-8u!fonyl)-p[peridin-4-yl]-6-methyl-1,4-dIhydrobenzo[ d][1,3]oxazin-2-one 774 1 -11 -{5hloro-naphthalene-2-sulfonyl)-plperldln-4-yl]-6-fluoro-1,4-dlhydrobenzo[ d1f1,3]oxazin-2-one 6-Methyl-1-[1-(3-methyl-quinoline-8-eulfonyl)-piperldin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazln- 2-one 77fi 6-Fluoro-1 -[1 -3-methyl-quinollne-8-sutfony[)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazln- 2-one 777 6,7-Dlfluoro-1-[1 -(3-methyl-quinollne-8-8Ulfonyl)-piperidln-4-yl]-1,4-dihydrobenzo[ d][1,3]oxazfn-2-one 77B 6-Chloro-1 -[1 - dlhydro-benzo[d][1,3]oxazin-2-one 779 6-Methyl-1 -[1 -(3-methyl-2-oxo-2,3-dlhydro-benzooxazole-e-8ulfonyl)-piperidin-4-yl]-1,4- dihydro-benzo[d][1,3]oxazlrv-2-one 780 " ' --(3-methyl-2-oxo-2I3-dihydro-bBnzooxazole-6-8Ulfonyl)-pIperidln-4-yl]-1,4- dihydro-benzo[dl[1,3]oxazin-2-one 7B1 6,7-Difluoro-l -[1-(3-methyl-2-oxo-2,3-dihydro-benzooxazole-6-su[fonyl)-plperidln-4-yl]-1,4- dihydro-benzo[d][1.31oxazin-2-one 7B2 5-Chloro-1 -[1 -(3-methyl-2-oxo-2,3-dihydro-benzooxazole-8-8ulfonyl)-piperidin-4-yl]-1,4- dihydro-benzo[d][1,31oxazin-2-one 783 6-Chloro-1 -[H4-methyl-3J4-dlhydro-2H-benzo[1 ^loxazine^-suIfonyO-plperidln^-yl]-! ,4- dlhydro-benzo[d][1.3]oxazin-2-one 784 6-Methyl-1 -[1 -{4-m8thyl-3,4-dihydro-2H-bBnzoI1,4]oxazine-7-8ulfonyl)-piperidin-4-yl]-1,4- dlhydrchbenzo[dl[1,3]oxazin-2-one 6-FIuoro-1-[1-(4-methy1-3,4-dihydro-2H-benzo[1l4]oxazine-7-8ultbnyl}-plperidin-4-yl]-1I4- dlhvdro-benzoFdlM .31oxazin-2-one 786 8-Methoxy-1 -{1 -(4-methyl-3,4-dlhydro-2H-benzo[1,4]oxazine-7-sulfonyl)-plperidln-4-yl]-1, dlhvdro-benzo[d][1,31oxazfn-2-one 787 5-Chloro-1-[1-(4-methyl-3,4-dlhydro-2H-benzo[1,4]oxazine-7-sulfonyl)-plperldin-4-yri-1,4- dlhydro-benzofdin ,3]oxazin-2-one. Preferably, the compound 1-[[(7T7-dimethyl-2-oxobfcyclo[2.2.1]hept-1- yl)methyl]sulfonyl]-4-(2-oxo-2H-3,1-benzoxazin-1(4H)-yl-piperidine may be excluded. More preferably, the compound 1-[[(7,7-dimethyl-2-oxobfcyclo[2.2.13hept-1- yl)methy(Jsuifonyl]-4-(2-oxo-2H-3,1-benzoxazin-1 (4H)-yl-piperidine, salts thereof and solvates thereof may be excluded. The compounds of general formula (Ib), their stereoisomers, corresponding salts and corresponding solvates may be obtained analogously by the methods described above for compounds of general-formula (I). For details of the process reference Is made to the description given above for compounds of general formula (I). Thus, in another aspect the present invention relates to a process for the preparation of benzoxazinone-derived sulfonamide compounds of general formula (Ib) given above, which comprises reacting at least one piperldine compound of general formula (Mb), wherein R1b to R9b have the meaning given above and/or a salt, preferably a hydrochloride salt, thereof, (Figure Removed with at least one compound of general formula (Ilib), (Figure Removed wherein Wb has the meaning given above, in a suitable reaction medium, optionally in the presence of at least one base and/or at least one auxiliary agent. in a further aspect the present Invention relates to a process for the preparation of a physiologically acceptable salt of the benzoxazinone-dertved sulphonamide compounds of general formula (Ib) given above or a corresponding stereoisomer thereof, characterized in that at least one compound of general formula (Ib) having at least one basic group is reacted with at least one acid, preferably an inorganic or organic acid, preferably in the presence of a suitable reaction medium. in a further aspect the present invention relates to a process for the preparation of a physiologically acceptable salt of the benzoxazinone-derived sulphonamide compounds of general formula (Ib) given above or a corresponding stereoisomer thereof, characterized in that at least one compound of genera] formula (Ib) having at least one acidic group is reacted with at least one base, preferably in the presence of a suitable reaction medium. In yet another aspect the present Invention relates to a pharmaceutical composition comprising at least one benzoxazinone-derived sulphonamide compound of general formula (!b) given above, optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, In any mixing ratio, or a physiologically acceptable salt thereof, or a solvate, respectively, and optionally one or more pharmaceutfcaliy acceptable adjuvants. 'In yet another aspect the present invention provides for a medicament comprising at least one benzoxazinone-derived sulphonamide compound of general formula (Figure Removed given above, optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or In form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a solvate, respectively, and optionally one or more pharmaceutically acceptable adjuvants. The medicament of the present invention is suitable for the prophylaxis and/or treatment of disorders that are at least partially mediated via 5-HTe-receptors. In particular, the medicament of the present Invention is suitable for the prophylaxis and/or treatment of food intake disorders, preferably for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, for the prophylaxis and/or treatment of bulimia, for the prophylaxis and/or treatment of anorexia, for the prophylaxis and/or treatment of cachexia, for the prophylaxis and/or treatment type II diabetes (non-Insulin dependent diabetes mellitus). Also in particular, the medicament of the present invention Is suitable for the prophylaxis and/or treatment of gastrointestinal disorders, preferably irritable colon syndrome; for the prophylaxis and/or treatment of disorders of the central nervous system; for the prophylaxis and/or treatment of anxiety; for the prophylaxis and/or treatment panic attacks; for the prophylaxis and/or treatment of depression; for the prophylaxis and/or treatment of bipolar disorders; for the prophylaxis and/or treatment cognitive disorders, preferably memory disorders; for improvement of cognition (for cognitive enhancement); for the prophylaxis and/or treatment of senile dementia; for the prophylaxis and/or treatment of psychosis; for the prophylaxis and/or treatment neurodegenerative disorders; preferably selected from the group consisting of Morbus Alzheimer, Morbus Parkinson, Morbus Huntington and Multiple Sclerosis; for the prophylaxis and/or treatment of schizophrenia or for the prophylaxis and/or treatment hyperactivity disorder (ADHD, attention deficit, hyperactivlty disorder). Another aspect of the present invention is the use of at least one benzoxazinonederived sulphonamide compound of general formula (ib) given above, optionally in form of one of its stereolsomers, preferably enantlomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or drastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a solvate, respectively, for the manufacture of a medicament for 5-HTe receptor-regulation, in particular for the manufacture of a medicament for the prophylaxis and/or treatment of disorders that are at least partially mediated via 5- HT6 receptors. . . Preferred is the use of at least one benzoxazinone-derived sulphonamide compound of general formula (Ib) given above, optionally in form of one of its stereolsomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a solvate, respectively, for the manufacture of a medicament for the prophylaxis and/or treatment of food intake disorders, preferably for the regulation of appetite, for the reduction, increase or maintenance of body weight; for the prophylaxis and/or treatment of obesity, for the prophylaxis and/or treatment of bulimia, for the prophylaxis and/or treatment of anorexia; for the prophylaxis and/or treatment of cachexla; or for the prophylaxis and/or treatment of type II diabetes. Also preferred is the use of at least one benzoxazinone-derived sulphonamide compound of general formula (Ib) given above, optionally in form of one of its stereolsomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a solvate, respectively, for the manufacture of a medicament for the prophylaxis and/or treatment of of gastrointestinal disorders, preferably irritable colon syndrome; for the prophylaxis and/or treatment of disorders of the central nervous system; for the prophylaxis and/or treatment of anxiety; for the prophylaxis and/or treatment panic attacks; for the prophylaxis and/or treatment of depression; for the prophylaxis and/or treatment of bipolar disorders; for the prophylaxis and/or treatment cognitive disorders, preferably memory disorders; for improvement of cognition (for cognitive enhancement); for the prophylaxis and/or treatment of senile dementia; for the prophylaxis and/or treatment of psychosis; for the prophylaxis and/or treatment neurodegenerative disorders; preferably selected from the group consisting of Morbus Alzheimer, Morbus Parkinson, Morbus Huntington and Multiple Sclerosis; for the prophylaxis and/or treatment of schizophrenia; or for the prophylaxis and/or treatment hyperactivity disorder (ADHD, attention deficit, hyperactivity disorder). The medicament according to the present invention may be in any form suitable for the application to humans and/or animals, particularly mammais, including humans, and can be produced by standard procedures known to those skilled in the art. The composition of the medicament may vary depending on the route of administration. The preparation of corresponding pharmaceutical compositions as well as of the formulated medicaments may be carried out by conventional methods known to those skilled in the art, e.g. from the tables of contents from .Pharmaceutics: the Science of Dosage Forms", Second Edition, Autton, M.E. (Ed.) Churchill Livingstone, Edinburgh (2002); .Encyclopedia of Pharmaceutical Technology", Second Edition, Swarbrick, J. and Boylan J.C. (Eds.), Marcel Dekker, Inc. New York (2002); ..Modern Pharmaceutics', Fourth Edition, Banker G.S. and Rhodes C.T. (Eds.) Marcel Dekker, Inc. New York 2002 and BThe Theory and Practice of Industrial Pharmacy", Lachman L, Lieberman H. and Kanig J. (Eds.), Lea & Febiger, Philadelphia (1986). The respective literature descriptions are incorporated by reference and are part of the disclosure. The pharmaceutical compositions as well as the formulated medicaments prepared according to the present invention may in addition to at least one compound of general formula (I), (la) or (Ib), optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a corresponding physiologically acceptable salt or a corresponding solvate, comprise further conventional auxiliary substances known to those skilled in the art, such as carriers, fillers, solvents, diluents, colouring agents, coating agents, matrix agents and/or binders. As is also known to those skilled In the art, the choice of the auxiliary substances and the amounts thereof to be used are dependent on the intended route of administration, e.g. oral, rectal, intravenous, intraperitoneal, intramuscular, fntranasal, buccal or topical route. Medicaments suitable for oral administration are for example, tablets, sugar-coated pills, capsules or multiparticulates, such as granules or pellets, optionally compressed into tablets, filled Into capsules or suspended in a suitable liquid, solutions or suspensions. Medicaments suitable for parenteral, topical or inhalatory administration may preferably be selected from the group consisting of solutions, suspensions, readily reconstitutable dry preparations and also sprays. Suitable medicaments, e.g. medicaments for oral or percutaneous use may release the compounds of general formula (I), (la) or (Ib) and/or in each case stereoisomers thereof in a delayed manner, whereby the preparation of these delayed release medicaments is generally known to those skilled in the art. Suitable delayed-release forms as weli as materials and methods for their preparation are known to those skilled in the art, e.g. from the tables of contents from «Modifled- Release Drug Delivery Technology", Rathbone, M. J. Hadgraft, J. and Roberts, M.S. (Eds.), Marcel Dekker, Inc., New York (2002); .Handbook of Pharmaceutical Controlled Release Technology", Wise, D.L. (Ed.), Marcel Dekker, Inc. New York, (2000);"Controlted Drug Delivery", Vol. I, Basic Concepts, Bruck, S.D. (Ed.), CRC Press Inc., Boca Raton (1983) and from Takada, K. and Yoshikawa, H., HOral Drug delivery", Encyclopedia of Controlled Drug Delivery, Mathiowitz, E. (Ed.), John Wiley & Sons, Inc., New York (1999), Vol. 2,728-742; Fix, J., .Oral drug delivery, small intestine and colon", Encylopedia of Controlled Drug Delivery, Mathiowitz, E. (Ed.), John Wiley & Sons, Inc., New York (1999), Vol. 2,698-728. The respective descriptions are incorporated by reference and are part of the disclosure. The medicament of the present invention may also have at least one enteric coating which dissolves as a function of pH. Because of this coating, the medicament can pass through the stomach undissolved and the compounds of general formula (I), (fa) or (Ib) are only released in the intestinal tract. The enteric coating preferably dissolves at a pH of between 5 and 7.5. Suitable materials and methods for the preparation of enteric coatings are also known to those skilled in the art The compositions of the present invention may also be administered topically or via a suppository. The above mentioned compositions include preferably 1 to 60 % by weight of one or more of the benzoxazinone-derived sulphonamide compounds of general formulas (I), (la) or (Ib), optionally inform of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers in any mixing ratio, or a physiologically acceptable salt thereof, or a solvate, respectively, and 40 to 99 % by weight of the appropriate pharmaceutical vehicle(s). The daily dosage for humans and animals may vary depending on factors that have their basis In the respective species or other factors, such as age, sex, weight or degree of illness and so forth. The daily dosage for humans usally ranges from 1 to 2000, preferably 1 to 1500, more preferably 1 to 1000 milligrams of substace to be administered during one or several intakes. Pharmacological Methods: BINDING TO SEROTONIN RECEPTOR 5HT6 Cell membranes of HEK-293 cells expressing the 5HTe-human recombinant receptor were supplied by Receptor Biology. In said membranes the receptor concentration is 2.18 pmol/mg protein and the protein concentration is 9.17 mg/ml. The experimental protocol follows the method of B. L. Roth et al. [B. L. Roth, S. C. Craigo, M. S. Choudhary, A. Uluer, F. J. Monsma, Y. Shen, H. Y. Melteer, D. R. Sibley: Binding of Typical and Atypical Antipsychotic Agents to 5-Hydroxytryptamine-6 and Hydroxytriptamine-7 Receptors. The Journal of Pharmacology and Experimental Therapeutics, 1994,268,1403] with the following slight changes. The respective part of the literature description is hereby incorporated by reference and forms part of the disclosure. The commercial membrane is diluted (1:40 dilution) with the binding buffer: 50 mM Tris-HCI, 10 mM MgCI2, 0.5 mM EDTA {pH 7.4). The radioligand used Is [3H]-LSD at a concentration of 2.7 nM with a final volume of 200 μl . incubation is initiated by adding 100μl of membrane suspension, (= 22.9 μg membrane protein), and is prolonged for 60 minutes at a temperature of 37 °C. The incubation is ended by fast filtration in a Brandel Cell Harvester through fiber glass filters made by Schleicher & Schuell GF 3362 pretreated with a solution of polyethylenimine at 0.5 %. The filters are washed three times with three mllliliters of buffer Tris-HCI 50 mM pH 7.4. The filters are transferred to flasks and 5 ml of Ecoscint H liquid scintillation cocktail are added to each flask. The flasks are allowed to reach equilibrium for several hours before counting with a Wallac Winspectral 1414 scintillation counter. Non-specific binding is determined in the presence of 100 μM of serotonin. Tests were made In triplicate. The inhibition constants (Ki, nM) were calculated by non-linear regression analysis using the program EBDA/LIGAND described in Munson and Rodbard, Analytical Biochemistry, 1980,107,220, which is hereby incorporated by reference and forms part of the disclosure. FOOD INTAKE MEASUREMENT (BEHAVIOURAL MODEL): Male W rats (200-270 g) obtained from Harlan, S.A. are used. The animals are acclimatized to the animal facility for at least 5 days before they are subjected to any treatment. During this period the animals are housed (in groups of five) In translucid cages and provided with food and water ad libitum. At least 24 hours before the treatment starts, the animals are adapted to single-housing conditions. The acute effect of the. inventively used sulphonamide derivatives of general formula (I) on food intake in fasted rats Is then determined as follows: The rats were fasted for 23 hours in their single homecages. After this period, the rats are orally or intraperitoneally dosed with a composition comprising a sulphonamide derivative of general formula (I) or a corresponding composition (vehicle) without said sulphonamide derivative. Immediately afterwards, the rat is left with preweighed food and cumulative food intake is measured after 1,2,4 and 6 hours. Said method of measuring food intake is also described in the literature publications of Kask et al., European Journal of Pharmacology 414 (2001), 215-224 and of Turnbull et al., Diabetes, Vol. 51, August 2002. The respective parts of the descriptions are hereby incorporated by reference and form part of the disclosure. The present invention is illustrated below with the aid of examples. These illustrations are given solely by way of example and do not limit the general spirit of the present Invention. Examples: The intermediates of general formulas (li) and (ill) were prepared by means of conventional organic chemistry methods known to those skilled in the art. The following example A shows the preparation of an intermediate of general formula (II): Example A: Synthesis of an intermediate compound of general formula (II) Preparation of 6-Chloro-1-(piperidine-4-yl)-1,4-dihydro-2H-3,1-benzoxazln-2-one Hydrochloride (Figure Removed a) 1-(tert-Butyloxycarbonyl)-4-[4-chloro-(2-hydroxymethylphenyiamlne)] plperidine A solution of 1-(tert-butyloxycarbonyl)-4-piperidinone (20 g, 0.10 mol), 2-amino-5- chlorobenzylic alcohol (17.34 g, 0.11 mol) and acetic acid (14 ml, 0.22 mol) in dry toluene (500 ml) was heated at reflux temperature, with water elimination by means of azeotrope distillation with Dean-Stark, for 6 hours. The mixture was then cooled and vacuum concentrated up to half volume. NaBHaCN (20 g, 0.32 mol) and dry THF (300 ml) were added to the resulting solution. Acetic acid (10 ml, 0.17 mol) was then dripped for one hour. The reaction was stirred at room temperature for 24 hours. The mixture was vacuum concentrated and the residue was dissolved In ethyl acetate (750 ml), washed with a NaHCO3-saturated solution (4 x 250 ml) and a NaCI-saturated solution (250 mL), dried and evaporated to dryness. The residue was purified by means of flash chromatography elutlng with a mixture of ethyl acetate: petroleum ether (1:3). The desired product was thus obtained as an oil (32.7 g, 96%). 1H NMR (CDCI3): 1.32 (d, =11.2 Hz, 2H), 1.41 (s, 9H), 1.92 (d, J11.2 Hz, 2H), 2.92 (t, J=12.0 Hz, 1H), 3.10 (s, 1H), 3.37 (m, 1H), 3.88 (d, J= 13.7 Hz. 2H), 4.49 (s, 2H), 4.75 (s, 1H), 6.52 (d, J= 8.6 Hz, 1H), 6.96 (s, 1H), 7.07 (d, J= 8.6 Hz, 1H). b.) 1-(1-fert-ButyloxycarbonyI-4-piperidinyl)-6-chlorO"1t4-d!hydro-2H-3f1- benzoxazin-2-one N, N-diisppropylethylamlne (DIEA) .(43 ml, 0.25 mol) and triphosgene (8.65 g, 29.2 mmol) were added to a solution of 1-(terf-Butyloxycarbonyl)-4-{(4- chloro-(2-hydroxymethyl) phenyi-am!no)]piperldine (27.0 g, 79 mmol) In dry THF (250 m!) cooled at 0°C. The reaction was stirred at 0°C for 1 h and at room temperature for 72 h. Ethyl ether was added and the mixture was cooled at 0°C for 3 h and the DIEA hydrochloride was then filtered. The filtered solution was evaporated to dryness and the residue was dissolved in ethyl acetate (750 ml), washed with 5% solution of critic acid (2 x 500 ml), water (250 ml) and NaHCOssaturated solution (2 x 500 ml). The ethyl acetate solution was dried (MgSQO, filtered and evaporated under reduced pressure. The residue was brought to the boil with ethyl ether until the whole solid was dissolved and then cooled overnight to yield the desired compound (n crystalline form (28.9 g, 67%). Melting point: 177-179 °C 1H NMR (CDCl3): 1.46 (s, 9H), 1.79 (d, J-10.1 Hz, 1H), 2.54 (m, 2H), 2.78 (m, 2H), 3.96 (m, 1 H), 4.28 (m, 2H), 5.02 (s, 2H), 6.98 (d, J= 8.7 Hz, 1 H) 7.13 (d, J=> 2.4 Hz, 1H), 7.28 (dd, J= 8.7 Hz, 2.4 Hz, 1H). c.) 6-chloro-1 -(piperidin-4-yl)-1,4-dihydro-2H-3,1 -benzoxazin-2-one hydrochloride A solution of l-KI-tert-ButyloxycarbonylJ-piperldlnyQ-e-chloro-l-dihydroH-S.Ibenzoxazin- 2-one (24 g, 65 mmol) in ethyl acetate (500 ml) was cooled at OeC. A 5 M solution of hydrogen chloride in ethyl ether (500 mL) was then added and the resulting mixture was stirred at 0°C for 4 h. The precipitate formed was collected by filtration, washed with ether and vacuum dried to yield the desired product as a solid (16.95 g, 97%). Melting point: 254-257 °C 1H NMR (CD3OD): 2.13 (d, J= 12.2 Hz, 2H), 2.88 (m, 2H), 3.20 (m, 2H), 3.53 (d, J= 12.8 Hz, 2H), 4.24 (m, 1H), 5.16 (s, 2H), 7.31 (m, 2H), 7.41 (dd, J= 8.8 Hz, J= 2.6 Hz, 1H). Several substituted 3,1-benzoxazin-2-one compounds were prepared via the . respectively substituted benzyl alcohols by reducing the respectively substituted anthranilic acids with lithium aluminium hydride and other known reducing agents by methods well known to those skilled In the art (see scheme 1), e.g. por ejemplo 6- methyl-1 ^(piperidin-4-yl)-1,4-dihydro-2H-3,1 -benzoxazin-2-one, 7-methyM -(piperidin- 4-ylM Adihydro^H-S.I-benzoxazin^-one, 8-methyl-1-(piperidin-4-yl)-1,4-dihydro- 2H-3.1-benzoxazin-2-one , 5-methoxy-1-(piperidin-4-yl)-1,4-dihydro-2H-3,1- benzoxazin-2-one, 6-fluoro-1 -(piperidin-4-yl)-1,4-dihydro-2H-3,1 -benzoxazin-2-one, S-methoxy-HpiperidinylJ-l^hydroH-S.I-benzoxazin^-one, 5-methyl-1- (piperidin-4-yl)-1,4-dihydro-2H-3,1-benzoxazin-2-one, 7-fluoro-1-(piperidin-4-yl)-1,4- dihydro-2H-3,1 -benzoxazin-2-one, 5-fluoro-1-(piperidin-4-yl)-1,4-dihydro-2H-3,1- benzoxazin-2-one, 6-methoxy-1 -(piperidinyl)-l ,4-dihydro-2H-3,1 -benzoxazin-2-one, 5-chloro-1-(piperidinyl)-1,4-dihydro-2H-3,1 -benzoxazin-2-one, 7-chloro-1- (piperidinyl)-l ,4-dihydro-2H-3,1 -benzoxazin-2-one, 8-chloro-1 -(piperidinyl)-1,4- dihydro-2H-3,1-benzoxazin-2-one and others. The reaction of the respective 5- methoxy-1 -(piperidinyl)-l ,4-dihydro-2H-3,1-benzoxazin-2-one, 8-methoxy-1- (piperidinyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one and 6-methoxy-1-(p1peridinyl)-1,4- dihydro-2H-3,1-benzoxazin-2-one compounds according to conventional methods, e.g. BBra in an inert organic solvent yields the respective 5-hydroxy-1-(plperidinyl)- 1,4-dihydro-2H-3,1 -benzoxazin-2-one, 8-hydroxy-1 -(piperldinyl)-l ,4-dihydro-2H-3,1 - benzoxazln-2-one and 6-hydroxy-1 -(piperldlnyl)-1,4-dlhydro-2H-3,1-benzoxazin-2- one compounds. The unsubstftuted benzoxazin-2-one 1-(plperidin-4-yl)-1,4-dihydro- 2H-3.1-benzoxazin-2-one is prepared according the method described in J. Med. Chem. 1995, 38, 4634 and J.Med.Chem. 1998,41,2146, which are hereby incorporated by reference and form part of the disclosure. The substituted anthranilic acids were reduced by conventional methods known to those skilled in the art, e.g. by the use of LIAIhU as reducing agent In anhydrous THF under an inert-gas atmosphere, e.g. argon or nitrogen. This process is very efficient and in most cases the respective 2-aminobenzylaIcohols are obtained in very good yields. General instruction for the reduction of substituted anthranilic acids: To a three neck flask, equipped with a mechanical stlrrer and an Inlet for gaseous . nitrogen, 100 ml anhydrous THF and 116,6 mmoles of LIAIhU were given and the resulting suspension cooled to 0 °C. After the addition of 58,3 mmoles of the respective substituted anthranilic acid in 150 ml anhydrous THF, the resulting reaction mixture is warmed to room temperature and stirred or about an hour. Under cooling to 0° C 4,7 ml water, 4,7 ml NaOH 15 wt-%, and finally 14 mL water are carefully added to the mixture. The resulting suspension is filtered and washed with ethyiacetate. The organic phase is washed with water, dried and the solvent evaporated. In most cases the resulting product may be used without further purification. Example 5: Preparation of 1-[1~quinolIne-8-su1fonyl)-piperidlne-4-yl]-1,4-dlhydrobenzo[ d][1,3]oxazin-2-one (Figure Removed 150 mg (0,66 mmol) quinoline-8-sutfbnyl chloride are added to a mixture of 1-(4- piperidiny!)-1,4-dihydro-2H-3,1 -benzoxazinone hydrochloride (161 mg, 0,60 mmol) and dfisopropylethylamin (230 mg, 1,80 mmol) In dichloromethane (10 ml) and the resulting reaction mixture was stirred overnight at room temperature. The reaction mixture was then washed with water (3x15 ml) and the organic phase was separated, dryed and evaporated to dryness. A solid was obtained, which was recrystallized from ethanok 182 mg of 1-[1-quinoline-8-sulfonyl-piperidine-4-y]>1l4- dihydro-benzo[d][1,3]oxazin-2-one were obtained as a white solid (yield 69 %). IR(crn1) KBr: 1712,1337,1291,1205,1162,1144,1034, 717, 583 1H-NMR(6 in ppm): 1.8 (d, J^9.5 Hz, 2 H) 2.6 (qd, J=12.6, 4.4 Hz, 2 H) 3.0 (td, J=12.8, 2.5 Hz, 2 H) 4.1 (tt, J=12.5, 3.8 Hz, 1 H) 4.3 (ddd, J=13.0, 2.3 Hz, 2 H) 5.0 (s, 2 H) 7.1 (m, 3 H) 7.3 (m, 1 H) 7.6 (dd, J=8.4, 4.2 Hz, 1 H) 7.6 (m, 1 H) 8.1 (dd, J=B2, 1.3 Hz, 1 H) 8.3 (dd, J=8.3,1.7 Hz, 1 H) 8.5 (dd, J=7.3,1.5 Hz, 1 H) 9.1 (dd, =4.2, 1.8Hz,1 H)(CDCI3-d). Melting point: 170-172 "C. The compounds according to examples 1-4 and 6-10 given in the following table I as well as the compounds according to lists A and B given above were prepared analogously to the methods described above (Table Removed) Pharmacological data: The binding of the benzoxazinone derived sulphonamide compounds of general formulas (I), (la) and (Ib) was determined as described above. The binding results of some these compounds are given in the following table 2 (Table Removed) WE CLAIM: Benzoxazlnone-derived sulfonamide compounds of general formula (I) (Formula Removed) wherein R1, R2, R3, R4 are each independently selected from the group consisting of hydrogen, halogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaiiphatjc radical, which may be bonded via an optionally at feast mono-substituted alfcyiene group and/or may be condensed with an optionally at least mono-eubstauted mono- or polycyclic ring-system, an optionally at least mono-substituted aryl- or heteroaiyf radical, which may be ponded via an optionally at feast mono-substituted alkylsns group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem, a nitro group, a cyano group, -OR10, -OC(=O)R11 -(C=Oy-OK", -SR12, ^SOR12, -SOZR12, -NH-SOZR12, -SOZNH2 and a -NR13R14 moiety. R5 represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical or a saturated or unsaturated, optionally at least mono-substftuted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, R6, R7, R8 R9 are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substftuted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, a cyano group and a -CC=OR16 moiety, W represents an unbranched or branched, saturated or unsaturated agnatic radical, which may be substituted by one or more substjtuents selected from the group consisting of hydroxy, halogen, branched or unbranched C1-4-alkoxy, branched or unbranched C1-4-perfluoroalKoxy, branched or unbranched Ci-r perfluoroalkyl, amino, carboxy, amtdo, cyano, nitro, -SO2NH2, -CO-C1-4-alkyl, -SO-C1-4aJkyl, -SOC1-4-alkyl, -NH-SO2-C1-4alkyl, wherein the C1-4-alkyl may in each case be branched or unbranched, an unsubstltuted or at least mono-substituted phenyl or naphthyl radical and an urisubstituted or at least mono-substftuted furanyl, thfenyl, pyrrofyi, fmidazoryl, pyrazolyl, pyrfdlnyl, pyrimidlnyl, qulnolinyl and isoquinolinyl radical, whereby said substltuents may be at least mono-substituted with F, CI, methyl and rnethoxy, a saturated or unsaturated, optionally at least one heteroatom as ring member containing cycloaliphatic radical, whereby said cycloaliphatic radical may be substituted by one or more substituents selected from the group consisting of hydroxy, nitro, carboxy, cyano, keto, halogen, C1-20-alkyl, partlafryfluorinated C1-4 alkyl, partially chlorinated C1-4 alkyl, partially bromlnated C1-4 alkyl, C1-5-alkoxy, partially fluorinated C1-4 alkoxy, partially chlorinated C1-4 alkoxy, partially brominated C1-4 alkoxy, CWalkenyl. SO2-C1-4-alkyl, -(C=O)-C1-5-alkyl, -(C=O)-alkyl, -(C=O)-C1, -S-C1-4-alkyl -(C=O)-H, -NH-(C=O)NH-C1-5 alkyl. -{C=O)-C1-4-pernuoroalkyl, -NRAR8, wherein RA and RB are independently selected from the group consisting of H, C1-4-alkyl and phenyl, NH-{C=O)-C1-5-alkyl, -C1-5-alkyl6n-(C=O)-C1-5-alkyl, (1,3-Dihydro-1-oxo-2H-isaindoi-2-yl), N-Phthaiimidfnyh (1,3-Dioxo-2-azaspiro[4,4]-noan-2-yl, substituted crunsubstituted phenyf, -SQrphenyl, phenoxy. pyrfdinyl, pyridinyloxy, pyrazolyl, pyrimidmyl, pyrrolidinyh -SO2-pynvlidinyl, morphollnyl, SO2-morpholinyl-, thiadiazolyl, oxadfazolyl, oxazolyi, thiazolyl, isoxasolyl, O-CHrihiazolyl, -NH-phenyl, and -C1-4-Alkylen-NH-{C=O)-phenyl, whereby said substituents may be substituted by one or more substituents selected from the group consisting of halogen, naro, cyano, hydroxy, -(C=O) C1-4alkyl, C1-4-alkyl, at least partially ffuorfnated C1-4alkyl, at least partially chlorinated C1-4-alkyl, at least partially brominated C1-4-alkyl, -S-C1-4-alkyl, -C(=O)-O-C1-5-alkyl. -(C=O)-CH2-F, -{C=O)-CH2-Cl and -(C=O)CHrBr, and whereby said cycloaliphatic radical may be bonded via an optionally mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted aromatic mono- or porycydlc ring-system, an optionally at least mono-substituted heteroaryl radical, which may be bonded via an optionally mono-substituted afcylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyciic ring-system, an optionally at least mono-substituted, monocyclic aryl radical, which is condensed with an optionally at least mono-substituted mono- or polycvcfic ring-system and which may be bonded via an optionally at least mono-substituted alkylene group, a -NR16R17-moiety, a -COR18-moiety, or a phenyl radical, which is at least mono-substituted with one of the substituents selected from the group consisting oft 2,2,2,-Triffuoroethoxy-, C2-6-AIkenyl-, 1,3-Dihydro-1-oxo-2H-isoindol-2-yl-, N-Phthalimidinyl [(Z-chloro-l.a-thlazolyl-5-yl)-methoxy, Ethyl-5-yl-2-methyI-3-furoate, Cn-20-alkyl-, 1,3-Dioxo-2-azaspiro[4,4]non-2-yh pyrazolyh (1,3-oxazol-5-yi)-, (5-MethyH,3,4-oxadiazoI-2-yl)-, difluoromethoxy, dlchJoromethoxy, 1-pymolidinylsulfonyl, morpholinosulfonyl, 2-methyl-4-pyrimidinyh a phenoxy group, which is at least mono-substituted with Ct-s-alkoxy, a phenyl group, which is at least mono-substituted with one of the substituents selected from the group consisting of nitro, C1-5-alkoxy, F, CI, Br, at least partially fluorinated C1-5-alkyl, at least partially chlorinated C1-5-alkyl, [(2-Chloro-1,3-thiazo!-5-yl}-methoxy]-, -(C=O)-H and -{C=O)-C1-5-alkyl, a pyridinyl group, which is at least mono-substituted with C1-5-alkoxy, a pyridinyloxy group, which is at least mono-substituted with C1-5alkoxy, a phenoxy group, which is at least d1-5ubstituted and a pyridinyloxy group, which Is at least di-subsftuted, with the proviso that W does not represent unsubstituted furyl-, unsubstituted thierryl- orthienyl substituted with a substituent selected from the group consisting of d-5-alkoxycarbonyl, C^-alkylcarbonyf, carboxyl and pyridyl, unsubstftuted pyrrolyl unsubstituted naphthyl, unsubstftuted Indolyl, unsubstftuted tetrahydronaphthyl, substituted or unsubstituted pyridyf, unsubstituted pyrazinyl, unsubstituted quinolinyl-, Cwralkyleubstituted pyrroryf-, and unsubstituted cyclohexyl or cyclohexyl substituted with one or two members selected from the group consisting of oxo, hydroxyl, C1-4-alkoxyl. C^ s-alkoxy-carbonylamino-C1-5 alkyl and amino-C^ alkyl, R10 represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloafiphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryi- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-ubstituted mono- or polycyclic ring-system, R11 represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted afiphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatorn as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with "an optionally at least mono-substituted mono- or polycyclic ring-system, R12 represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatorn as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- orpolycyclic ring-system, or an optionally at least mono-substituted aiyi- or heteroaryi radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, Rt3 and R14 each are independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatorn as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryi radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or R13 and R14 together with the bridging nitrogen atom form a saturated, unsaturated or aromatic heterocyclic ring, which may be at least rnono-substrtuted and/or contain at least one further heteroatorn as a ring member, R15 represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatam as ring member containing cycloaHphatfc radical or an optionally at least mono-substituted aryi- or heieroaryi radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or poiycyclic ring-system, R16 represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, R17 represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, and R1S represents an optionally at least mono-substituted aryi radical, optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate. 2. Compounds as claimed in claim 1, characterized in that R1, R2, R3, R4 are each independently selected from the group consisting of H. F, CI. Br, an unbranched or branched, saturated or unsaturated, optionally at least mono-.- substituted Ci-e-aHphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C^-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C1-6alkylene group and/or may be condensed with an optionally at feast mono-substituted mono- orporycycJic ring-system, an optionally at least mono-substituted, 5- or 6-membered aryi- or heteroaryf' radical, which may be bonded via an optionally at least mono-substftuted C1-6-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- orpolycyclic ringsystem, a nitro group, a cyano, -OR10, -OC^OJR11, -SR12, -SOR12, -SOzR12, -NH-SOzR12, -SOzNHz and a -NR13R14 moiety, preferably selected from the group consisting of H, F, Cf, Br, a saturated, branched or unbranched, optionally at least mono-substituted C1-3-aliphatic radical, a saturated, optionally at feast mono-substituted, optionally at least one heteroatom as ring member containing C5- or C6- cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C1-or Creflcylene group, a nitro, cyano, -OR10, -OC(=O)R11, -SR12 and -NR13R14 moiety, more preferably selected from the group consisting of H, F, CI, -CH3, -CH2CH3, -CF3, -CF2CF3, cyclopentyl, cyclohexyl, a nitro group, a cyano group and -OR10. 3. Compounds as claimed in claim 1 or 2, characterized in that R5 represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted d-a-aliphatic radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing Qj^-cyctoaliphatic radical, preferably represents H or a branched or unbranched C^-alkyl radical, more preferably represents H, -CH3 or-CHzCHs. 4. Compounds as claimed in any one of claims 1 to 3, characterized in that R6, R7, Rs, R9 are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at (east mono-substituted C1-5-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C3-8-cycloaIiphatic radical, a cyano group and a -CC=OR15 moiety, preferably selected from the group consisting of H, a branched or unbranched C1-3-alkyl radical, a cyano group and a -CC=OR15 group, more preferably from the group consisting of H, -CH3, -CH2CH3 and a cyano moiety. 5. Compounds as claimed in any one of claims 1 to 4, characterized in that W represents an unbranched or branched 0,1-20-alkyl radical, which may be substituted by one or more substituents selected from the group consisting of hydroxy, halogen, branched or unbranched C1-4-alkoxy, branched or unbranched C^-perfluoroalkoxy, branched or unbranched C1-4-perfluoroalkyl, amino, carboxy, arnldo, cyano, nitro, -SO2NH2, -CO-C1-4-alkyl, -SO-C1-4-alkyl, -SO2-C1-4-alkyl. -NH-SQ2-Ci-*-alkyl, wherein the C1-4-alkyl may in each case be branched or unbranched, an unsubstituted or at feast mono-substituted phenyl or naphthyl radical and an unsubstituted or at least mono-substituted furanyl, thienyl, pyrrolyf, imidazolyl, pyrazolyl, pyrtdinyt, pyrimldfinyl, quinolinyl and isoquinoiinyl radical, whereby said substituents may be at feast mono-substituted with f, CI, methyl and methoxy; a napthyl group, which is at least mono substituted, a quinolinyl group, which is at feast mono-substituted, a pyrrolyl group, which is at least mono-substituted by a substftuent other than Ci-3-alkylr an optionally at least mono-substituted thiazolyl benzo[b]|-trjiophenyl-, benzo[b]-furanyl-r isoquinoHnyl-, tetrahydrofeoqufnolinyh pyrazoJyh isoazofyl-, chrornanyl-, benzothiadiazoryh imidazolyl-, benzofurazanyl dIbenzoIb,d3-ftjranyl-, benzoxadiazolyl-, imidazo{2,1-b]-thtazolyl anthracenyl-, coumarinyl-, 2,3-DBiydro-1 ,4-benzodloxinyl-, 2,3-Dthydrobenzo[b]furanyl-, 3,4-Dihydro-2H-1,4^enzoxazlnyl-, 3,4-EHhydro-2H-1,5-Benzodioxepinyl-, Benzothlazolyf-, lmidazo[1,2-a]-pyridlnyl-, a chromonyl-group, an Isatlnyf group, a perrtamethytoihydrobenzofuranyl group, a cyctopropyl- or cycloperrtyl-group whereby said cyclopropyl or cyclopeniyl group may be substituted by one or more substituents selected selected from the group consisting of hydroxy, nitro, carboxy, cyano, keto, halogen, C1-20 alkyl, partially fiuorlnated C1-4 alkyl, partiaily chlorinated C1.4 alkyl, partially brominated C1-4 alkyl, C-wralkoxy, partially fluorinated C1-4 alkoxy, partially chlorinated C1-4 altoxy, partially brominated C1-4 alkoxy, C2-5-alkenyl, SO2-C1-4 alkyl, -(C=O)C1-4-alkyl. -(C=O)O-C1-5-alkyl, -(C=O)-C1. -S-C1-4-alkyl-, -(C=O) H, -NH-(C=O)-NH-C1-5-alkyl. -(C=O)-C1-4-pernuoroaIkyl. -NRARB, wherein RA and Re are independently selected from the group consisting of H, C1-4-alkyl and phenyl, NH-(C=O)-C1-5alkyl, -C1-4-alkylen-(C=O)-C1-5-alkyl (1,3-Dfhydro- oxo-2H-koindol-2-yl). N-PhthaJimfdJnyl-, (1.3-Dioxo-2-azaspiro[4,4>non-2-yl, substituted or unsubstituted phenyl, -SOz-phenyl, phenoxy, pyridinyl. pyridfnyloxy, pyrazolyl, pyrimldinyl, pyrrolidinyl-, -SOz-pyrrolidinyl, morpholinyl, SO2-morpholinyl-, thladtazolyl, oxadiazolyl, oxazoiyl, thiazolyf, isoxazolyl, O-CHr-thiazolyl. -NH-phenyl, and -C1-4-Alkylen-NH-(C=O)-phenyl, whereby said substftuents may be substituted by one or more substftuents selected from the group consisting of halogen, nitro, cyano, hydroxy, -(C=O)-C1-4-alkyl, C1-4-alkyl, at feast partially ftuorinatBd C1-4-alkyl, at least partially chlorinated C1-4-alkyl, at least partially brominated C1-4alkyl, -S-C1-4ralkyl, -C(=O)-O-C1-5-alkyl. -(C=O)CH2-F, -(C=O)-CH2-CI and -(C=O)-CH2-Br, a2K1.343ioxo-1,3klihydro-lsoJndoI-2-yl-)-erthyl, a thlenyl group, which is at least mono-substituted by one or more substftuents independently selected from the group consisting of F, CI, Br, Ct-s-alkoxy-, CF3, -SQz-Ct^-alkyl and optionally at least mono substituted benzoyfaminomethyl-, phenylsulfbnyf-, isoxazolyi-, benzamidometfiyl-, pyrimidyl-. thlazolyf-, pyrazolyl, phenyl-, 1,2,4-thiadiazolyl-, 1,3-oxazolyt- or 1,2,4-oxadiazolyh a furyi group, which is at least mono-substituted by one or more subsftutents independently selected from the group consisting of a C1-5-alkyl radical, which may be at least partially fJuorinated or chlorinated, an optionally at least mono-substituted phenyl and a -(C=O)-O-C1-5alkyl group, a NRiaRtr-moiety, a COR18~moiety, or a phenyl radical, which is at feast mono-substituted with one of the substftuents selected from the group consisting of: 2,2,2,-Trtfluoroethoxy-, Qz-s-Alkenyl-; 1,3-Dihydn>-l-oxo-2H-isoindol-2-yl-, N-Phthalimidlnyl-, [(2-chIoro-1,3-thiazolyl-5-yl}-methoxy, Ethyl5-yl-2-methyl-3-furoate, C11-20-alkyl-, 1,3-Dioxo-2-a2aspiro[4,4]non-2-yl-, pyrazolyl-, (1,3-oxazo1-5-yl)-, (6-Methyl-1,3,4-oxadiazol-2-yl}-, difluoromethoxy, dichloromethoxy, 1-pyrrolidinylsuJfonyl, morpholinosurfonyl, 2-methy1-4-pyrfmidinyl-, a phenoxy group, which is at least rncirto-substituted with C1-5-alkoxy, a phenyl group, which is at least mono-substituted with one of the substrtuents selected from the group consisting of nitro, C1-5-atkoxy, F. Cl, Br, ' - at least partially fluonnated C1-5r-alkyl. at least partially chlorinated C1-5-afkyl, [(2-Chtoro-1,3-thfeizol-a-ylHnethoxy]-. -(C=O)-H and -(C=O)-C1-5-alkyl, a pyridinyl group, which is at least mono-substituted with C1-5-alkoxy, a pyrfdinyloxy group, which Is at feast mono-substituted with C1-5-alkoxy, a phenoxy group, which Is at teast df-substituted and a pyridinyloxy group, which is at least d1-5ubsituted, more preferably W represents a moiety selected from the group consisting of 5-Dlmemylamlno-napth-1-yl, 2-Ace4amfdo-4-nisthyl-5-ihlazDlyh Trrfluoromethyh TrichJoromethyh Isopnopyl Methyl-, 2,2,2-TnTIuoiioethyh Ethyl-, Hexadecyl 2-Chlaroethyl n-Propyl 3-ChJoro-propyl n-Butyh Dichloiomethyl-, ChloromeBiyl-, Dodecyl-, 1-OctyH 6-(p-foluidmo)-naphth-2-yi-, 4,S-Dibromo-thlophene-2-yl BenzDyldTloride-3-yh 1-Octadecyh 4-Bromo-2.5-d«chIoro-miophene-3-yl 2,5-Dichloro-thiophene-3-yl 5-Chlono-thfophene-2-yI-, 1-Decyl-, 3,5-Dichloro-4-{2-diloro-4-nfirophenoxy)-phenyl-, 2,3-Dlchlorothtophene-5-yl-, 3-Bromc-2-chloro-thiophene-5-yl-, 3-6romo-5-chton>-thiophene-2-yl-, 2-(BenzDylaminomethyl)-thjophene~5-yl-., 4-(Phenyf-sulphonyl)thIaphena-2-yl 2-Phenyt-sulphonyl-thlophene-S-yl-, 2-[1-Meihyl-5-(1iif[uoit)nriethyl)pyrezDl-3-y^ttitophene-5-yl-, 5-Chloro-1,3-drmethylpyrazole-4-yl-, 3,5-Dimethylisoxazole-4-yl 2-{2,4-Dlchlorophenoxy>-phenyl, 4-(2-Chlc>ro-B-nitrc-phenoxy)-pb«nyl-, 4^3phenyl-, 5-{Dhn-propytemino)-naphih-1-y{-, 2,2,5,7,8-Pentamethyl-chroman-^S-yl 5-Chloro-4-nfbo-thlopnene-2-yl 2,1,3-BenzDthiadtazole-4-yh 1-Methyf-imidazote-4-yl-, Benzcfurazan-4-yl 5- y (IsoxazoJ-3-yT>tn!ophene-2-yl--, Vinyl-phenyW-yl 5-ttchIon>rnethyMurari-2-y|-, 5-Bromo-thJophene-Z-yl-, 5-{4^hloroberi2anrildornefliyl)-thiophene-2->*-, Dlbenzo]rb,dHuran-2-yl 5-Chforo-3-methylben2o033-thiophene-2-yl-, 3-M8thoxy-44methoxycarbonyl)thlophene-2-yl-, 5-[2-(MfettTytthio>pyrimidin-4-yl-J-thiophene-2-yl-, 4-Chloro-2,1,3-Benzoxadiazole-7-yl 5-Chloro-2,1,3-Benzo?cadiazx>le-4-yi-, 6-Chloro-imWazo(2,1-b>thiazoteK5-yl-, 3-Methyl-benzs|b>th!ophene-2-yl4-{p-Chfon>5-(^ , 5-CWoro-naphth-1-yl 5-Chloro-naphth-2~yh 9,10-Dibromoanthracene-2-yl-, teoqulnoline-5-yl 4-Methoxy-2,3,6-trimethylbenzoyl-, 4-Nltro-biph9nyt-4-yl-, (1,3-Dlhydro-1-oxo-2HHsaBidol-2-yl-)-4-phenyl-, 5-(2-MethyM,3-thiazofe-4-yf)- hiophene-2~yl 5-(1-Meihyl-3-(trifluoiiomethyf)pyr^ 5- [5-Trffluoromethy{)-feoxazol-3-yl]-thJophen8-2-yl-, p-Dodecyl-phenyh 4-[(3~ Cyano-4-methoxy-2-pyrtdlnyl)oxy]^heny»-,4-(N-phthallmldlnyl)-phenyf-, 1,2,3,4-T0trahydro-2-thioph©ne-3-yl 4-(4-Mothoxy-phenaxy>iJhenyl-1 [4-(3,5-Dictilorophenoxy)phsnyQ-, J4^3,4-Dichtarophenoxy)phenyfh [443,6)-B!s(triftuoromettiylphenoxy}phenyO-, 3-{2-Methoxy-fjhenoxy)-phenyl, 3«{4-Methoxy-phenyO-phenyl 3-(4-Chlora-phenyl)-phenyl-, 3-(3,5-Dichton>-phenyl)-phenyl-t 3-{3,4-DidWoro-phenyll)-phenyl 3-(4-F{uorophenyl)-phenyt-, 344-(Tiffluorom«thyl)-phenyll-phenyl-, 3-[3,5-Bis-(Trifluorofnethyl)-phenyf}-phenyl 4^2-Methoxy-phenoxy)-phenyl-, 4-(2-Methyl-ph0noxy)-ph©nyl-, 4- Dichforopheriyl)-phenyl-, 4-{3,4-Dichtorophenyl)-phenyh 4-(4-nuoroph«nyl)-phenyl-, 4-[4-(Trifluornie4hy])-phenyl]-phenyl-, 4-[3,5-Bis-(Trifluorornethyl)-phenyQ-phenyh Cyclopropyl-, 2-(2-Chlorophenyl)-2-Phenylelfiyl 2-(2-Trifluoiomettiylphenyl)-2-phenytethyl-, 5H[4-Cyano-l-metthyl-5-methylthio)-1 H-pyrazol-S-yl-thiophene-a-yl-, 3^yano-2,4-bis-(2,2,2-Trifiuorothoxy)-ph9nyl-, 4-[(2-Chloro-1,3-Thlazol-6-yl)-methoxy]-phenyl 2-(1,3-DIoxo-1,3-dihydro-isoindol-2-yl}-ethyl-, 5-lodo-naphtfi-1-yf-, Ethyl-2,5HJIrnethyl-1i3heiiyfpyTrol6-4-carboxylate-3-yl-. Ethyl-2-methyl-1,6-diphenyl-1H-pyrrole-^caftoxylate-4-y{-, Ethyl^^4-chlorophenyl)-2-methyl-3-fyroats-4-yf, Ettiyt-5-(4-ch!orophenyl)-2-methyl-1-phenyl3-carboxylate-4-yf-, E*yl-2,5-dlinethyf-3-fiHtaate-4-y{-, 3- Chloro-4-(1,-3-dioxo-2-Azaspiro[4,43non-2-yl)-phenyl-, Coumarfn-6-yf, 3-(4-Motho^phenoxy^honyh [3-(3,5-Dichioropheno>y)}-phenyl [3-(3,4 Dichtorophenoxy)I-phenyh 3,5HBis(TrifluoromethyI)phenoxyphenyt~, 2,2-Diphenylethyl 4-Pheny1-5-{ftrifluofomethyl3-thiophene-3-yl-, JVtethy1-4-Phenyl-5-(Trifluorom©th^>miophene-2-caii30xytatefe-3-Cart3oxyiate-4-yl 4-F?uoro-naphth-1-yl 5-Buoro-3-methylben2DO03Hhiophene-2-yl-, Ms*yl-2,5-dfmethyl-3-ftjrDate-4-y}-, Methyl-2-furoate-5-yh Methyl-2-methyl-3-furoate-5-yl MethyM-methyt-1H^yrrote-2-Carboxylate-5-yl-, 2-(5-Chloro-1,2,4-Thiadiazol-3-yl)-thlophen9-S-yI-, 1,3,5- Trimethyl-1H-pyrazole-4-yh Pentafluoroethoxytetrafluoroethyl-, 5-(5-lsoxazyI)-thiophene-2-yh 5-{5-lsoxazol-yl)-2-furyl-, 5-Methyl-2,1,3-benzothiadiazole-4-y*, 2,3-Dihydro-1,4-benzodioxine-6-yi-, 4-Methyl-Naphth-l-yl-, 5-Methyl-2-Qrifluormethyl)-3-Furyh 2,3-Dibydrpberizo[b]furan-5-yl 1-Benzothiophene-3-yl-, 4-Methyl-3,4^ihydro-2H-1,4-Benzoxazlne-7-yl-, 5-MethyM-phenyMH- pyrazole-4-yl-, 4-(1H-Pyrazol-1-yl)-phenyl-, 3,4-Dihydro-2H-1, 5- benzodioxepine-7-yl-, 5-(1,3-Oxazol-5-yl)-2-thienyl-,4-(1,3-Oxazol-5-yl)-phenyl-, 5-Methyl-4-isoxazolyl, 2,1,3-Benzothiadiazole-5-yl-, 5-Acetamido-naphth-1-yl-, 3-methyl-8-Quinolinyl-, 1,3-Benzothiazole-6-yl, 2,5-Dimethyl-3-thienyl-, 5-[5- (ChJoromethylM,2,4-oxadiazo!-3-yl]-2-trtienyh Ethyl-3-{5-yh2-thienyl-;|1,2,4-oxadlazole-5-carboxylate-, 3-(5-Methyl-1,3,4-oxadiazDl-2-yl)phenyf-, 4-(Difiuoromethoxyl-phenyl-, 3-(Difluorometboxy)-phenyh 2,2-Dimethyl-6-Chromanyh Ethyl-3,5-dimethyf~lHi3yiTol9-2-cartK5xylate-4-yl lmidazo[1,2-A3pyridIne-3-yh 3^1,3-Oxazo*-5-yf)-phenyh Ethyl~5-[4-yl)-phenyl]-2-niethyl-3-furoate, 1-PyrroIidinyfphenylsuHbnyh Methyl-5-yl-4-methyl-2-thiophene-carboxylate, Methyl-3-yl-4-(isopropylsulfonyl)-2-thiophene, 7-Chlorochromone~ 3-yl 4-Bromobiphenyt-4-yl-, 4 -Acetyf-bipheny1-4-yh 4'-Brorno-2*-fluon> biphenyl-4-yl-, 1-Methyl-5-isatinyf-, 2-Chlorc~3-thiophenecarboxylic-acid-5-yl 2-Methoxy-5-(N-phthaIimidinyl)-phenyl-, 1 -Benzothiophene-2-yh Morpholinophenylsulfonyl- and 3-{2-Methyl-4-pyrimfdinyl)-pheny{- 6. Compounds as claimed in any one of claims 1 to 5, characterized in that R10 represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C%e-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C^s-cycloaliphatfc radical, which may be bonded via an optionally at least mono-substituted C1-4-alkylene group and/or may be condensed with an optionally at least mono-substituted mono-or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6-membered aryi- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C1-4-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably H, a linear or branched C1-4-alkyl radical, a cyclohexyf radical or a phenyl radical, more preferably H, -CH3, -C2HS or phenyl. 7. Compounds as claimed in any one of claims 1 to 6, characterized in that R11 ^represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C-r-s-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C1-4-cycloaliphattc radical, which may be bonded via an optionally at least mono-substituted Cmj-alkylene group and/or may be condensed with an optionally at least mono-substituted mono-or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted Ci-e-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably H, a linear or branched Cr4-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably H, -CH3, -C2H5 or phenyl. 8. Compounds as claimed in any one of claims 1 to 7, characterized in that R12 represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted d-e-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing CVs-cycloaliphatic radical, which may be bonded via an / optionally at least mono-substituted Ci-e-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6- membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C1^-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably represents H, a linear or branched C-j-a-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably H, -CH3, -CzH5 or phenyl. 9. Compounds as claimed in any one of claims 1 to 8, characterized in that R13 and R14 are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at "feast mono-substituted Ci-g-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing Ca-a-cycloaliphatic radical, whfch may be bonded via an optionally at least mono-substituted CWalkylene group and/or may be condensed with an optionally at least mono-substituted mono- or pofycyclic ring-system, or an optionally at least mono-substituted, 5- or 6-membered aryl-or heteroaryi radical, which may be bonded via an optionally at least mono-substituted Ci-e-alkyfene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably are each independently selected from the group consisting of H, a linear or branched C1-4-aIkyl radical, a cydohexyf radical and a phenyl radical, more preferably are each independently selected from the group consisting of H, -CH3, -C2H5 and phenyl. 10. Compounds as claimed in any one of claims 1 to 8, characterized in that R13 and R14 together with the bridging nitrogen atom form a saturated, unsaturated or aromatic, 5- or 6-membered heterocyclic ring, which may be at least mono-substituted and/or contain at Jeast one further heteroatom as a ring member, preferably form an unsubstituted piperidin or morpholine group. 11. Compounds as claimed in any one of claims 1 to 10, characterized in that R15 represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at feast mono-substituted C^-^-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C3^-cycIoaIiphatic radical or an optionally at least mono-substituted, 5- or 6- membered aryl- or heteroaryi radical, which may be bonded via an optionally at least mono-substituted C1-4-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably represents H, a linear or branched C1-4-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably represents H, -CH3, -C2H5 or phenyl. 12. Compounds as claimed in any one of claims 1 to 11, characterized in that R16 represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted Ci_e aliphatic radical, preferably an unbranched or branched, saturated, unsubstrtuted C1-4 alkyt radical, more preferably a methyl radical. 13. Compounds as claimed in any one of claims 1 to 12, characterized in that R17 represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted Cve aliphatic radical, preferably an unbranched or branched, saturated, unsubstrtuted Ctj alkyl radical, more preferably a methyl radical. 14. Compounds as claimed in one or more of claims 1 to 13: 1 -[1 -(5-Chloro-3-rnethyl-benzoEbJUiiophenyl-2-sulfonyl)p1peridine-4-yQ-1,4-^ dihyd ro-ben2D[d][1,3]oxazin-2-one, 1 -[1 -(5-Dimethylamino dihydro-benzo[d J[1 ,3]oxazin-2-one, 1 -[1 -(5-Dimethylarnino-naphthyM -sulfonyl)-p jperidine-4-yl]-1,4-dihydro-benzo[d][1,3Joxazin-2-one, and corresponding salts thereof, and corresponding solvates. 15. Process for the preparation of benzoxazinone-derived sulfonamide compounds of general formula (I) as claimed in one or more of claims 1 to 14, characterized in that it comprises reacting at least one piperidine compound of general formula (II), wherein R1, to R9 have the meaning as claimed in claim 1, and/or a salt, preferably a hydrochloride salt, thereof, (Formula Removed) with at least one compound of general formula (HI), (Formula Removed) wherein W has the meaning as claimed in claim 1, in a suitable reaction medium, optionally in the presence of at least one base and/or at least one auxiliary agent. 16. Process for the preparation of physiologically acceptable salt of the benzoxazinone-derived sulphonamide compounds as claimed in claims 1 to 14, characterized In that at least one compound of general formula (f) having at least one basic group is reacted with at least one add, preferably an inorganic or organic acid, preferably in the presence of a suitable reaction medium. 17. Process for the preparation of a physiologically acceptable salt of the benzoxazinone-derived sulphonamide compounds as claimed in claims 1 to 14, e" aracterized in that at least one compound of general fbimufa (I) having at least one acidic group is reacted with at least one base, preferably in the presence of a suitable reaction medium. 18. The compound as claimed in claims 1 to 14 as and when used in the preparation of a medicament for prophylaxis and treatment of diseases as herein defined. 19. Benzoxazinone-derived sulphonamide compound as claimed in claims 1 to 14, optionally in form of one of its stereosiomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers in any mixing ratio, or a physiologically acceptable salt thereof, or a solvate, for use in the manufacture of a medicament for cognitive enhancement, for the prophylaxis and/ore treatment of fC=Od ingestion (fC=Od intake) disorders, particularly for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, bulimia, anorexis, cachexia or type II diabetes (Non-Insulin Dependent Diabetes MeJIitus}, preferably type II diabetes, which Is caused by obesity, disorders of the central nervous system, disorders of the gastrointestinal tract, such as irritable intestine syndrom, anxiety, panic, depression, cognitive memory disorders, senile dementia disorders, such as Morbus Alzheimer, Morbus Parkinson and Morbus Huntington, schizophrenia, psychosis, infantile hyperkinesia or ADHC (attention deficit, hyperactivity disorders). 20. Benzoxazinone-derived sulphonamide compound of general formula (la). (Formula Removed) wherein Rla, R23, R33, R43 are each independently selected from the group consisting of hydrogen, halogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted ajkylene group and/or may bs condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkytene group and/or may be condensed vvith an optionally at least mono-substituted mono- or polycyclic ringsystem, a nitro group, a cyano group, -OR10a, -OC(=O)R11a, -(C=O)-OR11a, -SRlZa, -SOR1Za, -SOaR123, -NH-SO2R123, -SOzNH2 and a -NR13aR14a moiety, R5a represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, R63, Rra, R83, R" are each independently selected from the group consisting of -^hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycioaliphatic radical, a cyano group and a -CC=OR15a moiety, Wa represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycioaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may ring-system, an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, a NRl6aR17a-moiety or a COR18a-moiety, R10a represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally atleast one heteroatom as ring member containing cycioaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed wnth an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryj radical, which may be bonded vfa an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, R11a represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated «r unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkyjene group and/or may be condensed with an optionally at least mono-substituted mono- or poJyeycJic ring-system, or an optionally at least mono-substituted aryf- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, R12a represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at feast mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycydfc ring-system, or an optionally at least mono-substituted aryj- or heteroaryl radical, which may be bonded via an optionally at feast mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, R13a and R14a each are independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyciic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be -ponded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- orpolycycfic ring-system, or R13a and R14a together with the bridging nitrogen atom form a saturated, unsaturated or aromatic heterocyclic ring, which may be at least mono-substituted and/or contain at least one further heteroatom as a ring member, R1sa represents hydrogen, an unbranched or branched, saturated or x unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycfoaliphatic radical or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or potycycfic ring-system. R16a represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, R17a represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, R1Ba represents an optionally at least mono-subsituted aryl radical, optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a solvate, respectively, for use in manufacture of a medicament for the prophylaxis and/or treatment of fC=Od intake disorders; anxiety; panic; depression; cognitive disorders; preferably memory disorders; senile dementia processes, preferably selected from the group consisting of Morbus Alzheimer, Morbus Parkinson, Morbus Huntington; psychosis; Infantile hyperkinesia; ADHC (attention Jeficit/hyperacftrvify disorder); disorders of the gastrointestinal tract, preferably intestine syndrom; schizophrenia or for cognitive enhancement 21. The compound as claimed in claim 20, characterized in that R1a, R2a, R3a, R4a are each independently selected from the group consisting of H, F, CI, Br, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted Cve-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member y containing Qj*-cyeioafiphatic radical, which may be bonded via an optionally at least mono-substituted Cj.e-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- orpolycyoRc ring-system, an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryf radical, which may be bonded via an optionally at least mono-substituted d^-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem, a nitro group, a cyano group, -OR1Da, -OC(=O)R11a, -SRl2a, -SOR12a, -SO2Rn2a, -NH-SOzR12a, -SQzNrfeand a -NRl3aR14a moiety, preferably selected from the group consisting of H, F, CI, Br, a saturated, branched or unbranched, optionally at least mono-substituted Ci_3-aliphatic radical, a saturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing Cs~ or Cg-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C-r or Qralkylene group, a nitro group, a cyano group, -OR10*, -0C(=O)R"*, -SR1Za and -NR13aRlJta moiety, more preferably selected from the group consisting of H, F, CI, -CH3, -CH2CH3, -CF3. -CF2CF3, cyclopentyl, cydohexyl, nitro, cyano and -ORl0a. 22. The compound as claimed in claim 20 or 21, characterized in that R5 represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted Ct-e-aliphatic radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C3^-cycIoalrphatic radical, preferably represents H or a branched or unbranched C-3-alkyl radical, more preferably H, -CH3 or -CH2CH3. 23. The compound as claimed in any one of claims 20 to 22, characterized in that R6a, R7a, R8a, R9a are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted Ci_g-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing Cs*-cycloaliphatic radical, a cyano group and a -CC=OR15" moiety, preferably selected from the group consisting of H, a branched or unbranched C^a-alkyl radical, a cyano group and a CC=OR1Sa group, more preferably from the group consisting of H, -CH3, -CH2CH3 and a cyano moiety. 24. The compound as claimed in any one of claims 20 to 23, characterized in that Wa represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C^ aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C3-8 cycloafiphatic radical, which may be bonded via an optionally at least mono-substituted C1-4-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycycJic ring-system, an optionally at least mono-substituted, 5- or 5-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted CW alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycycJic ring-system, a NR1BaR1TS-moiety or a CORl8a-moiety, preferably is selected from the group consisting of 1-Naphthyh 5-Dimethylamino-napth-1-yI, 2-Naphthyl-, 2-Acetamido-4-methyl-5-thiazoJyi-, 2-Thienyl 8~Quino[inyl-, Phenyh Perrtafluorophenyh 2,4,5-Trichloro-phenyl 2,5-Dichloro-phenyl-. 2-Nitrophenyl-, 2,4-Dinitro-phenyl-, 3,5-DichJoro-2-hydroxy-phenyl-, 2,4,6-Trisisopropyl-phenyl-, 2-Mesityi-, 3-Nitro-phenyl 4-Bromo-phenyl-, 4-FIuoro-phenyl-, 4-Chlorophenyl-, 4-ChJoro-3-nitro-phenyl-, 4-fodo-phenyl-, N-Acetyf-suffanifyf-, 4-Nrtro-phenyf-, 4-Methoxy-phenyl Benzoioacid-4-yl 4-tert-Butyl-phenyl-, p-Tolyl-, Trifluoromethyl-, Tricfcianamethyl Isopropyl Methyl-, Benzol-, trans-styiyf-, 2,2,2-Trifluoroethyl Ethyl-, Hexadecyh 2-ChloroethyI-, n-Propyl-, 3-Ch!oro-propyt-, , T-Butyt-, Methyf-benzoate-2-yh 24*tro-ihenyl-, 3,5-Bfe-(Trifluoromett»yf>|jheny(-, Dichloromethyf-, CWoromethyl Dodecyl-, 1-Octyt-, 2,3,4-TrfchIoro-phenyt-, 2,5-Dimethaxy-phenyl o-ToIyl-, p-xylyt-2-yh Benzsic-acfd-3--yh 4-ChJoro-3-(trf|fuorom6thyI}i3henyl 4-ChIo(p-5-nftro- ' benzoic acid-3-yl 6-(p-to!uidino>naprrth-2-yh 4-Methoxy-2,3,6-trimethyfphenyl 3,4-Didh!orophenyt-, 4,5-Dfbronw-thiophene-2-yl 3-Chloro-4-fluoro-phenyl-, 4-Ethytf>henyt-, 4-n-Propyt-phenyl-, 4--2-yl-, Benzoyl chJoride-3-yt-, 2-OiJoro-phanyl-, 1-Octadecyh 4-BromcH2,S^rchtoro^toph«r»-3-yl-, 2,5-D$chloro-thIophene-3-yh S^hloro-thiophene-2-yh 2-Methy}-5-nitra-phenyl 2-ro-B~rnethyl-, 5-Bromo-2-meflioxyi3henyl-, 3,4-D»methoxy-phenyl 2-3-Dfchloro-phenyl 2-Bromo-phenyl-, 3,5-Dlchloro-4^2-^rjkjfo^nitrdphBnaxy>-phenyl-, 2,3^lchlon>thioph©rie-5-.y{-, 3-Bromo-2-chIoro-thioph9ne-5-yl-, 3-Bromo-5-chIoro-tti1ophene-2-yl-, 2HBenzoylamfnomethyt}^|ophene-5-yh, 4-(Phenyl-su!phonyl)-thlophene-2-yl-. 2HPhenyMulphonylhiopherie-5-yh 3-Chtoro-2-me8iy{-phen>4-, 2-fl -M8thyr-5K^1fluoTOmetriy0pyra2oh3-yfJ-thiophene-5-yl 5-PyFid~2-yMhSophena-2-yf-, 2-Chtoro-5-(trifluoromethyl}-phesnyh 2.6-Dichloro-phenyh 3-Bromo-phenyl-, 2-(Trif5uoromalhoxy>-phanyl-, 4-Cyano-phenyh 2-Cyano-phenyh 4-n-Butaxy-phenyl-, 4-AcetamIdo-3-chIcsro-phenyf, 2.5-DJbromo-3.6-dffluoro-phenyl-, 5-Chforo-1,3-dime»iylpyTa2X»le-4-yt», 3,5-Dirnethylisoxazo!e-4-yl-, 2-(2,4-Dichforophenoxy)-phenyl-, 4-(2-Chforo-6-nftro-pheno5cy>phenyl-, 4-(3-Chtoro-2-cyano-ph€MrToxy)-phenyl-, 2,4-Dfchloro-phenyl 2,4-Pimethyl-1,3-thfeizol6-5-yl-, Methyl-methane-sulfonyl, 2,5-Bls-(2,2,2-Trifluoroethoxy)-phenyl 2-Chtoro-4-(liffluoromethy1)-prienyl-, 2-Chloro-4-fluoro-phenyl-, 5-FIuora-2-methyl-phenyt-, 5-Ch!oro-2-metfioxy-phenyl-, 2,4,6-TrfchIoro-phenyl-, 2-Hydroxy-benzofc acid-5-yh 5^Di-n-propylarn{no>. naphth-1-yh e-Methoxy-m-tolyl-, 2„5-Dif!uoro-pheriyl 2,4-Dimeihoxy-prienyh 2,5-Dibromo-phenyl 3,4-Oibromo-phenyl-, 2,2,5J,8-Pentarnethyf-chrarnan-6- yh 2-Methcjxy-benzofc-acid-5-yl 5-Chloro-4-nitr^thtophene-2-yl 2,1,3- 8wzofhf.adiazDl3-4-yH 1-MethyMmJdazole-4-.yh BenzofurazartA-yl-, 2- ;Me(hoxycart»onyf>-tfw3phefie-3-yf-, 8^tsaKawl-3-yt)-1tiiapttem&yl-, Z.4,5- Trfffuoro-phenyf-, BiphenyW-yl Vfnyl-pbenyW-yf-, 2-NtC=O-foenzyl-, 5-Dfchloro- mathyl-furan-2-yh 5HBromo-ihiophene-2-yh 5-- thJophene-2-yl-, 2,6-Dlfluoro-phenyl 2,5-Dlm6*oxy^nSra^henyl Dibenzo[b.dHuran-2-yh 2,3,4-TrifluorD-phenyl-, 3-Nitro-p-tolyl-, 4-Methoxy-2- nftro-phenyh 3,4-Dffluoro-phenyh 4^BromoethyI)-phenyh 3,5-DichIoro-4- hydroxy-phenyl 4-n-Amyl-phenyl-, 5-Chlort>3-methylben2D{b>th!ophene«2-yl- , 3-Methoxy^meftoxycari3onyl)-thlophefie-2-yI-, 4-n-Butyl-phenyf-, 2-Chloro- 4-cyano-phenyl--, 5-^MethyRhla>^yrfmfdfn-4->4-3-th?ophene-2-yl 3,5-DfnJtro- 4-metfioxy-phenyf-, 4^romo^K*^twromethoxy)-pfienyf-, 4-Chloro-2,f,3- Benzoxadfazole-7-yf-, 2-(1-Naphtftyf}-ethyf-, 3-Cyano-phenyf-, 5-CWoro-2,1,3- Benzoxadiazote-4-yl 3-CWoro-4-m«ttTyH>h©nyl-, 4-Bromo-2-ethylphenyl-, 2,443Ichton>-6-methyl-phenyh 6-ChlorD-lmida20{2,1-BHb«az33te-5-yl-, 3- MethyMsen2so{b}4hiophene-2-yl-. 4-Methylsulphonyhphenyl-, 2-Methyl~ sulphanyl-phenyl 4-Bromo-2-methyl-pheriyl 2,6-Dfcfttaro^trffiuoromethyl}- phenyh 4HJ3^hton>^W1tuoioni8th^^ 5-Chioro- naphth-1-yh 5-ChIoro-naphth-2-yl 9/IO-Dibromoanthracene-2-yh Isoqulnoilne-s-yl 4-MethcC=Ofc2.3,6-trime4byl-phenyl-14'-Nltro-biph©nyM-yl-, K4-Phancwy)-phenyl-, (1,3^iltydn>-1^xo-2H-KOJndcrf-2-yf-H-phenyl 4-Acetyf-phenyh 5- phenyl 4-(3,5-Dfchforo-pfterw^)-phenyh 4^3,4-DfchIoro-pheno*y)-phenyl 4^4~Ruon>phenoxy)-phenyh 4-phenyf-, 3-(2-Meifjy*r phenoxy)-phenyh 4-I2-(Trifluoitimethyl)-phenoxyl-phenyl-, 3-Phenyl-phenyh 3-(4-Methoxy-phenyl)ph9nyh 3^4~Chtoro-phenyf>ph©riyl 3-{3,5-Dichlofo-phenyf}-pfrenyl 3^3,4-Dichforaftoenyl)i3hertyl 3-(4-Fluorephenyl)-phenyt-, 3-(4-MethyIphejiyl)-phenyh 3-{4-(Trifluoromethyl)-pbenyr|i3henyl-, 3-[3,5-Bte-(Trtfluoromathyl)pheny^phonyl 4-phenyl 4-(2-Methyf-phenoxy>-phenyl 4-(4-Methoxy-phenaxy>-phervyl-. 4^4-Oiloropheriyl)-pheriyl 4-{3,5-DfchlorophenyD-phenyh 4-(3,4-DichIorophenyl)-ph9nyl-, 4-(4-Fluorophenyl)-phenyl 4-(4-Metfiylpheny})>phenyf-r 4H£4 {4-Ch!orophenyl)-mBthyl (3,5-Okdtforophenyl)-mettryt-, (3,5-EMchlorophBnyl)-methyl (4-Fluorophenyl)-methyt-, 4-*4ethylphenylmethyl-, [4hBnylethyl-, 544-C^no-1-m^hyt-5-{melhyfltilo)-1H-pyrazofc3-yl-thfophene~2-yl 3-Cyano-2,4-Ws-(2»2,2-Trffluorothoxy>-phenyl-, 4~ [(2-Chloix>l,3-Thfazot-5^)-m©thco(y}-pheny}-r 3-Nttrp-phenylfnethyl-, 4-Formyiphenyl 2^1>Dioxo-1.3^^yciro-isoincio}-2-yf>-ethy}-, J3,5-Bis-(TrtfluoromethyI)-phany5-rr»thyl-, (4-(2-Pyridyloxy)-pheny{)-, (4-{3-Pyrtdyloxy> phenyl}-, 5-todo-naphth-1-yf-, Ethyt-2,5-dim8thyf-T-f>fienyfpyrn3Fe-4-carboxylate-3-yh Ethyl-2-methyl-1,5^iphenyl-l!+pyiToI©-3-carboxylate-4--yi-, Ethy^^-{4-chIoropheny^>2-methyl-3-furoat&-4-yl, Ethyl-5-(4-chlorophenyl)-2-mathyM-pheny^3-cartwxy/afe-4-yl Eihyl-2,5-dim^hyf-3-furoate-4-yf-, 3-CWoro-4-phenoxy>-phenyl-, 3-(3,5-Dichforophenoxy)-pheriyh 3-(3,4-Oichtorx3phencBcy)-phenyt-, 3-(4-Ruorophenoxyj-phenyl-, 3-(4-Methylphenoxy)-phenyl 3-£4-(TriffuoromethyO-pheno^J-pheny^ 3-[2-{TrifJuorometfiyl)phenoxy}-pheny^, 2,2-Dfphenylethyf-, 4-Phenyf-5-(trffluoromethylHh>°Phen^^Vi-, Methyl-4-Phenyl-5-(Tnfluoromethyl)- thfophane-2-cartHa>^at©^-yl Me^^ yl 4-Ruon>naphtM-yl-, 3,5-Dffluorophenyh 3-FJuoro-4-methoxy-phen>*-, 4--> • Chtero-2,5-drf?uarapf»8nyl-, 2^hforo-4,5-drfluoro-phenyl-, S-FTuoro-3-methyIbenzo£b]-thiophene-2-yhM^ Dihydrocinnamfc AcW-4-yl Metnyl-2,5--5-fIuon>-2-rnethylpheriy{-, Pe^tafluoroethcjxytetrafluoroett^-, 5^5-JsoxazyfHhfophene-2-yI-> 5-(5-IsoxazoJ-yfK-ftjryl-, S^^byl-^I.S-benzothiadlazsote-^yt-, BJphenyl-2-yh 2,3-Dihydix>-l,4-benzodfc«ine-8-yl-, 4-M©thyt-Naphth-1-yl 5-Methyl-2-(TrffruormethylJ-3-Furyl 2,3~Dihydrobenzo{p]fura»vS-yh 1-Benzptfifophene-3-yl-, 4-Mxadne-7-yl-, S-MethyM-pftenyMH-pyrazols-4-yh B-Morpholino-3-PyiWinyl-, ^IH-PyraswH-yf^phenyl-, 6-Phenoxy-3-Pyridyl-, 3,4-DIhydro-2H-1,5-benzodlt»»pIn6-7-yl-, 5-(1,3-QxazDi~ 5-yl)-2~thienyh 4-{1,3-Oxazo1-5~yl)-pheriyl 5-Methyl-4-!sc»cazolyl, 2,1,3-BereothiadJazple^S-yl 3-Thtenyl 2-Methyl-benzyl 3-Chlofo-benzyl-, 5-Acetamfclo-naphth-1-yl-, 3-Methyl-8-Quinolinyl-, 4-Chloro-2-nftropberiyh 8-QuInoBnyl-. 1,3-Benzrthiazote-6~yl 2-NADrphoJlpo-3-Pyridy)-, 2,5-Dirneibyl-3-thienyl 5-j^Chloromethyl)-1,2,4-oxadjazof-3-yl3-2-ttiianyl-, BHtyl-^{5-yi-2-thfenyl-J1,2,4-oxadteu!:ofe-5-cart)oxytate-, 3-(5-MethyH,3,4-axad?azol-2-yi}~ phenyl-, 4~!sopropoxyphenyf-r 2,4-Dibromophenyl-, 3-C/ano-4-fluorc^phenyl 2,5-Bls-(Trffluaromattiyl)phenyl, 2-Bromo-4-fiuopjphenyl-, 4-8romo-3-fiuoraphenyl-, 4-(Drffuoromethoxy)-phenyl-, 3-(D"rfluorDmethoxyH>henyl-, 5-Chloitx-2-fluoro-phanyl 3-Chlpro-2-fluonophanyl-, 2-Ftuorch4-methyfphenyf-, 4 Nttro-3-(lrifluorofnethyl)-ph»iyi-, 3-Fluoro-4-metfiy|phenyl, 4-FIuoro-2-methylphenyh 4-Bromo-3-{tifluoromethyI)-phenyl-. 4-Bromo-2-(trtfluoromethylVphenyl 3-Bromo-5-{trif!uoromethyl)-phenyl-, Z-Bromo-4-(i*ifluorometfiyl)pbenyl 2-Bromo-5-(trff!uoromethyl)-pheriyl 2,4-DichJoro-5-fluoropbenyl-, 4,5-DIct>loTO-2-f}iiorophenyl-, 3,4,5-Tf/fluorapbenyl 4-C1-4ora-2-fluorophenyf-, 2-Bromo-4,6-DIUuoropheny}-, 2-Etttylphenyt-, 4-BromoZ-chforophenyh 4-Bromo-2.6-d«cWorophenyf-, Z-Bromo-4,6-dichforo-phenyf-, 4-Bromo-2.6-dimethylphenyl-, 3,5-DlmethyIphenyl 4-Bfomo-3-methytph«nyl 2-Methoxy-4-nitraphenyl 2,2-Dfmethyt~6-Chromanyl Ethyl-3,5-dimethyM B- pyrrole-2-carboxylate-4~yl-, imidazoP,2-A]pyridine-3-yl 3-{1,3-OxazDl-5-yl)- phenyh Ethyf-S-[4-yl)-pfienylJ-2-methyt-3-fuit3ate> Methyf-3-(yl}-4- -•34-{3-propyI-Ureido)-phenyh'3-(-Bromoacetyl)-phenyl2^^ phenyl-, 1-Methyl-5-isafinyl 4~lsopropyl-benzolc-acid-3-yf-, 2-CnJoro-3-thiopnenecarboxylio-acid-5-yh 3-Pyridyh Cyclahexylmethyl 2-Methoxy-5-(N-phtha!imidinyl)-phenyl-, 1-Benzothiophene-2-yl-, Morpholinophenylsurfonyl-, 3-(2-Methyf-4-pyrimidinyf)-phenyf-J and 2-Cyano-5-methyfphenyf-. 25. The compound as claimed in any one of claims 20 to 24, characterized in R10a represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted Cj^-aliphatic radical, a saturated or unsaturated, optionally at (east mono-substituted, optionally at feast one heteroatom as ring member containing Qj^-cycloaiiphatlc radical, which may be bonded via an optionally at least mono-substituted CWalkylene group and/or may be condensed with an optionally at least mono-substituted mono-or poJycyclic ring-system, or an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted Ci-^-alkytene group and/or may be condensed with an optionally at least mono-substituted mono- orpolycydic ring-system, preferably H, a linear or branched C-,-4-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably H, -CH3, -C2H5 or phenyl. 26. The compound as claimed in any one of claims 20 to 25, characterized in R11a represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C-i-e-aliphatic radical, a saturated or y-unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C3^-cycloa(iphatfc radical, which may be bonded via an optionally at least mono-substituted d.B-alkylene group and/or may be condensed with an optionally at least mono-substituted mono-or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6- membered aryl- or heteroaryl radical, which may be bonded via an optionally at feast mono-substituted Ct-e-alkytene group and/or may be condensed with r^ optionally at least mono-substituted mono- or polycyclic ring-system, preferably H, a linear or branched C^-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably H, -CHa, -C2H5 or phenyl. 27. The compound as claimed in any one of claims 20 to 26, characterized in that R12a represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C^-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C^-cycloalFphatic radical, which may be bonded via an optionally at least mono-substituted Ci_6-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6- membered aryl- or heteroaryf radical, which may be bonded via an optionally at least mono-substituted Ci-e-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably represents H, a linear or branched Cr4~alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably H, -CH3, -CzHs or phenyl, 28. The compound as claimed in any one of claims 20 to 27, characterized in that R13a and R14a are each independently selected from the group consisting of hydrogen an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted Cj^-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C^s-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted Ci,e-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or-an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C1-4-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably are each independently selected from the group consisting of H, a linear or branched C1-4-alkyl radical. cyclohexyi and a phenyl radical, more preferably are each independently selected from the group consisting of H, -CH3. -C2H3 and phenyl. 29. The compound as claimed in any one of claims 20 to 28, characterized in that R13a and R14a together with the bridging nitrogen atom form a saturated, unsaturated or aromatic, 5- or 6-membered heterocyclic ring, which may be at (east mono-substituted and/or contain at least one further heteroatom as a ring member, preferably form an unsubstituted piperidin or morpholine group. 30. The compound as claimed in any one of claims 20 to 29, characterized in that R15a represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C^alipnaiic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing Qj^-cycloalfphatic radical or an optionally at least mono-substituted, 5- or 6- membered aryl- or heteroaryl radical, which may be banded via an optionally at least mono-substituted Oj^-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or porycyclic ring-system, preferably represents H. a linear or branched C-j-4-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably represents H, -Oth, ~C^HS or phenyl. 31. The compound as claimed in any one of claims 20 to 30, characterized in That R16a represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C|-e aliphatic radical, preferably an unbranched or branched, saturated, unsubstituted CV3 a'tyl radical, more preferably a methyl radical. / 32. The compound as claimed in any one of claims 20 to 31, characterized in that R17a represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted d^ aliphatic radical, preferably an unbranched or branched, saturated, unsubstituted C^ alkyl radical, more preferably a methyl radical. 33. The compound as claimed in any one of claims 20 to 32, characterized in that one or more benzoxazinone-derived sulfonamide compounds of generally formula (la) a*'1 selected from the group consisting of: 1-{1 -(Naphthyl-1 -sulfonyl}-pFpend?ne-4-yrj-1,4-dihydfo-benzo[d}£1,33o>azin-2- one, . 1-(1-Ph6nyl$ulfonyl-piperfdine-4-yl}-1,4-dihydro-benz»[d][1,3]-oxaztn-2-one, 1-[1 K5^hlon»-3Hmethvl-benz^,4- df hydro-benzo|djtjFJI,3JoxazinH2-ane, 8-MeftyI-1-fl-naphthyM-sutfony{)-pfperidJne-4-y^1,4Miihydro~ benzo[d][1,3Joxazin-2-ane, 1-{1-(quinoIine-«^ulfbnyr>piperf^^ one, 8-MethyH-[1 -(qu!noflne-S^uHbnyf)-piperfdfiv4-yfj-1,4-dfhydro-benzo JdJfJ,3]axazin-2-orie, 1HP^5-DimethylaminoHnephthyM dihydroberi2O[dH1,33oxazIn-2-ori0» y 1-[1^545imethytaTnino-naphthyl-1-sutftm^^ benzo[d][1 ,3]oxazJn--2-orie, 1-(1-(2,3-DIchtoro-phenyteu}fonyl)-piperjdm&-4-yQ-1,4-dfhydro-benz»[dl[1,3]oxazin-2-ane, HH2,3-DicMaro-phenyteuffon^ benzo[d]f1,3]oxa23n-2-one, and corresponding salts thereof, or corresponding solvates thereof. 34. The compound as claimed in any one of claims 20 to 33, for the regulation of appetite. 35. The compound as claimed in any one of claims 20 to 33 for the reduction, increase or maintenance of body weight. 36. The compound as claimed in any one of claims 20 to 33 for the prophylaxis and/or treatment of obesity. 37. The compound as claimed in any one of claims 20 to 33 for the prophylaxis and/or treatment of bulimia. 38. The compound as claimed in any one of claims 20 to 33 for the prophylaxis and/or treatment of anorexia. 39. The compound as claimed in any one of claims 20 to 33 for the prophylaxis and/or treatment of cachexia. 40. The compound as claimed in any one of claims 20 to 33 for the prophylaxis and/or treatment of type II diabetes. 41. Benzoxazinone-derived sulfonamide compounds of general formula (lb). (Formula Removed) wherein R1b, R26, R3", R46 are each independently selected from the group consisting of hydrogen, halogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least ons / heteroatom as ring member containing cycfoaliphatic radical, which may be bonded via an optionally at least mono-substituted ajkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least mono-substftuted aryl- or heteroaryi radical, v SOzNH2 and a -NR13bR,4b moiety. Wb represents an unbranched or branched, saturated or unsaturated, aliphatic radical, which may be substituted by one or more substituents selected from the group consisting of hydroxy, halogen, branched or unbranched C^-alkoxy, branched or unbranched C^-perfluoroalkoxy, branched or unbranched C-H,- perfluoroalkyl, amino, carboxy, arnido, cyano, nitro, -SO2NH2, -CO-C^-alkyl, - SO-C1-4-alkyl. -SOz-d-q-alkyl, -NH-SOz-C^-alkyl, wherein the C^-alkyl may in each case be branched or unbranched, an unsubstituted or at least mono- substiiuted phenyl or naphthyl radical and an unsubstituted or at least mono- substituted furanyh thienyl pyrrolyh imidazoryl-, pyrazolyl-, pyridinyl-, pyrimidinyl-, quinolinyl- and jsofluinolinyl radical, ' whereby said substituents may be at least mono-substituted with F, CI, methyl and methoxy, a saturated or unsaturated, optionally at least one heteroatom as ring member containing cycloaliphatic radical, whereby said cycloaliphatic radical may be substituted by one or more substituents selected from the group selected from the group consisting of hydroxy, nitro, carboxy, cyano, keto, halogen, C>2o-alkyl, partially fluorinated C1-4 alkyl, partially chlorinated C1-4 alkyl, partially brominated Ct-* alkyl. Cs-alkoxy, partially fluorinated C^ slkoxy, partially chlorinated d-4 alkoxy, partially brominated d-4 alkoxy, CWalkenyl, SOz-d^-alkyl, -(C^J-C1-5-alkyl, .(C=O-O-CLs-alkyl. -(C=O)C|, -S-C^-alkyl-, -(C=O)-H, -NH-(C=O)NH-d^- independently selected from the group cansfetfng of H, C^-alkyl and phenyl, NHKC=O)-C,.5-alkyl, -^^-aflcylenKCsO^d^-allcyl, (1,3-Dihydro-1-oxD-2H-'^oindol-2-yl), N-PhthaHmldinyh (1,3-Dioxo-2-aza^)ln3[4,4J-non-2-v|, substituted or unsubstituted phenyl, -SO2phenyl, phenoxy, pyridinyl, pyridlnyloxy, pyrazolyl, pyrimldfnyl, pynnoBdinyl -SOjrPyrrolidinyl, morpholinyl, SOz-morpholinyl-, thiadiazolyl, oxadtazolyt, oxazolyi, thiazolyl, isoxazoryl, O-CrVthiazolyi, \NH-phenyl, and -^rAIKyl9n-NH-{C==O)-pheny}, whereby said substltuents maybe substituted by one or more substituenta selected from the group consisting of halogen, nftro, cyano, hydroxy, -{C=O}-C1-4-alkyl, Ct-A-alkyl, at least partially fluorinatod Ct~ralkyt, at least partially chlorinated Ct-a-atkyl, at least partially bromlnated CWa&yU -S-C^-alkyl, -C(=O)-O-Ci«ralkyl. -(C=O)-CHz-F, -(C=O)-CHz-CI and -(C=O)-CH2-Br. and whereby said cydoaliphatic radical may be bonded via an optionally at least mono-substituted alkylena group and/or may be condensed with an optionally at least mono-eubstltuted aromatic mono- or polycycfic rtng-system. an optionally at least mono-substituted aryt- or heteroaryf radical, which may be bonded Vm an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, a NR1BbR17b-moiety or a COR18b-rnoiety. R*®8 represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cydoaliphatic radical, which may be bonded via an optionally at least mono-substituted atkylene group and/or may be condensed wtth an optionaBy at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryi radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, Rm represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated ~" »• unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cyctoaiiphatic radical, which may be bonded via an optionally at least mono-substituted alkytene group and/or may be condensed with an optionally at least monc^subHsdWuted mono- or polycydfc ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substftuted mono- or polycyciic ring-system, R12b represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at teast mono-substituted, optionally at feast one heteroatom as ring member containing cycfoaliphatic radical, wftfch may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed wfth an optionally at least mono-substituted mono- or polycycltc ringrsystern, or an optionally at least mono-substituted aryl- or heteroaryl radical which may be bonded via an optionally at least mono/-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycycfic ring-system, R'36 and R14b each are independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at teast one heteroatom as ring member containing cycloaliphatJc radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substftuted mono- or polycycltc ring-system, or an optionally at least mono-substituted aryi- or heteroaryi radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or porycyciic ring-system, or R13b and R1* together with the bridging nitrogen atom form a saturated, unsaturated or aromatic heterocyclic ring, which may be at least mono---"yjbstituted and/or contain at least one further heteroatom as a ring member, R1Sb represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloallphatfc radical or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, R16b represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, R17b represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical. R1Btl represents an optionally at least mono-subsituted aryl radical, optionally in form of one of its stereoisomers, preferably enantiomers or dia5tereomers. rts racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a physiologically acceptable saH thereof, or a solvate, respectively. 42. Compounds as claimed in claim 41, characterized in that R1b, R2b, R3b, R each independently selected from the group consisting of H, F, CI, Br, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C-i-e-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing Qj^-cycloaffphafic radical, which may be bonded via an optionally at feast mono-substituted CWafkyfene group and/or may be condensed with an optionally at feast mono-substituted mono- or polycyclic ring-system, an optionally at feast mono-substituted, 5- or 5-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted Cj-s-alkylene group and/or may be condensed with an optionally at least mono-~1ibstituted mono- or polycyciic ringsystem, a nrtio group, a cyano group, -OR10*, -OC(=O)R11b, -SR1Zb, -SOR12b, -SO2R1a\ -NH-SO2R12b, -SO2NH2 and a -NR13bRMa moiety, preferably selected from the group consisting of H, F, CI, Br, a saturated, branched or unbranched. optionally at least mono-substituted Cvyalrphatic radical, a saturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C5- or Cg-cycloaHphatic radical, which may be bonded via an optionally at least mono-substituted Ci- or C2-alkylene group, a nrtro group, a cyano group, -OR1to, -OC(=O)R11b, -SR12a and -NR1*R14b moiety, more preferably selected from the group consisting of H, F, CI, Br, -CH3, -CH2CH3. -CF3. -CF2CF3, cyclopentyl, cyclohexyl, nftro, cyano and -OR10*. 43. Compounds as claimed in claim 41 or 42, characterized in that R5b represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C!^-alfphatic radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing Cg-a-cycloaliphatic radical, preferably represents Hora branched or unbranched Ci.3-a!kyl radical, more preferably H, -CH3 or -CHgChfe, most preferably a hydrogen atom. 44. Compounds as claimed in any one of claims 41 to 43, characterized in that R6b, R7b RBb^ ^9b are eacn independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted Ci-6-aIipbatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing Qwrcycloafiphatic radical, a cyano group and a -CC=OR15b moiety, preferably selected from the group consisting of H, a branched or unbranched Ci-3-alkyl radical, a cyano group and a CC=OR1Sb group, more preferably from the group consisting of H, -CH?, -CH2CH3 and a cyano moiety, most preferably each of Ra, R76, R811 and R* represent a hydrogen atom. 45. Compounds as claimed in any one of claims 41 to 44, characterized in that Wb represents an unbranched or branched, saturated or unsaturated, C1.20 aliphatic radical, which may be substituted by one or more substituents selected from the group consisting of hydroxy, halogen, branched or unbranched Ct^-alkoxy, branched or unbranched Cj^-perfluoroalkoxy, branched or unbranched C^perfluoroalkyl, amino, carboxy, amido, cyano, nitre. -SO2NH2, -CO-C^-alkyl, -SO-Ct-*-alky|, -SOr-Ci-ralkyl. -NH-SQrC^- alkyl, wherein the d-4-aJM may In each case be branched or unbranched, an unsubstttuted or at least mono-substituted phenyl or naphtftyf radical and an unsubstttuted or at least mono-substituted furanyl-, thienyf-, pyrroiyl-, imidazoryh pyrazoryh pyrfdlnyl-, pyrimidinyh quinolinyt- and isoqutnofinyf radical, whereby said substituents may be at least mono-substituted with F, CI, methyl and methoxy; a saturated or unsaturated, optionally at least one heteroatom as ring member containing C»* cycloaJlphatlc radical, s whereby said C3* cyclosliphatic radical may be substituted by one or more substituents selected from the group selected from the group consisting of hydroxy, nltro, carboxy, cyano, keto, halogen, C-Hzo-alkyl, partially fluorinated d-4 alkyl, partially chlorinated Gj-4 alkyl, partially brornfnated C1-4 afkyl. C1-5-alkoxy, partially fluorinated C1-4 alkoxy, partially chlorinated C^ alkoxy, partially brominated d^ alkoxy, Qwralkenyl, SO2d-4-alkyl, -(C^O^d.s-aftyl, ^C=OKJ-C^-alkyl. -(C=O)-CI, -S-C,.*-alkyl -(C=O)H, -NH-(C-0)-NH-Ci*-alkyl, -(0*0>C-rperftuoroalkyl, -NF^R3, wherein R* and RB are independently selected from the group consisting of H, d-4-alkyl and phenyl, NH-(C=O)-C1^-alkyl) -C1-4-alkyteri-CCsO^d^-alkyl, (1,3-Dihydro-1-oxo-2H-isolndol~2-y0, N-PhthaEmHinyh (1,3-Dioxo-2-azasp0o(4/4]-non-2-yl, substituted or unsubstttuted phenyl, -SC>2-phenyl, phenoxy, pyridioyl, pyrldinyfoxy, pyrazolyl, pyrimidinyl, pyrrolldinyl-, -SOz-pynolldinyt, morphollnyf, SO2-morpholfnyl thiadfetzolyl, oxadiazoryl, oxazolyl, thlazolyl, isoxazojyl, O-CHa-thfezoJyl, -NH-phenyl, and -C1^AIkyfen-NH-{C=O).phenyf, whereby said substituents may be substituted by one or more substituente selected from the group consisting of halogen, nitro, cyano, hydroxy, HPO}* C-1-4-alkyl, Gj-4-sikyf,a* te35* partially fluorinated d-r-alkyl. a*Ieast partially chforinated d-r^M. at least partially brominated C^-alkyl, -S~d-»-alkyl) -C(=O)-O.C,^a|kyl, -(C=O)-CH2-F. -(r>0)-CHrCI and -(C=OJ-CHr8r, and whereby said C-wjcycJoallphatfc radical may be bonded via an optionally at least mono-substituted d-e-aJkytene group and/or may be condensed with ' ^n optionally at feast mono-substituted aromatic mono- or polycyclic ring-system, an optionally at least mono-substituted, 5- or S-mernbered ajyf- or heteroary} radical, which may be bonded via an optionaHy at teast mono-substituted Cj.*-alkylene group ami/or may be condensed with an optionally at least mono-substituted mono- or porycycflc ring-system, a NRtebR17b-moiety or a CORtfb-molety, preferably Wb represents a linear or branched Ct-ao-alkyl radical, preferably an alkyl radical selected from the group consisting of methyl, ethyl, n-propyl, Iso-propyl, tvbutyl, iso-butyl, ssc-butyl, tart-butyl and 1,1-dirnethyl-propyl; a linear or branched C^zo-alkenyl radical; preferably a vinyl radical; -CF3; -CHF2; -CH2F; -CCfe; -CHCfe; -CHzCf; -CHrCF3; -CHz-CHz-Cl; -CHz-CHz-CHz-CI; -CH^(=O)2-CH3; a cyctopropyl radical; a cydobutyl radical; a cycJopentyf radical; a cyctohaxyf radical; -CH2-cyclopropyl; -CHz-cydobutyl; -CHjrcyeJapentyf: -CFfercyclohexyi; -N(CH3k; -HtPzHeh; -N(n-CH2-CHrCH3fe; phenyl; benzyl; naphthyl; -CH*CH-phenyl; -(CF2)-(CF2)-0-phenyl; - 2-oxo-2,3-dlhydnj-benzC=Oxazolyt; 3,4-dihydro-2H-benzo[1,43oxaz3nyl; or 2,1,3-benzoxadiazoiyi; whereby each of these afore mentioned cyclic moieties may optionally be substituted with l„ 2,3,4 or 5 substrtuents independently selected from the group consisting of methyl; ethyl; n-propyl; iso-propyl; n-butyl; iso-butyl; sec-butyl; tert-butyt; 1,1-dirnethyl-propyl; n-pentyl; vinyl; cydopropyi; cyclobutyl; cyclopentyl; cyclohexy}; morphiolino; methoxy; ethoxy, n-piopoxy; iso-propoxy; n-propoxy; F; Cl; Br, I; -CN; -OH; ~CF3; -CF2H; -Cl-feF; -CCb: -CCIHa; -CHCfo -CHrF; -CHrCK-CrVBr; -(C=O) CH2-B17 -OCFa; -O-CH2-CF3; -0-CHF2; -NO* -NHZ; -^(CHsfe; -NfCaHsfci -NCrM^Hz-CHz-CHafe -WCn-CH^HrCHrCHak'-NH-iC=OJ-CHa,* -NH-phenyl; ~(C=O)-CF3; -(00}-OH; =O (oxo); -{f>0)-H; -S^Ofe-CHa; -S(=O]brlsopropyl; -S{*=O)rphenyl; -S(=Ofe-pyrraffa inyf; -S(=sO>s-morpholino; ^CH2y{ZHz}iOyO-CHi; -NH^CsO^NH-CHa-CHz-CHs; -(C=OJ-CH* -{C=O)-O-CHa; -(Osoyo-Citts; -{CH2>-NH-{C=O)phenyl; -CHrC{H}(phenylXphenyl),- -O-CHrthiazolyl; 1,3-dioxo-2-az2spiro[4.4Jnon-2-yl; phenyl; phenoxy; isoxazoryl; 1,3-oxazoIy|; 1,2,4-oxadiazolyl; 1,3,4~oxadiazoiyi; pyridinyl; pyridinyloxy; pyrazolyt; pyrimidinyf and phthafirnidinyf; and whereby each of the cyclic moieties of these afore mentioned substttuerrts may optionally be substituted wfth 1,2,3,4 or 5 , substftuents independently selected from the group consisting of methyl; ethyl; n-propyl; iso-propyl; F; CI; Br;!; CN; -CHrF; -CH2-CI; -CHz-Bn ~CF3 and -S-CH3, more preferably Wh represents an alkyl radical selected from the group consisting of methyl; ethyl; n-prbpyl; iso-propyl; n-butyi; secbutyt iso-butyl and tert-butyl; vinyl (CrV=CH-); -N(CH3fe 1-naphihyl; benzyl; 2-naphtyl; phenyl; 2-methyl-phenyf; 3-methyl-phenyl; 4-methyI-phenyl; 2-ethyj-phenyl; 3-ethyl-phenyfc 4-ethyt-phenyl; 2-n-propyl-phenyl: 3-n-propyl-phenyf; 4-n-propyl-phenyl; 24sopropy|-phenyl; 3- isopropyl-phanyf; 4-lsopropyl-phenyt,* 2-n-btrtyl-phenyt; 3-tv*utyi-phenyf; 4-n-butyt-phenyl; 2-fso-buiyt-phenyf; 3-iso-hutyf-phenyf; 4-fSO-butyf-phenyt; 2-tert-J $utyl-phenyl; 3-tsrt-butyl-phenyl; 4-tert4sutyl-phenyt; Ll-dimethytpropyl-phenyl; 2-cyctopen^-phenyl; 3-cryctopenfyt-pftenyl; 4-cydopentyl-phefryf 2-cyclohexyl-phenyl; 3-€yclohexyl-.phenyl; 4-cydohexyl-ph«Tyi; 2-methoxy-phenyl; 3-methoxy-phenyf; 4-methoxyphenyt; 2-ethoxy^jhenyfc 3-ethaxy» phenyl; 4-0thoxy-phenyl; 2-n-propoxy-phenyfc 3-n-propoxy-phenyl; 4-n* propoxy-phonyl; 24so-propoxy-phenyl; 3-feo-propox/-phenyfc 4-Jsopropoxy-phenyl^-fluoro-phenyl; 3-fluoro-ptienyl; 4-fluoro-phenyl; 2>-chloro-phenyfc 3-chforo-phenyf; 4-chtaro-phenyl; 2-btomo-phmyl; 3-bromo-phenyl; 4-bronw>-phanyl; 2-tilfliioromethyl-pheriyl; 3-tffluoromethyl-phenyl; 44rifluorometftyt-phenyf; 2-trifIuorornethoxy-phenyf,* S-triftuorometfroxy-phenyl; Ar trffkioromeftboxy-phenyl; 2-carboxy-phenyl; 3-carboxy-pheny); 4-carboxy-phenyl; 2-acetyt-pJienyl; 3nacefyf~phanyl; 4-^acetyf-phenyl; Z-{O=O}-O-€Ht-phenyt; 3-(C=O)-0-CH:rphenyl; 4^C=O)O-CHrphenyl; 2-(CHzMCH2KC=O)-O-Chhl 3-CCHzHCHzHC=O)-OCH3>- 4-phenyf; 4-(4-bromophenoxy)-phenyl; 2-methyfeulfonyl~phenyl; 3-metfiyjlsulfonyf-phenyfe 4-methylsuKbnyl-phenyl; 2-phenyf-phenyl (blphenyl-2-yl); 3-pbenyl-phenyl (bJphenyl-3-y)fc 4-pbenyl-phenyl (brphenyl-4-yf); 2-phenoxy-phenyl; 3-phenoxy-phenyf: 4-pherioxy-phenyt; 2,4-dlmethyl-phenyl; 3,4Hdime!hyl-pftenyl,- 2,4,6-trimetbyf-phenyl; 2,3,5,6-t0trame4hyH3henyl; pentamethyl-phenyl; 2,5-dlmethaxy-phenyl; 3,4-dlmethoxy-phenyl; 2,3-dichforo-phenyfc 2,4Hdichlofo-phenyl; 2,5-dicNoro-phenyl; 3,4-dlchJoro-ph©nyl,-3,5-d$chloro-phenyl; 2,6-dfchloro-phenyf; 2,4-dffluoro-phwiyl; 3,4-drfluoro-phenyl; 2,5-difluoro-pheny}; 2,6-difluoro-pheny>; 3~chIaro-2-fiuoro^3henyl; 3-GhIora-4-fluoro~phenyl; 5-chloro-Z-ffuoro-phenyf; 2,3,4-trichlaru-phenyl; 2,4,5-trfchloro-phenyt; 2,4,6-trfchlora-phenyl; 2A^Jffiuoro-phertyl; 2,3r44rifiuoro~ phenyls 2-chtoro-4,5-difIuoro-phenyl; 2-bfomo-4-fFuoro-phenyl; 2-broma-4,6-diffuoro-phenyl; 4-chIarx>-2,6-dffluoro~phenyl; 5-chloro-2,4-difiuora-phenyl; 4-bromo-2,5-dtf?uoro-pheny{; 5-bromo-2,4-dfnuoro-phenyl; pentafluoro-phenyf; 2,4-dinitrophenyl; 4-chloro-3-nttro-phenyl; 2-metbyl-5-nltro-phenyl; 5-bromo-2-methoxy-phenyf; 3«chioro-2-meth}4-phenyf; 4~bromo-3-rn9thyf-phenyl; 4-chloro-2,S-dimeihyl-phenyl; 4-fluoro-3-methyl-phenyl; 5-fIuora-2-methyt- phenyl; 2-nitro-4-trifluoromethyl-phenyl; Z-methoxy-4-methyl-phenyl: 3,5-dlcftIoro-2-hydroxy-phenyl; 3,5-dichloro-4-hydroxy-phenyl; 5-chJop>.2,4-* Ifluoro-phenyf; 3~chloro«4-(NHKC=O)-CH3-phenyl; 2-chforo-6-methyr-phenyl; 2-chtoro-5-tnfluoroniethyl-phenyl; 2-chlom-5-trifiuoromethoxy-phenyl; 4-bromo-2-trifluoromethoxy-phenyl; 4-bromo-2-trifluoromethyl-phenyl; 4-bromo-3-trifluoromethyf-phenyl; 3-cart)0xy-4-t?uoro-phenyl; 3-carboxy-4~chloro-6-fluoro-phenyl; 4~methoxy-2A6-trimethyl-phenyl^; or one of the following groups: (Formula Removed) whereby in each case X denotes the position by which the respective substituent Wb is bonded to the -SO2 group of formula (Jb). 46. Compounds as claimed in any one of claims 41 to 45, characterized in that R 10b represents hydrogen, an unbranched or branched, saturated or unsaturated, optionaHy at least mono-substituted d^aliphatic radical, a saturated or -^saturated, optionally at least mono-substituted, optionaliy at least one heteroatom as ring member containing C3^cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted Ci-e-alkytene group and/or maybe condensed with an optionally at least mono-substituted mono-or pclycyclic ring-system, or an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryf radical, which may be bonded via an optionally at least mono-substituted Gj,5-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polyoyclic ring-system, preferably H, a linear or branched C^a-alkyl radical, a cycfohexyi radical or a phenyl radical, more preferably H, -CH3, -C2Ha or phenyl. 47. Compounds as claimed in any one of claims 41 to 46, characterized in that R11b represents hydrogen, an unbranched or branched, saturated or unsaturated, optionaliy at least mono-substituted Ci-e-aliphatrc radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at feast one* heteroatom as ring member containing Cas-cyeloaliphatic radical, which may be bonded via an optionally at least mono-substituted C^^-alkylene group and/or may be condensed with an optionally at least mono-substituted mono-or pofycyclic ring-system, or an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C^alkytene group and/or may be condensed with an optionaliy at least mono-substituted mono- or polycyclic ring-system, preferably H, a linear or branched C1-4-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably H, -CH3, -C2H5 or phenyl. 48. Compounds as claimed in any one of claims 41 to 47, characterized in that R12b represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted CVe-aJiphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing CVs-cydoaliphatic radical, which may be banded via an optionally at least mono-substituted C1-4-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycycllc ring-systern, or an optionally at least mono-substituted, 5- or 6- membered ^1- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C1-4-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or pofycyclic ring-system, preferably represents H, a linear or branched C1-4-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably H, -CH3, -C2H5 or phenyl. 49. Compounds as claimed in any one of claims 41 to 48, characterized in that R1: and R14b are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C^^-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C3-a-cycfoaliphatic radical, which may be bonded via an optionally at least mono-substituted Cj^-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycydic ring-system, or an optionally at least mono-substituted, 5- or 6-mernbered aryl-or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C1-5-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably are each independently selected from the group consisting of H, a linear or branched C1-4-alkyl radical, cyclohexyl and a phenyl radical, more preferably are each independently selected from the group consisting of H, -CH3, -CgHs and phenyl. 50. Compounds as claimed in any one of claims 41 to 49, characterized in that R1 and R14b together with the bridging nitrogen atom form a saturated, unsaturated or aromatic, 5- or 6-membered heterocyclic ring, which may be'at least mono-substituted and/or contain at least one further heteroatom as a ring member, preferably form an unsubstituted piperidin or morpholine group. 51. Compounds as claimed in any one of claims 41 to 50, characterized in that15b represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C1-5-aHphalic radical, a saturated or -^saturated, optionally at least mono-substituted, optionally at least one heteroatorn as ring member containing CWcycloaliphatic radical or an optionally at least mono-substftuted, 5- or 6- membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted Ci-e-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably represents H, a linear or branched C-»-4-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably represents H, -CH3, -CzHs or phenyl. 52. Compounds as claimed in any one of claims 41 to 51, characterized in that R1 represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C1-4 aliphatic radical, preferably an unbranched or branched, saturated, unsubstftuted C1.3 alkyl radical, more preferably a methyl radical. 53. Compounds as claimed in any one of claims 41 to 52, characterized in that R1 represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C1-6 aliphatic radical, preferably an unbranched or branched, saturated, unsubstftuted C1.3 alM radical, more preferably a methyl radical. 54. Compounds as claimed in any one of claims 41 to 53, characterized in that R1 represents a phenyl radical, which is optionally at least mono-substituted by a Cf& aliphatic radical, more preferably a phenyl radical, which is optionally at /east mono-substituted by a methyl group. 55. Compounds as claimed in any one of claims 41 to 54, characterized in that R,b, R2b, R3b, R4* are each independently selected from the group consisting of a hydrogen atom; a fluorine atom; a chlorine atom; a bromine atom; a methyl group and a methoxy group; R5b represents a hydrogen atom; -if, R7b, R8", R9" each represent a hydrogen atom; Wb represents an alkyl radical selected from the group consisting of methyl; ethyl; n-propyl; iso-propyl; n-butyl; seabutyt; iso-butyf and tert-butyl; vinyl (CH2=CH-); - ' N(CH3fe; 1-naphthyl; benzyl; 2-naphtyl; phenyl; 2-methyf-phenyf; 3-methyl-phenyl; 4-methyI-phenyl; 2-ethyl-phenyl; 3-ethyl-phenyl; 4-ethyf-phenyl; 2-n-propyl-phenyl; 3-n-propyl-phenyl; 4-n-propyf-phenyl; 2-isopropyi-pheny): 3-isopropyl-phenyl; 4-isopropyl-phenyl; 2-n-butyl-phenyl; 3-n-butyl-phenyl; 4~n-butyl-phenyl; 2-iso-butyl-phenyl; 3-iso-buryI-phenyl; 4-iso-butyUphenyl; 2-tert-butyl-phenyl; 3-tert-butyt-phenyl; 4*-tert-butyl-pheny1; 1,1-dimethylpropyl-phenyl; 2-cyclopentylphenyl; 3-cydopentyI-phenyt; 4-cydopentyl-phenyl 2-cydohexyf-phenyf; 3-cycfohexyf-phenyl; 4-cyclohexyl-phenyfc 2-methoxy^-phenyt; 3-methoxy-phenyl: 4-methoxy-pherryl; 2-ethoxy-phenyl; 3-etfioxy-phenyl; 4-ethoxy^phenyl; 2-n-propoxy-phenyl; 3-n-prapoxy-phenyl; 4-n-propoxy-phenyl; 2-iso-propoay-phenyl; 3-Jso-propoxy-phenyl; 4~}sopnjpoxy-phenyl;2-fluoro-phenyl; 3-fluoro-phenyl; 4-f5uoro-phenyl; 2-chloro-phenyl; 3-chloro-phenyl; 4-chJoro-phenyl; 2-bromo-phenyl; 3-bromo-phenyl; 4-bromo-phenyl; 2-irifluoromethyl-phenyl; 3-trifluoromethyl-phenyl; 4-trifluoromethyl-phenyl; 2-4rifluoromethoxy-phenyl; 3-trifluoromethoxy-phenyl; 4-trffluoromethoxy-phenyl; 2-carboxy-phenyl; 3-carboxy-phenyl; 4-carboxy-phenyl; 2-acetyI-phenyl; 3-acetyl-phenyl; 4-acetyf-phenyl; 2-(C=O3-0-CH3-phenyl; 3-{C=QyO~CH3-phenyl: 4-(C=O)-0-CH3-phenyf; 2-(CH2KCH2KC=O)-0-CH3: 3-(CH2HCHzHC=O)-0-CH3; 4-(CH2)-(CHz)-(C-0)-0-CH3; 2-cyano- phenyl; 3-cyano-phenyl; 4-cyano-phenyl; 2-nltro-phenyl; 3-nftro-phenyl; 4-nifro-phenyl; 4-(4~bramophenoxy)-phenyf; 2-rnethylsuHbnyl-phenyl; 3-njethylsulfonyl-phenyl; 4-methylsulfbnyl-phenyl; 2-phenyl-phenyf (biphenyl-2->,); 3-phenyl-phenyl (blphenyt-3-yI); 4-phenyl-phenyl (biphenyl-4-yl); 2-phenoxy-phenyf; 3-phenoxy-phenyl; 4-phenoxy-phenyf; 2,4-dImetnyf-pftenyl; 3,4-dimethyl-phenyl; 2,4,6-trimethyl-phenyl; 2,3,5,6-tetra.methyl-phenyt; pentarnethyl-phenyl; 2,5-dimethoxy-phenyl; 3,4-dlmethoxy-pbenyl; 2,3-dichloro-phenyl; 2,4-dlchloro-phenyl; 2,5-dichlaro-phenyl; 3,4-dichtoro-pnenyl; 3,5-dichloro-phenyl; 2,6-dichloro-pherryl; 2,4-difluoro-phenyl; 3,4-difluoro-phenyl; 2,5-difluoro-phenyl; 2,6-difluoro-phenyl; 3-chtoro-2-fluoro-phenyl; 3-chtoro-^-fluoro-phenyl; 5-chtoro-2-fluoro-pnenyl; 2,3,4-trichloro-phenyl; 2,4.5-trichloro-phenyl; 2,4,6-trichloro-phenyl; 2,4,5-trifluoro-phenyl; 2,3,4-trifluoro-phenyl-; 2-chloro-4,5-difluoro-phenyl; 2-bromo-4-fluoro-phenyl; 2-bromo-4,6-dffluaro-phenyl; 4-chJoro-2,5-drfluQro-phenyl; 5-chJoro-2,4-drfluoro-phenyl; 4-brorno-2,5-drfluoro-phenyl; 5-bromo-2,4-dlfluoro-phenyl; pentafluoro-phenyl; 2,4-dinrtro-phenyl; 4-chlono-3-nitro-phenyl; 2-methyl-5-nitro-phenyl; 5-bromo-2-methaxy-phenyl; 3-chloro-2-methyl-pbenyl; 4~bro/7)o-3-metfiyl-phenyl; 4-chloro-2,5-d5methyI-phQnyl; 4-fluoru-3-methyI-phenyl; 5-fluoro-2-methyl-phenyl; 2-nitro-^trifluoromethy^henyl; 2-methoxy-4-methyl-pbenyl; 3,5-dicbIojti-2-hydroxy-phenyl; 3,5-dlchloro-4-hydroxy-phenyl; 5-chIoro-2,4~ dffluoro-phenyl; 3-chforo-4-(NH)-(C=O)-CH3-phenyf; 2-chJoro-6-rnethyl-phenyl; 2-chloro-5-trifluoromethy^phenyl; 2-chioro-5-trifluoromethoxy-phenyl; 4-bromo-2-trifluoromethoxy-phenyl; 4-bromo-2-trifluoromethyl-phenyl; 4-bromo-3-trifluoromethyf-phenyl; 3-carboxy-4-fluorD-phenyf; 3-carboxy-4-chJoro-6-fluoro-phenyl; 4-metboxy-2,3,6-trimethyl-phenyl-; or one of the following groups: (Formula Removed) whereby in each case X denotes the position by which the respective substituent W* is bonded to the ~SOz group of formula (lb). optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mbcing ratio, or a physiologically acceptable salt thereof, or a solvate, respectively. 56. Compounds as claimed in any one of claims 41 to 55 selected from the following group (Table Removed) 57. Process for the preparation of benzoxazinone-derived sulfonamide compounds of general formula (lb) as claimed in one or more of claims 41 to 56, characterized in that comprises reacting at least one piperidine compound of general formula (Mb), wherein R1b to R9b have the meaning according to one or more of claims 41 to 56 and/or a salt, preferably a hydrochloride salt, thereof, (Formula Removed) (lib) with at least one compound of general formula (Hlb), (Formula Removed) wherein Wb has the meaning according to one or more of claims 42-57, in a suitable reaction medium, optionally in the presence of at least one base and/or at least one auxiliary agent 58. Process for the preparation of a physiologically acceptable salt of the benzoxazinone-derived sulphonamide compounds as claimed in claims 41 to 56, characterized in that at least one compound of general formula (lb) having at least one basic group is reacted with at least one acid, preferably an inorganic or organic acid, preferably in the presence of a suitable reaction medium. 59. Process for the preparation of a physiologically acceptable salt of the benzoxazinone-derived sulphonamide compounds as claimed in claims 41 to 56, characterized In that at least one compound of general formula (lb) having at least one acidic group is reacted with at least one base, preferably in the presence of a suitable reaction medium. 60. The compound as claimed in any one of claims 41 to 56 as and when used in the preparation of a medicament for prophylaxis and treatment of diseases as herein def/red. 61. Benzoxazinone-derived sulphonamide compound as claimed in any one of claims 41 to 56 for the manufacture of a medicament for the prophylaxis and/or treatment of fC=Od intake disorders. 62. The compounds as claimed in claim 61 for the regulation of appetite, for the reduction, increase or maintenance of body weight; for the prophylaxis and/or treatment of obesity, for the prophylaxis and/or treatment of bulimia, for the prophylaxis, and/or treatment of anorexia; for the prophylaxis and/or treatment of cachexia; or for the prophylaxis and/or treatment of type II diabetes. 63. Benzoxazinone-derived sulphonamide compound as claimed in any one o^ claims 41 to 56 for the use in the manufacture of a medicament for the prophylaxis and/or treatment of of gastrointestinal disorders, preferably irritable colon syndrome; for the prophylaxis and/or treatment of disorders of the central nervous system; for the prophylaxis and/or treatment of anxiety; for the prophylaxis and/or treatment panic attacks; for the prophylaxis and/or treatment of depression: for the prophylaxis and/or treatment of bipolar disorders; for the prophylaxis and/or treatment cognitive disorders, preferably memory disorders; for improvement of cognition (for cognitive enhancement); for the prophylaxis and/or treatment of senile dementia; for the prophylaxfe and/or treatment of psychosis; for the prophylaxis and/or treatment neurodegenerative disorders; preferably selected from the group consisting of Morbus Alzheimer, Morbus Parkinson, Morbus Huntington and Multiple Sclerosis; for the prophylaxis and/or treatment of schizophrenia; or for the prophylaxis and/or treatment hyperactivity disorder (ADHD, attention deficit, hyperactivity disorder).

Documents:

188-DELNP-2006-Abstract-(10-12-2008).pdf

188-DELNP-2006-Abstract-(13-04-2009).pdf

188-delnp-2006-abstract.pdf

188-DELNP-2006-Claims-(10-12-2008).pdf

188-DELNP-2006-Claims-(13-04-2009).pdf

188-delnp-2006-claims.pdf

188-DELNP-2006-Correspondence-Others-(10-12-2008).pdf

188-DELNP-2006-Correspondence-Others-(13-04-2009).pdf

188-delnp-2006-correspondence-others..pdf

188-delnp-2006-correspondence-others.pdf

188-DELNP-2006-Description (Complete)-(10-12-2008).pdf

188-delnp-2006-description (complete).pdf

188-DELNP-2006-Form-1-(10-12-2008).pdf

188-delnp-2006-form-1.pdf

188-delnp-2006-form-18.pdf

188-DELNP-2006-Form-2-(10-12-2008).pdf

188-delnp-2006-form-2.pdf

188-delnp-2006-form-3.pdf

188-delnp-2006-form-5.pdf

188-DELNP-2006-GPA-(10-12-2008).pdf

188-delnp-2006-gpa.pdf

188-delnp-2006-pct-210.pdf

188-delnp-2006-pct-304.pdf

188-delnp-2006-pct-409.pdf

188-delnp-2006-pct-416.pdf

188-DELNP-2006-Petition-137-(10-12-2008).pdf

188-DELNP-2006-Petition-138-(10-12-2008).pdf